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Chronic otitis media with effusion (COME) is the most common cause of acquired 
hearing loss in young children. Bacterial biofilm is an important contributor to the 
aetiopathogenesis of COME, although conventional culture generally recovers few 
microorganisms from the middle ear. Extracellular DNA (eDNA) is a key structural 
component within the matrix of many microbial biofilms including those associated with 
COME. The aims of this study were to characterise microbial populations associated with 
COME, and to explore the efficacy of the DNase, NucB, to control in vitro biofilms 
associated with COME. 
Methods were established to culture biofilms in vitro and to challenge with NucB. 
NucB efficiently disrupted biofilms of clinically isolated Staphylococcus aureus strains either 
alone or in combination with the antibiotic Co-amoxiclav. Concentrations of NucB 100-fold 
higher than those required for biofilm inhibition had no toxic effects on human epithelial 
cells. 
Twenty-seven bacterial species were isolated from middle ear effusion fluids (MEEFs) 
of 34 patients with COME. Culture-positive MEEFs were increased two-fold following 
optimisation of the culture methods. Microbiome analysis of MEEFs by 16S rDNA 
sequencing identified the majority of the cultured species and several additional species. 
Similar species were also detected by 16S rRNA gene sequencing of microbial DNA from 
adenoids.  
The ability of 23 bacterial isolates from MEEF to form biofilm was assessed. Twenty 
strains formed biofilms, and 16 of these were sensitive to NucB. Imaging analysis showed 
significant structural alterations in biofilms of the selected COME isolates after NucB 
treatment. 
In conclusion, this study has provided further insights into the microbiology of middle 
ear infections and has shown that many bacteria from this environment are capable of forming 
biofilms. NucB alone or in combination with antibiotics may potentially be a potent and safe 
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Chapter 1. Review of the literature  
1.1 Chronic otitis media with effusion  
 Chronic otitis media with effusion (COME) is defined as the persistence of non-
purulent middle ear fluid behind the intact ear drum (tympanic membrane) beyond 12 weeks 
in the absence of signs and symptoms of acute inflammation. It is distinct from persistent 
effusion after acute otitis media, which resolves spontaneously after two months in 90% of 
cases (Blanc et al., 2018). Hearing impairment is the most common presenting symptom of 
COME. The effusion fluid may be thin (serous) or thick (mucoid). When it is tenacious and 
very thick, it is also known as “glue ear” (Robb and Williamson, 2012). Histologically, 
COME is characterised by chronic inflammation in the middle ear mucosa which leads to 
overproduction of mucin-predominant middle ear effusion. Other components including 
bacteria have been identified in the middle ear effusion fluid (Kubba et al., 2000).   
Chronic otitis media with effusion is the most common childhood ear problem and the 
commonest cause of hearing loss in children in the developed world. COME is commonly 
asymptomatic, and therefore accurate determination of its prevalence and incidence in 
children is difficult. Nevertheless, estimates demonstrate that children between one and six 
years old are most likely to be affected. The prevalence of COME in children around 2 years 
of age is approximately 20% (Atkinson et al., 2015). There are two peaks in the prevalence of 
COME, an initial one at the age of 2 years, and a second at the age of 5 years. The incidence 
rate of COME then decreases to around 8% at 8 years of age (Atkinson et al., 2015, Zielhuis 
et al., 1989). It is estimated that COME affects about 80% of children at some stage in their 
development (Kubba et al., 2000, NICE, 2016).  
Although COME resolves spontaneously in most cases, complications are not 
uncommon. A persistence of hearing loss particularly in younger children may negatively 
impact speech, language development, behaviour, social skills, and school performance (Hall 
et al., 2009, Qureishi et al., 2014, Rosenfeld et al., 2016). In cases where COME persists for 
over 3 months of watchful waiting and has considerable effects on the child’s quality of life, 
the insertion of ventilation tubes (VTs, grommets) may be indicated (Lous et al., 2005, NICE, 
2016). Currently, tympanotomy and insertion of VT is the gold standard for surgical 
management of COME, and in some cases may be combined with an adenoidectomy 
(Qureishi et al., 2014, NICE, 2016). COME is the leading cause of elective surgery in 
children in the developed world (Rovers et al., 2004), and throughout 2018/2019, 22,000 
operations of myringotomy with the insertion of VT were performed in England (HES, 2019). 
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COME should be differentiated from other closely related middle ear infections such as acute 
otitis media (AOM) and recurrent AOM (rAOM). Acute otitis media (AOM) involves a rapid 
onset of inflammation that may be caused by bacteria or viruses (Kubba et al., 2000, Schilder 
et al., 2016). It is characterised by otalgia and fever in a generally ill child. By contrast, 
COME is a chronic inflammatory condition with an absence of pain and fever that can persist 
for several months. Within 7 days of AOM, a proportion of cases may be complicated by 
tympanic membrane perforation which is associated with drainage of the purulent discharge 
out of the middle ear and subsequent improvement of the symptoms. Acute otitis media may 
also affect patients with existing VTs resulting in purulent ear discharge (otorrhoea) which is 
also classified as AOM with tympanic membrane perforation. Persistence of purulent 
otorrhoea for more than 2 weeks is described as chronic suppurative otitis media. Recurrent 
AOM is characterised by 3 or more episodes of AOM in 6 months or more than 4 episodes 
within 12 months (Berman, 1995, Schilder et al., 2016). The clinical types of otitis media are 
shown in Figure 1. 1 with an illustration of ear anatomy in Figure 1. 2. 
The diagnostic criteria for COME include a history of hearing impairment, poor 
attention, delayed speech and language development, and abnormal behaviour (SIGN, 2003, 
Rosenfeld et al., 2016). Furthermore, COME is the leading cause of balance problems in 
childhood that are observed in approximately 50% of children with COME (Golz et al., 
1998). The most important diagnostic method is pneumatic otoscopic examination of the 
tympanic membrane, which combines visual inspection of the tympanic membrane with 
assessment of its mobility, and has an estimated sensitivity and specificity of 94% and 80%, 
respectively (Shekelle et al., 2002). Other clinical findings are less clear, and include changes 
in the colour (yellow, amber, blue), shape (retracted or concave) of the ear drum, and ear-fluid 
levels. The gold standard for diagnosing COME is confirmation of middle ear effusion via 
needle aspiration of middle ear effusion fluid (tympanocentesis); however, tympanocentesis is 
an invasive procedure and difficult to perform in outpatient clinic. Further adjunctive 
confirmation of the diagnosis is obtained via tympanogram and tone audiometric 
measurement. The tympanogram quantitatively measures both tympanic membrane mobility 
and middle ear function, and usually demonstrates a flat curve. Many studies have 
demonstrated high reliability of the tympanogram for the diagnosis of COME (NICE 2008). 
The sensitivity and specificity are approximately 93% and 70%, respectively (NICE, 2008, 
Sassen et al., 1994, Shekelle et al., 2002, Watters et al., 1997). Audiometric examination can 
be applied on children around the age of 4 years. Most children with COME show a hearing 
impairment and can only detect sounds above 20-30 dB (normal hearing is between 0 and 20 
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dB). The extent of impairment is dependent on the amount of the middle ear fluid, but not the 
viscosity. In contrast to the tympanogram, the reliability of audiometry is not entirely clear 
and studies on this topic are rare. The estimated sensitivity and specificity are in the region of 
52-88% and 53-92%, respectively (Haapaniemi, 1997, Mitchell et al., 1990, Vaughan-Jones 


























Figure 1. 1 Types of otitis media and clinical images  
List of otitis media types (upper box). Clinical images show normal tympanic membrane (TM); pale, 
grey semi-translucent membrane (A), AOM; congested and bulged TM (B), COME; effusion fluid 
behind dull and retracted TM (C), severe retraction of TM (Atelectasis) (D), CSOM; perforated TM 
with purulent middle ear discharge (E), Cholesteatoma; whitish-yellow cystic skin lesion can be seen 
in the middle ear (F). A-D and F (Hawke, 2004), E (Rudyard, 2012). 
A                                                    B                                                 C 
       D                                                     E                                                   F 
Otitis Media  
Acute otitis media (AOM): Acute onset of middle ear space infection. 
Recurrent AOM (rAOM): 3 or more attacks of AOM within 6 months or more than 4 episodes 
within 12 months. 
Chronic otitis media with effusion (COME): Accumulation of fluid in middle ear without signs 
and symptoms of acute infection beyond 12 weeks. 
Chronic suppurative otitis media: Persistent middle ear inflammation usually associated with a 
perforated ear drum and persistent drainage from middle ear for more than 2-6 weeks. 






Figure 1. 2 Anatomy of the ear (Biographix, 2006)   
The external ear formed by the pinna and external auditory canal is separated by the TM from 
the middle ear cavity that houses auditory ossicles (Malleus, Incus and Stapes). This in turn is 
connected to the nasopharynx via the Eustachian tube and is medially related to the inner ear 
that consists of semi-circular canals and the cochlea.  
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1.2 Current therapeutic options for COME 
Children with COME should undergo an age-specific hearing test to establish their 
baseline hearing level. Visual response audiometry is commonly used to assess hearing in 
children aged 8 months to 2.5 years and can provide reliable results in infants as young as 6 
months when performed by an experienced audiologist (Widen et al., 2000). Play audiometry 
is the most suitable hearing test to assess hearing in children aged 2.5-4 years. This involves 
children carrying out a task such as placing a toy in a container in response to an auditory 
stimulus (Rosenfeld et al., 2016). For children older than 4, formal audiometric examination 
using a pure tone audiogram is the gold standard test to assess hearing (Harlor and Bower, 
2009). The current NICE guidelines recommend a 3-month period of active “watchful 
waiting” in children presenting with persistent bilateral (affecting both ears) COME unless the 
hearing loss is judged to have a significant impact on the child’s developmental, social and 
educational status (NICE, 2016). During this “watchful waiting”, all children with COME 
undergo frequent evaluations of their hearing loss and the impact it has on their 
developmental status prior to indicating the need for surgical intervention. However, there is 
frequent non- compliance with these guidelines (NICE 2008). 
   One reason for the lack of compliance with guidelines is that COME resolves 
spontaneously in the majority of cases without treatment and the possibility of the 
spontaneous resolution depends on the cause and duration of COME (Rosenfeld and Kay, 
2003). Approximately 75-90% of children who develop COME following an episode of AOM 
show spontaneous resolution of the symptoms within 3 months (Teele et al., 1989). However, 
in children with COME of unknown duration, the rate of spontaneous resolution is estimated 
to be as low as 28% after 3 months, 42% at 6 months, and 59% by 9 months as determined by 
tympanometric criteria (Rosenfeld and Kay, 2003). Therefore, the decision between 
conservative treatment and surgical intervention should be weighed cautiously. 
 Many other medical treatments have been trialled for COME, such as antibiotics, 
steroids, and antihistamines. The use of antibiotics for the treatment of COME is controversial 
(Venekamp et al., 2016). Although short term benefits of antibiotic administration have been 
reported, there was no significant long-term benefit after discontinuation of the treatment 
(Venekamp et al., 2016, Rosenfeld et al., 2016). Furthermore, there are adverse effects, 
elevated costs, and a risk of bacterial resistance (van Zon et al., 2012, Venekamp et al., 2016).  
A meta-analysis studied the effects of topical or oral steroids in conjunction with or 
without antibiotics for the treatment of COME (Simpson et al., 2011b). Although there was a 
7 
 
short-term benefit consistent with increasing COME resolution rate, there was no evidence of 
long-term advantages. Specifically, oral steroids did not significantly resolve the effusion or 
reduce the level of hearing loss in children with COME. However, steroids were associated 
with significant adverse effects including behavioural disturbances, weight gain, and 
idiosyncratic reactions (Berkman et al., 2013). The application of antibiotics, steroids, 
antihistamines, and decongestants either alone or in combination are not recommended in the 
UK (NICE, 2016). Additional conservative strategies include the Politzer manoeuvre to 
relieve Eustachian tube dysfunction by blowing air up the nostril using a balloon or other 
devices. However, these approaches, in order to be effective, should be carried out frequently 
and it is difficult for the younger children to comply with them (Bidarian-Moniri et al., 2014, 
Robb, 2006). 
According to the current NICE guidelines, the only efficient surgical treatment to 
improve hearing is myringotomy with or without ventilation tube placement (NICE, 2016). 
This approach is recommended only in children with bilateral and persistent COME beyond 3 
months with a degree of hearing loss degree in the better ear of 25-30 dB or more. According 
to the guidelines, surgical intervention is not recommended in children with short-term 
COME or when COME has a minimal or negligible impact on the child’s quality of life and 
development. Different types of ventilation tubes have been used over the last decades. These 
are either short-term tubes such as Shepard, Shah, Armstrong and Reuter Bobine devices that 
last from 6 months to 24 months and are indicated for most children who undergo primary VT 
insertion, or long-term tubes including T-tubes and Permavents that last for several years and 
are generally used in cases where multiple sets of short acting VTs fail to resolve the disease 
(Lindstrom et al., 2004, Yaman et al., 2010). 
The placement of VTs has been shown to reduce the duration of middle ear effusion 
symptoms by 32% and is also associated with short-term mild improvement of hearing loss by 
4.2-10 dB at 6-9 months when compared with the conservative therapy. However, this 
improvement in hearing level was lost after 1 year (Berkman et al., 2013, Browning et al., 
2010). Furthermore, the impact of VTs insertion on children’s language development remains 
inconclusive. No improvement in language development was found in surgical treatment 
compared with conservative management of COME in several trials (Berkman et al., 2013, 
Browning et al., 2010). Nevertheless, the insertion of VTs has been shown to improve speech 
and language development in COME patients with cleft palate (Kuo et al., 2014).    
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Several short- and long-term complications have been associated with the insertion of 
VTs including purulent ear discharge (10%-26%), early expulsion of VTs (4%), displacement 
of VT into middle ear cavity (0.5%), tympanosclerosis (39%-65%), permanent ear drum 
perforation (3% overall, and around 24% of patients with long-term T-tubes), and retraction 
pockets (21%) (Kay et al., 2001, Rosenfeld et al., 2013). Furthermore, a trial reported that 
20%-25 % of the cases treated with short-lasting tubes required further surgical intervention 
within 2 years, and on average more than two operations per case were performed (Daniel et 
al., 2012a, Vlastarakos et al., 2007). 
Another surgical treatment which is considered effective in preventing the recurrence of 
COME is adenoidectomy as an adjunct treatment to VT placement. Adenoidectomy is not 
recommended in children younger than 4 years undergoing a primary grommet insertion 
because of COME unless there is a strong indication such as nasal obstruction or chronic 
adenoiditis that exists other than COME (NICE, 2016, Rosenfeld et al., 2016). This is because 
the surgical risks of adenoidectomy do not outweigh the limited, short-term advantage in 
young children without previous history of VT placement (Paradise et al., 1999). Risks 
associated with adenoidectomy include longer duration of anaesthesia, small risk of post-
surgical bleeding and a prolonged recovery period (24-48 h). Therefore,  adenoidectomy is 
usually preserved for children older than 4 years of age with recurrent or chronic upper 
respiratory tract infections (van den Aardweg et al., 2010, NICE, 2016).  
1.3 Pathogenesis of COME 
The pathogenesis of COME is still not well understood. There is a general agreement that 
COME is a multifactorial disease and a combination of several host and environmental factors 
are thought to be involved in the development of COME (Blanc et al., 2018, Qureishi et al., 
2014). Eustachian tube dysfunction, laryngopharyngeal reflux, cleft palate, and several 
genetic factors are important host factors that predispose for the development of COME. 
Furthermore, there are a number of environmental factors that have been implicated in 
increasing the risk of AOM and COME such as bacterial infection, allergy, childcare 
attendance, exposure to tobacco smoke, and lack of breastfeeding. Many of these 
environmental factors also have an impact on general health in the population and they have 
been the subject of interest for policy makers and public health authorities. Regardless of the 
mechanism involved in pathogenesis of COME, the resulting middle ear effusion fluids 
generally consist of water, host cells and cell debris, bacterial cells and products, and many 
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other components that may be produced secondary to bacterial inflammatory reactions such as 
immunoglobulins, complement, cytokines, and others. In addition many other components 
such as minerals and macromolecules including proteins, lipids, mucins and DNA have been 
detected in middle ear effusions, indicating that middle ear fluid is an exudate (Kubba et al., 
2000, Smirnova et al., 2002).      
Eustachian tube (ET) dysfunction has been considered an important underlying 
pathophysiological factor implicated in the pathogenesis of COME. The ET is a muscular 
tube that provides a connection between the middle ear cavity and the nasopharynx (Figure 1. 
2). It is lined by ciliated respiratory epithelium and it is involved in maintaining normal 
middle ear function through three essential roles: (i) pressure balance between the outer and 
middle ear, (ii) drainage of middle ear fluid, and (iii) prevention of retrograde ascension of 
pathogens and other external insults from the upper respiratory and gastrointestinal tracts into 
the middle ear (Rovers et al., 2004). In children, the ET is shorter, more horizontal, and less 
rigid than in adults, which is thought to increase the risk of otitis media (Minovi and Dazert, 
2014). For this reason, the prevalence of COME decreases with age (approximately 3-7 years) 
in correlation with the normalisation of ET function. The potential role of ET dysfunction in 
the pathogenesis of COME has been studied extensively for decades. Traditionally, it has 
been thought that mechanical obstruction of the ET in the nasopharynx due to enlarged 
adenoids, nasopharyngeal mass or other factors leads to negative pressure within the middle 
ear cavity which ultimately results in transudation of fluid from the epithelial mucosa into 
middle ear space (Coticchia et al., 2013, Minovi and Dazert, 2014). This concept has some 
limitations including that middle ear effusion fluid in COME is an actively secreted exudate 
and it does not adequately explain the chronic inflammatory process and metaplasia 
associated with COME (Sade and Weissman, 1977).  
The aetiopathogenesis of COME is much more complicated than can be explained by 
ET obstruction only. Evidence is accumulating that ET dysfunction, rather than ET 
obstruction, is the major contributor to the pathogenesis of COME. Children with premature, 
horizontally oriented malfunctioning ET are more likely to develop COME (Iwano et al., 
1993). However, there is still some controversy regarding whether ET dysfunction is the 
primary cause of COME or whether it is the result of a prolonged chronic inflammatory 
reaction. In experimental animal models, it has been shown that creation of negative pressure 
within the middle ear cavity by ET occlusion did not lead to the accumulation of effusion 
fluid unless bacterial infection was present (Ovesen and Borglum, 1998). Furthermore, it is 
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still debated whether the observed therapeutic efficacy of adenoidectomy in children with 
recurrent COME is due to removal of the potential physical obstruction, or due to the removal 
of the reservoir that allows direct ascension of pathogens from the nasopharynx into the 
middle ear (Hoa et al., 2010, Saafan et al., 2013). A combination of ET dysfunction and 
retrograde ascending infection is perhaps the most likely mechanism that leads to the 
development of COME.   
Pathologically, COME is a chronic inflammatory condition of the middle ear. The 
inflammatory irritation of the middle ear mucosa leads to the production of cytokines and 
secretion of an exudate rich in proteins and other inflammatory mediators. Furthermore, the 
associated vasodilatation enhances absorption of the air and ultimately induces negative 
pressure within the middle ear space (Li et al., 2013). Prolonged inflammation of the middle 
ear mucosa leads to epithelial metaplasia and an increase in the number of mucous secreting 
cells which leads to over-secretion of mucous and the production of altered mucin types 
(Kubba et al., 2000). These changes in the mucous result in the impairment of middle ear 
mucosal ciliary clearance action and ET dysfunction with subsequent retention of thick, 
tenacious, mucin-enriched middle ear fluid (Rovers et al., 2004). Although COME is clearly a 
chronic inflammatory condition, the source of the persistent inflammatory stimulus has been 
difficult to establish (Kubba et al., 2000). Chronic otitis media with effusion is hypothesized 
to be initiated by inflammation and immune reaction against ascending infections from the 
adenoid and nasopharynx (Vanneste and Page, 2019).  
1.3.1 The role of bacteria in COME 
Bacterial infections have been implicated to play a key role in the pathogenesis of 
AOM and COME. Lines of evidence that support an “infective aetiology” of COME include a 
strong association between AOM and COME: more than 50% of cases of COME are 
preceded by an episode of AOM (Kubba et al., 2000). Moreover, some of the high-risk groups 
of children such as younger siblings, nursery children, and absence of breast feeding, are 
those that are susceptible to infections, also supporting an infective aetiology of COME 
(Robb, 2006). In addition, as noted above, the nature of the effusion fluid in COME is an 
exudate not transudate, which is again consistent with a localised infection. However, lack of 
the typical signs and symptoms of acute bacterial infections such as ear pain, fever, and other 
constitutional symptoms is more difficult to rationalise with an infective aetiology. 
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COME has been considered by some researchers to be a non-infective inflammatory 
condition because of the failure to culture bacteria from middle ear effusion in approximately 
half of samples (21%-70%) (Bluestone et al., 1992, Gok et al., 2001, Hall-Stoodley et al., 
2006). However, additional studies that examined middle ear effusions using polymerase 
chain reaction (PCR) found pathogenic bacterial DNA in more than 80% of culture-negative 
effusions (Kubba et al., 2000, Post et al., 1995, Rayner et al., 1998). Furthermore, this DNA is 
simultaneously present with a short half-life bacterial-specific mRNA, indicating the presence 
of metabolically active bacteria in culture-negative COME (Rayner et al., 1998). One 
hypothesis behind this inconsistency between the high negative cultures and high PCR-
positive rate is that the majority of bacteria within the middle ear of patients with COME exist 
within a biofilm form and are not easily recovered and isolated (Fergie et al., 2004). Previous 
studies using experimental chinchilla otitis media models have demonstrated biofilm 
formation on the middle ear mucosa using confocal laser microscopy and/or scanning electron 
microscopy (SEM) (Ehrlich et al., 2002, Post, 2001). 
 Strong evidence for the role of biofilms in COME was obtained though the direct 
detection of bacterial biofilms by confocal laser microscopy on the middle ear mucosa of 
children with COME and rAOM in up to 92% of cases, but not in any studied control 
samples, strongly supporting the role of bacterial biofilms in the pathogenesis of COME and 
rAOM (Hall-Stoodley et al., 2006). Similarly, polymicrobial biofilms have been demonstrated 
on 65% of middle ear mucosal samples collected from 20 children with both COME and 
rAOM (Thornton et al., 2011). In addition to the polymicrobial biofilms, intracellular bacteria 
resembling cocci were also observed within epithelial cells of the middle ear mucosa using 
transmission electron microscopy. Using both universal and species-specific fluorescence in 
situ hybridization (FISH) probes, they were able to visualise unidentified bacterial species in 
addition to the three common otopathogens (Streptococcus pneumoniae, Haemophilus 
influenzae, and Moraxella catarrhalis) within these samples, suggesting that previously 
unidentified bacterial species are also involved in biofilm formation within the middle ear of 
COME and rAOM patients. 
 Furthermore, middle ear bacterial biofilms have also been demonstrated in patients 
with chronic suppurative OM (CSOM) (Homoe et al., 2009, Jensen et al., 2017) and with 
cholesteatoma (Chole and Faddis, 2002, Park et al., 2009). Recently, biofilms have also been 
shown on the surface of ventilation tubes removed from children with COME (Barakate et al., 
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2007, Wang et al., 2014) or free floating within the middle ear effusion fluids recovered from 
patients with COME (Daniel et al., 2012b, Van Hoecke et al., 2016)   
The most common bacterial species identified in patients with AOM are S. 
pneumoniae (27.8%), H. influenzae (23.1), and M. catarrhalis (7%). H. influenzae is more 
frequently isolated from patients with rAOM and AOM with a perforated tympanic membrane 
(H. influenzae 22.8% versus 18.6% for S. pneumoniae and 4.1% M. catarrhalis (Ngo et al., 
2016). However, in patients with COME, the most commonly identified bacterial pathogen is 
H. influenzae (11.6%), followed by S. pneumoniae (6.5%), although bacteria are less likely to 
be identified compared to AOM (Ngo et al., 2016). All the three most commonly recognised 
otopathogens have been shown to have the ability to form biofilms in vitro and in vivo 
(Bakaletz, 2012, Hall-Stoodley and Stoodley, 2009, Silva and Sillankorva, 2019). 
Staphylococcus aureus, coagulase-negative staphylococci, Veillonella species, and numerous 
other bacterial pathogens are also often isolated from middle ear effusions (Bluestone et al., 
1992, Hyden et al., 2006, Daniel et al., 2012b, Papp et al., 2016).  
Studies suggest that the existence of biofilms on adenoids may be an essential pre-
requisite for the initiation and development of biofilms within the middle ear, and that the 
adenoids potentially act as a reservoir for biofilm-forming otopathogens (Hoa et al., 2009, 
Hoa et al., 2010, Zuliani et al., 2009, Van Hoecke et al., 2016). With this in mind, it is 
believed that the therapeutic advantages of adenoidectomy are related to the debulking of 
nasopharyngeal biofilms, changing the microbial community in the nasopharynx, and 
minimizing the rate of H. influenzae and S. pneumoniae colonization (Aarts et al., 2010). 
Significantly higher biofilm formation on the adenoid mucosa was reported in children with 
rAOM and/or COME in comparison with children with adenoid hypertrophy only (Hoa et al., 
2010, Saafan et al., 2013, Zuliani et al., 2009). The adenoids play key roles in regulating 
systemic and local immunity in children. However, evidence confirming their role in the 
pathogenesis of COME is scarce and further investigations are still required.  
1.3.2 Other etiological theories for the pathogenesis of COME 
A range of hypotheses have been proposed to explain the role of underlying 
pathophysiological factors that are thought to have a contribution in the pathogenesis of 
COME. A common process unifying these hypotheses is inflammation resulting in over-
secretion and accumulation of thick and viscous mucus in the middle ear cavity combined 
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with impaired mucociliary clearance because of high mucous viscosity. The complex 
interaction of different risk factors predisposing to COME is illustrated in Figure 1. 3. 
The potential role of ET dysfunction whether as a primary cause of inflammation or as 
a sequela of prolong inflammation that ultimately leads to development of COME are 
described in detail above. Several other host and environmental factors are also thought to 
have a role in COME including laryngopharyngeal reflux (LPR), respiratory allergy, genetic 
factors and exposure to tobacco smoking. 
The link between LPR and COME has been suspected ever since digestive enzymes of 
the stomach such as pepsin and its proenzyme form, pepsinogen, were detected in high 
concentrations in middle ear aspirates of patients with COME (Miura et al., 2012, Formánek 
et al., 2015, Doğru et al., 2015). Furthermore, Helicobacter pylori DNA, retrieved from 
bacteria that primarily colonise the stomach and duodenum, have been detected in 6-18% of 
middle ear effusion samples using PCR and enzyme-linked immunosorbent assay (ELISA) 
(Boronat-Echeverría et al., 2016). However, despite these findings, a direct causal relationship 
between LPR and COME has not been determined (Miura et al., 2012, Kariya et al., 2014). 
Similarly, several published studies have suggested an association between respiratory 
allergy, specifically allergic rhinitis, and COME (Kreiner‐Møller et al., 2012, Pau and Ng, 
2016). Again, a causal relationship has been difficult to prove, and no significant alteration in 
COME progression was demonstrated when anti-allergy treatments such as topical and oral 
steroids were used (Simpson et al., 2011a). 
Chronic otitis media with effusion might also be initiated by the activation of certain 
inherited genes regulating mucin expression, mucin production, and host response against 
bacteria in the middle ear. Twelve such genes have been identified to date (Kubba et al., 2000, 
Vanneste and Page, 2019). Higher concentrations of mucins have been found to correlate with 
increased viscosity of middle ear effusions (Carrie et al., 1992), which can subsequently result 
in impaired mucociliary clearance of middle ear effusion. MUC5AC and MUC5B that are 
encoded at chromosome 11p15 are examples of respiratory mucin molecules that are thought 
to be involved in the accumulation of mucous in the middle ear cavity (Tsuboi et al., 2001, 
Kubba et al., 2000). Furthermore, hereditary diseases such as primary ciliary dyskinesia that 
affect mucociliary clearance and congenital malformations including cleft palate, Down 
syndrome and immune deficiency have also been associated with ET dysfunction followed by 
COME (Flynn et al., 2009, Hoffman et al., 2013, Qureishi et al., 2014). The association 
between COME and exposure to cigarette smoke has been highlighted in many studies, 
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however, a causal relationship has not yet been established. The presence of parental smoking 
has been shown to increase the risk of COME and rAOM by 66% (Jacoby et al., 2008), and 
the risk associated with passive smoking increases with age (Mansour et al., 2018). One 
potential mechanism is due to overexpression of mucin genes in response to passive smoking, 
which impairs the normal mucociliary function of the middle ear and leads to COME 
(Preciado et al., 2010).  
Several clinical features of COME are consistent with biofilm infection including 
frequent spontaneous resolution, but higher rates of disease recurrence and the failure of 
antibiotic treatment to eradicate bacteria present in the middle ear (Harimaya et al., 2006). In 
addition, bacteria within biofilms may initiate low grade subacute inflammation and thus 
ultimately prolong the presence of middle ear effusion. However, dispersal of planktonic 
bacteria from the biofilm can result in an episode of acute infection with an associated intense 
inflammatory reaction. Therefore, children with COME are 5 times more likely to develop 
AOM compared to those without COME (Teele et al., 1989). A better understanding of the 





Figure 1. 3 Pathogenesis of COME, adapted from (Qureishi et al., 2014).  
The figure shows the interaction of different host and environmental risk factors that are 
thought to have role in the pathogenesis of COME. A common mechanism unifying these 
factors is the inflammatory irritation of the middle ear mucosa leading to the production of 
cytokines, over-secretion and accumulation of thick and viscous mucus in the middle ear 
cavity combined with impaired mucociliary clearance that ultimately leads to development of 
COME. Eustachian tube dysfunction, either caused by an enlarged adenoid or as a sequela of 
acute viral or bacterial infection, leads to impaired mucociliary clearance that eventually 
result in COME. Prolonged inflammatory irritation induced by biofilms, allergy, and LPR can 
result in COME as described above. Exposure to cigarettes smoke or activation of certain 
inherited genes may lead to overexpression of mucin, which impairs the normal mucociliary 





1.4 Bacterial biofilms and their formation 
It has been estimated that approximately 40-80% of bacteria on Earth tend to aggregate 
on surfaces within biofilms rather than living in a planktonic (free-living) state (Flemming 
and Wuertz, 2019). The term ‘biofilm’ refers to an aggregation of microbial cells enclosed in 
a self-produced extracellular polymeric matrix that is irreversibly attached to an inert or living 
surface or interface (Costerton et al., 1999, Fergie et al., 2004, Yang et al., 2008). Parsek and 
Singh (2003) have proposed additional criteria to define medically relevant biofilm infections. 
These criteria include tolerance of biofilm cells to antibiotic treatment, despite the sensitivity 
of their planktonic counterparts to the antibiotic, and that the infection must be localised to a 
particular site. The protective structure of biofilms facilitates bacterial survival in hostile 
environments, the dissemination of genetic material, and resistance to the host's immune 
system  (Hoiby et al., 2011, de la Fuente-Nunez et al., 2013).  
The mechanism of biofilm formation and development has been extensively investigated 
in model microorganisms such as Pseudomonas aeruginosa (Sauer et al., 2002, Reichhardt 
and Parsek, 2019) and Bacillus subtilis (Vlamakis et al., 2013, Kovács and Dragoš, 2019). 
Basically, biofilm formation involves several phases initiated by reversible attachment of 
microorganisms to the surface which occurs when the attractive forces (Lifshitz-Van der 
Waals forces) overcome the repulsive forces (electrostatic forces on the microbial cell surface 
and substratum). This early phase is facilitated by the pre-coating of the substratum by a 
conditioning film, commonly consisting of proteins or glycoproteins, that forms on surfaces 
when they are exposed to a fluid or gas. Furthermore, complex interactions between other 
forces such as gravity, surface hydrophobicity, steering tensions, and Brownian motion can 
also influence initial microbial adhesion. Following the establishment of a stable attachment 
to the surface, the ability of microorganisms to stay irreversibly adherent is determined by a 
critical interaction between bacterial surface adhesins and specific receptors in the 
conditioning film (Gupta et al., 2016).  
Following irreversible adhesion, microbes multiply, form micro-colonies and initiate 
production of extracellular matrix which enhances microbial adhesion to the surface, cell to 
cell cohesion and has many other functions. The mechanism of synthesis of the components 
of the biofilm matrix is not well understood. It has been proposed that quorum-sensing signals 
participate in P. aeruginosa and Vibrio cholerae polymeric matrix synthesis (Gupta et al., 
2016, Bridges and Bassler, 2019). When the essential structure of the biofilms has 
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established, the biofilm enters the maturation phase in which the microorganisms multiply 
and aggregate, in some cases forming three-dimensional towers. Eventually, the bacterial cells 
in the outer layers will be detached and dispersed either individually or in aggregates to start a 
new cycle of surface colonisation and establishment of new biofilms (Otto, 2013). Bacterial 
dispersal and seeding from the biofilm surface is thought to be important for the 
dissemination of infections to the other parts of the host like a septic embolus (Fleming and 
Rumbaugh, 2018) and is driven by external forces such as the shearing force of high fluid 
flow (Oder et al., 2018) or by self-induced processes of dispersal such as enzymatic 
degradation of the extracellular polymeric matrix (Cho et al., 2015, Guilhen et al., 2017). 
Increasingly, these bacterial enzymes have been investigated for their potential to disperse 
pathogenic biofilms. Examples of these biofilm degrading microbial enzymes include the 
glycosidases dispersin B and alginate lyase, and deoxyribonucleases such as NucB of Bacillus 
licheniformis (Nijland et al., 2010, Fleming and Rumbaugh, 2017, Bou Haidar et al., 2020). 
1.5  Biofilms and their clinical importance 
Bacteria residing in biofilms display complex biological characteristics and activities. 
For example, cell-to-cell communication through quorum sensing involves dissemination of 
signalling molecules and genetic material among microbes which impacts on microbial 
virulence, co-aggregation, biofilm structure, and responses to environmental stresses (Hall-
Stoodley and Stoodley, 2009, Wolska et al., 2016). Furthermore, the high tolerance of the 
biofilm to antibiotic treatment and host immune actions is linked to complex microbial 
communities within biofilms and the protective functions of the biofilm matrix (Hoiby et al., 
2011, Flemming et al., 2016). 
The potential role of bacterial biofilms in chronic infections was first described when 
P. aeruginosa was found colonizing the bronchial tree of patients with cystic fibrosis (Hoiby 
et al., 1977, Lam et al., 1980). Subsequently, biofilms were shown to contribute to the 
pathogenesis of chronic human infections such as chronic rhinosinusitis (CRS), otitis media, 
dental caries and others  (Jakubovics, 2015, Van Hoecke et al., 2016, Rostami et al., 2017, Di 
Luca et al., 2017). Moreover, the increasing application of different kinds of medical implants 
poses challenges for controlling biofilm infections since artificial surfaces within the body 
provide new sites for microbial attachment and colonisation resulting in biofilm formation on 
almost all kinds of indwelling medical implants and devices (Donlan and Costerton, 2002, 
Arciola et al., 2018, Zatorska et al., 2017). 
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The US National Institutes of Health have estimated that biofilms account for over 
80% of chronic infections and 65% of all microbial infections in the human body  (Jamal et 
al., 2018). The role of bacterial biofilms in the pathogenesis of chronic infectious diseases can 
be difficult to establish because microorganisms residing within biofilms tend to resist 
traditional culture methods (Hall-Stoodley et al., 2006). Parsek and Singh (2003) have 
proposed a number of specific criteria that should be present in a medically relevant infection 
in order to be considered as a biofilm infection. These criteria include (i) bacterial attachment 
to a surface or substratum, (ii) bacterial aggregates or micro-colonies should be embedded in 
extracellular matrix, (iii) the infection is generally localised to one site, and (iv) biofilm cells 
are resistant to eradication by antibiotics, despite the sensitivity of planktonic counterparts to 
the same antibiotic. Later on, an additional feature was suggested to be added to the 
diagnostic criteria of biofilm infections by Hall-Stoodley and Stoodley (2009): evidence of 
impaired host immunity against bacterial aggregates in culture-negative cases with 
documented signs and symptoms of bacterial infection. Visualisation of localised bacterial 
aggregates surrounded by immune cells such as neutrophils and macrophages significantly 
increases the suspicion of biofilm infection. Furthermore, additional culture-independent 
diagnostic tools such as PCR and FISH were also recommended in addition to traditional 
culture approaches to increase the detection rate of bacteria within biofilms (Hall-Stoodley et 
al., 2006). Increasingly, other culture-independent molecular based techniques such as high 
throughput 16S rRNA gene sequencing are being employed to identify bacteria which are 
fastidious, non-cultivable, and those that are living within biofilms (Di Luca et al., 2017). 
Culture-independent molecular analysis is discussed in more detail in sections 1.8 and 1.9.  
Due to the intrinsic tolerance of bacteria within biofilms to antimicrobial therapy and 
the immune response, the treatment and prevention of biofilm-associated chronic infections 
have been difficult. The protective organisation of biofilms enhances bacterial survival 
against different external stresses such as UV light, heavy metals, and changes in temperature, 
moisture, acidity, and host phagocytic defences (Espeland and Wetzel, 2001, Le Magrex-
Debar et al., 2000, Leid et al., 2002, Teitzel and Parsek, 2003, Flemming et al., 2016). 
Furthermore, bacteria in biofilms exhibit tolerance to high concentrations of antimicrobials, 
typically more than 1,000 times higher than their planktonic counterparts. Different possible 
mechanisms have been proposed to explain this characteristic (Singh et al., 2017, Flemming 
et al., 2016). These include: (i) the nature of biofilm matrix impairs the penetration of 
antibiotics to reach bacteria within biofilms, (ii) diverse physiochemical niches within biofilm 
structure may affect antimicrobial efficacy directly or indirectly by altering the growth of 
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microorganisms in the anaerobic environment within the core of the biofilm, (iii) surface-
attached bacterial cells in biofilms exhibit phenotypic and genotypic alterations consistent 
with changes in gene transcription and physiologic parameters that may ultimately affect their 
sensitivity to antibiotics, (iv) the presence of metabolically dormant populations of bacterial 
cells known as persister cells which exhibit high tolerance to antimicrobial agents, (v) slow 
bacterial growth rate makes them less vulnerable to antibiotics. These mechanisms can act 
individually or in combination (Yan and Bassler, 2019).  
Bacteria within biofilms behave differently from their planktonic counterparts. 
Therefore, treatment of biofilm infections using planktonic bacteria-based Minimum 
Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) is often not 
suitable (Andrews, 2001). The need for an assay that can provide relevant and effective 
antibiotic dose recommendations for the eradication of bacterial biofilms led to the 
development of Minimum Biofilm Eradication Concentration (MBEC) assay as an alternative 
to MIC (Ceri et al., 1999). Minimum Biofilm Eradication Concentration is up to 1,000 times 
greater than MIC. Unfortunately, it is often not possible to deliver such high effective 
concentrations of antimicrobial agents due to toxicity. Therefore, attention has been directed 
towards the development of anti-biofilm agents that can return bacteria to their susceptible 
planktonic state. Extracellular polymeric substances (EPS) in the matrix of biofilms provide 
bacteria within biofilms with a wide range of protective advantages that will be discussed in 
the next section. Several components of EPS, including proteins, extracellular DNA (eDNA), 
and exopolysaccharides can be involved in these protective functions (Fleming and 
Rumbaugh, 2017). Of these components, eDNA has increasingly been shown to be a key 
structural component within the biofilm matrix of many bacteria that plays a pivotal role in 
enhancing biofilm formation and maintaining the structural integrity of biofilms (Jakubovics 
et al., 2013, Jakubovics and Burgess, 2015, Okshevsky et al., 2015).    
1.6       Extracellular DNA and its role in bacterial biofilms 
The amount and the composition of EPS in biofilms differ greatly among different 
microbial species. It has been estimated that EPS constitutes around 90% of the overall 
biomass in many biofilms, whereas the microbial cells accounts for less than 10% (Flemming 
and Wingender, 2010). The EPS of microbial biofilms plays a key role in maintaining the 
stable adhesion of the bacterial colonies to the substratum, boosting cell to cell cohesion, 
conserving nutrients, and disseminating genetic material. Furthermore, EPS helps to protect 
the microorganisms from external stresses such as heavy metals, antibiotics, and host 
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phagocytic activity (Flemming et al., 2016). Originally, polysaccharides were considered 
ubiquitous and thought to be the key component of biofilm EPS, hence it was often known as 
“exopolysaccharides”. Later on, further investigations demonstrated that there are numerous 
other macromolecules including eDNA, proteins, and lipids present in considerable amounts 
in the biofilm matrix (Flemming and Wingender, 2010, Fleming and Rumbaugh, 2017). The 
heterogeneous composition of biofilm EPS, in addition to the complexity of the mechanisms 
via which the EPS components are produced and act, make it difficult to target bacteria within 
biofilms using traditional antimicrobial agents and disinfection procedures. Therefore, some 
researchers have switched their focus to targeting the EPS of biofilms to interfere with its 
protective functions, and disperse the bacteria which are sheltered within it. In theory, the 
release of bacterial cells from biofilms will enhance their susceptibility to antimicrobial 
treatment and host defence actions. One approach to target extracellular matrices of biofilms 
is through the application of DNase enzymes to degrade eDNA in the matrix (Jakubovics et 
al., 2013, Okshevsky et al., 2015). 
Initially, eDNA was described as a “slime” enclosing bacteria and predisposing to the 
formation of a thin film in broth cultures (Catlin, 1956, Catlin and Cunningham, 1958). This 
eDNA was observed in Staphylococcus aureus broth cultures in spite of the well-known 
ability of S. aureus to synthesize abundant amounts of DNase enzymes. Importantly, 
inhibition of DNase in S. aureus, using low calcium with low pH culture conditions, was 
associated with excess production of eDNA (Catlin and Cunningham, 1958) . The critical role 
of eDNA in maintaining the structural integrity of bacterial biofilms was first described by 
Whitchurch et al. (2002) when they found substantial dispersal of P. aeruginosa biofilms 
treated with DNase I enzyme. These observations have led researchers to focus on 
understanding the structural roles of eDNA with the EPS of biofilms formed by wide range of 
microorganisms. The exact role of eDNA within biofilm is not well-understood. However, 
eDNA appears to have several functions within the extracellular matrix of many bacterial 
biofilms. These include facilitating the initial adhesion of microbial cells, maintaining the 
structural stability of biofilm, promoting the exchange of genetic material, acting as a nutrient 
source, and providing protection against antimicrobial and host defence actions.  
 
1.6.1  Extracellular DNA enhances biofilm formation and structural stability 
As mentioned earlier, the first study that discovered the role of eDNA in supporting 
the structural stability of P. aeruginosa biofilm was performed by Whitchurch et al. using 
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DNase I. Subsequently, several other investigations have confirmed important roles of eDNA 
in enhancing bacterial adhesion and maintaining the structural stability of biofilm using 
DNase enzymes as a tool (Table 1. 1). The amount of eDNA present within biofilm matrix 
varies greatly among different bacterial strains and is not necessarily related to its role in 
maintaining the structural integrity of biofilms (Izano et al., 2008, Mann et al., 2009). 
Importantly, mature biofilms have been shown to be less sensitive to DNase treatment in 
comparison to newly formed biofilms. This finding has been found in biofilms formed by 
different bacterial species such as Staphylococcus epidermidis (susceptibility to DNase 
reduced at 12 hours) (Qin et al., 2007b), P. aeruginosa (after 80 hours) (Whitchurch et al., 
2002), and for Vibrio cholerae (after 72 hours) (Seper et al., 2011b). In contrast, efficient 
disruption of young biofilms as a result of an exogenous addition of DNase suggests that the 
eDNA plays a key role in maintaining the structural stability of newly formed biofilms 
(Fredheim et al., 2009, Harmsen et al., 2010, Nijland et al., 2010, Tetz et al., 2009, Rose et al., 
2015, Ibáñez de Aldecoa et al., 2017). The reasons for the observed reductions in the efficacy 
of DNases against mature biofilms are not well understood. However, the transient sensitivity 
of young biofilms to DNase treatment suggests either that other components of EPS such as 
exopolysaccharides or proteins are replacing or complementing the structural role of eDNA 
within mature biofilms or that eDNA is being protected from the enzymatic degradation of 
DNases by forming complexes with other components of the matrix (Okshevsky et al., 2014, 
Sugimoto et al., 2018, Zetzmann et al., 2015b). Alternatively, eDNA may form duplexes with 
RNA over time. It has recently been shown that eDNA in Pseudomonas spp. biofilms forms 
complexes with RNA including non-canonical base paired structures that contribute to the 
elasticity of the biofilm (Seviour et al., 2019). 
Several studies have investigated the role of eDNA in enhancing bacterial adhesion in 
the early phase of biofilm formation. For instance, in the case of Bacillus cereus, eDNA 
surrounded bacterial cells and enhanced biofilm formation when cells reached the exponential 
phase of growth, whereas these cells did not exhibit the same behaviour during the stationary 
growth phase (Vilain et al., 2009). In contrast, other studies have shown that Bacillus cereus 
and S. pneumoniae produce eDNA in the stationary growth phase (Lorenz et al., 1991, 
Moscoso and Claverys, 2004). This difference may be due to different methods, growth 
conditions and bacterial species used in these studies.  
Furthermore, other studies also have highlighted the important role of eDNA in 
facilitating the initial attachment of S. epidermidis and Acidovorax temporans cells to abiotic 
substrata such as glass or polystyrene and glass wool (Heijstra et al., 2009, Qin et al., 2007a). 
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However, subsequent investigations suggested that eDNA requires other components to 
enhance the early adhesion. This may explain why numerous DNase treated bacterial species 
cannot regain their biofilm formation capability by the exogenous addition of DNA (Lappann 
et al., 2010, Harmsen et al., 2010, Das et al., 2011). Dispersal of Listeria monocytogenes 
biofilms using exogenous DNase I demonstrated that eDNA is necessary for the initial 
attachment of young biofilm. However, in the absence of eDNA, it was shown that the 
addition of genomic DNA could not restore the ability of L. monocytogenes cells to adhere 
and form biofilm in the absence of other essential components, such as N-acetylglucosamine. 
These observations indicate that the interaction of other components with eDNA is necessary 
for eDNA-mediated biofilm formation (Harmsen et al., 2010).   
Indeed, it seems that eDNA enhances early microbial adhesion to the surface and boosts 
cell to cell cohesion in young biofilms. However, the role of eDNA in maintaining the 
structural integrity of mature biofilms and its interaction with other components in the matrix 
requires further investigation.   
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1.6.2 Extracellular DNA provides protection from antimicrobial and host defense action 
Potential mechanisms contributing to the observed increased tolerance of biofilms 
bacteria to antimicrobials were described in section 1.5. Impaired penetration of antibiotics 
through EPS is suggested to be caused by interactions of matrix components such as proteins 
and exopolysaccharide with antibiotics (Flemming and Wingender, 2010). The protective role 
of eDNA against antibiotics and host immune action is linked to its ability to bind and chelate 
host-produced cationic antimicrobial peptides or cationic antimicrobials. For instance, eDNA 
has been shown to bind and inhibit the antimicrobial activity of the antimicrobial host defence 
protein β-defensin-3 (hBD-3) against biofilms formed by non-typeable H. influenzae, a 
pathogen commonly implicated in COME (Jones et al., 2013). Interestingly, exogenous 
addition of both DNase I and recombinant hBD-3 led to substantial decreases in biofilm 
formation and enhanced the antimicrobial action of hBD-3. Similarly, the susceptibility of P. 
aeruginosa  biofilms to aminoglycoside antibiotics was reduced by exogenous addition of 
DNA through the same mechanism (Chiang et al., 2013).  
Numerous other investigations have demonstrated that eDNA can indirectly enhance 
resistance of biofilms to antibiotics  by chelating divalent cations such as Mg+2, Mn+2, Zn+2, 
and Ca+2  which leads to expression of  genes or other virulence factors that modify 
physiological parameters of bacterial cells and make them more tolerant to cationic antibiotics 
and antimicrobial peptides (Johnson et al., 2012, Mulcahy et al., 2008).  Furthermore, 
acidification produced by eDNA within biofilms formed by P. aeruginosa is a stimulus to 
induce resistance against aminoglycosides and antimicrobial peptides (Mulcahy et al., 2008, 
Wilton et al., 2016, Lewenza, 2013). However, eDNA may also have a negative impact on the 
viability of bacterial cells. It has been shown that excess eDNA can significantly affect the 
integrity of bacterial cell membrane by chelating cations such as Mg+2 and Ca+2 and leading to 
bacterial cell lysis (Mulcahy et al., 2008). It is unknown whether excess eDNA will have 
same effect on pathogenic bacteria in vivo.  
Moreover, bacterial eDNA is thought to play a role  in stimulating immune 
inflammatory reactions in the lungs of patients with cystic fibrosis (Lipford et al., 1998).  
Human inflammatory cells, such as macrophages, lymphocytes and dendritic cells identify 
eDNA on the bacterial surface as a foreign antigen. This results in triggering host innate 
immune action by stimulating Toll-like receptors of host immune cells (Pietrocola et al., 
2011, Dapunt et al., 2016). The inflammatory reaction associated with chronic biofilm-
mediated diseases such as COME and CRS may also be attributed to the role of bacterial 
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surface eDNA in triggering the host immune system. Although, eDNA can play a role in 
stimulating host immunity against pathogenic bacteria, bacteria within biofilms can develop 
complex protective strategies against host immune action. A good example is that biofilm 
growth can increase S. aureus resistance to the phagocytic action of host macrophages  
(Thurlow et al., 2011, Herzog et al., 2019). There is mounting evidence that eDNA is a key 
component within biofilm matrix of a wide range of microorganisms, and its critical roles in 
enhancing biofilm formation and maintaining biofilm stability outweigh the disadvantage of 
triggering host immune responses (Jakubovics et al., 2013, Okshevsky et al., 2015). 
 
1.6.3 eDNA origin and turnover 
Extracellular DNA is a ubiquitous structural component with the EPS of biofilms 
formed by many bacteria. Several  studies have investigated the origin (whether plasmid 
DNA, or genomic DNA, or something else) or production of eDNA in bacterial biofilms such 
as L. monocytogenes, P. aeruginosa, and Aspergillus fumigatus (Harmsen et al., 2010, 
Steinberger and Holden, 2005, Allesen-Holm et al., 2006, Rajendran et al., 2013). Most of 
these studies found that eDNA in the biofilm matrix is identical to genomic DNA in mono-
species biofilms. However, in multispecies biofilms, one study found that eDNA within 
biofilm matrix formed by four different species was significantly different from either 
genomic DNA of cells or total DNA of the same multispecies biofilm (Steinberger and 
Holden, 2005). Furthermore, it has been shown that eDNA within biofilms present in the 
sputum of patients with cystic fibrosis mostly originates from the human body (Lethem et al., 
1990, Gray et al., 2018). It was also shown that the presence of some cellular components of 
host neutrophils can serve as biological matrix to enhance biofilm formation by P. aeruginosa 
(Walker et al., 2005). The role of eDNA in enhancing the ability of E. coli to form biofilms 
has been shown to be unrelated to its origin. The exogenous addition of genomic, plasmid, 
and even mammalian DNA to E. coli cultures did not enhance the ability of E. coli to form 
biofilm (Liu et al., 2012). However, further investigations are still required to validate these 
findings. 
Many studies have shown that cell lysis is the main source for the release of eDNA 
into the extracellular compartment. Cells lysis leading to eDNA release in bacterial biofilms is 
mediated by different mechanisms. For instance, in P. aeruginosa and S. pneumoniae, it was 
shown that bacteriophage-mediated lysis constitutes an important source of eDNA for the 
biofilm matrix (Carrolo et al., 2010, Webb et al., 2003). In several species of Streptococcus, 
25 
 
including S. pneumoniae, eDNA production is thought to mediated by production of hydrogen 
peroxide (Regev-Yochay et al., 2006).  Autolysis is the most commonly described mechanism 
of cell lysis, which is similar in some regards to apoptosis or programmed cell death in 
eukaryotes (Rice and Bayles, 2003, Bao et al., 2015, Domenech and Garcia, 2018) . In 
microbial fratricide a proportion of cells in a microbial population trigger the lysis of their 
siblings. The eDNA released from damaged cells enhances biofilm formation and 
coaggregation of the rest of microbial population. Several studies have shown that autolysins 
play a key role in quorum sensing-based cell lysis. Deletion of genes encoding these 
autolysins in S. aureus resulted in mutants lacking biofilm formation capacity (Bao et al., 
2015). Autolysins are surface-attached enzymes that can degrade peptidoglycan. Their roles in 
eDNA production and biofilm formation have been extensively studied in several bacteria  
including  S. epidermidis (Qin et al., 2007b, Wu et al., 2018), S. aureus (Mann et al., 2009, 
Fernández et al., 2017), Neisseria meningitidis (Lappann et al., 2010, Sigurlasdottir et al., 
2019), S. warneri (Yokoi et al., 2008), and S. pneumoniae (Havarstein et al., 2006, Domenech 
and Garcia, 2018).  
Another form of fratricide-mediated cell lysis has been described in E. faecalis 
biofilms, and is linked to protease (gelatinase)-mediated cell lysis involving a minor 
proportion of bacterial cells lacking the quorum sensing and gelatinase production (Thomas et 
al., 2009). Production of gelatinase by the overwhelming predatory population causes 
fratricidal cell lysis of a minority prey subpopulation. Co-expression of an immunity protein 
by the predatory population protects them from the cell lysis activity of their gelatinase. 
Another suggested mechanism leading to eDNA release in bacterial cells is the formation of 
DNA-containing membrane vesicles (Dorward and Garon, 1990, Schooling et al., 2009, 
Grande et al., 2015, Puca et al., 2019) . These vesicles have been demonstrated in 
exponentially growing Acinetobacter baunmannii (Sahu et al., 2012), in single-species 
biofilms of P. aeruginosa, and in mixed-species biofilms of dental plaque (Schooling and 
Beveridge, 2006, Frank, 1970, Holliday et al., 2015). Furthermore, the formation of vesicles 
in Pseudomonas spp. has been associated with increased biofilm formation (Baumgarten et 
al., 2012). It has been shown that these membrane vesicles can fuse to the outer membrane of 
cells in Gram-negative bacteria and attach to the external cell wall of Gram-positive bacteria 
(Domenech and Garcia, 2018).  
A genomic screen of 3,985 non-lethal mutations in  E. coli has shown that the global 
regulator hns gene is required for eDNA production. Deletion of the hns gene was associated 
with a dramatic reduction in eDNA production, but only a mild decrease in cell lysis and a 
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three-fold increase in membrane vesicle production. Therefore, it appears that there is another 
mechanism for eDNA release in E. coli cells lacking hns, possibly the active secretion of 
eDNA from living bacterial cells (Sanchez-Torres et al., 2010). In N. gonorrhoeae, a genetic-
based eDNA releasing system via the type IV secretion system was observed in 80% of 
bacterial cell genomes, and disruption of this secretion system led to a profound reduction in 
eDNA release (Hamilton et al., 2005). Recently, Jurcisek et al. (2017) have shown that eDNA 
and associated DNABII proteins can also be actively released to the extracellular matrix of  
H. influenzae biofilms. These components are translocated from the bacterial cytoplasm to the 
periplasm via an inner-membrane pore complex (TraC and TraG) with homology to the type 
IV secretion system. The exact contribution of each mechanism to the total eDNA present 
within the extracellular matrix still not well understood (Jakubovics et al., 2013). 
Many microbial species have been shown to produce extracellular DNase enzymes that 
are either attached to the bacterial cell wall or released to  the extracellular niche (Jakubovics 
et al., 2013). The secretion of DNases by various bacterial strains seem to be independent of 
their reliance on eDNA during biofilm formation (Shields et al., 2013). The release of 
extracellular DNase enzymes appears to be a common feature for wide range of 
microorganisms, including Cryptococcus neoformans (Almeida et al., 2015), many oral 
bacteria (Palmer et al., 2012, Jakubovics and Burgess, 2015), anaerobic bacteria such as 
Fusobacterium spp. (Porschen and Sonntag, 1974, Doke et al., 2017), S. pneumoniae (Zhu et 
al., 2013, Jhelum et al., 2018), Streptococcus pyogenes (Hasegawa et al., 2010, Chalmers et 
al., 2017), H. influenzae (Cho et al., 2015, Chan et al., 2018), Streptococcus suis  (de Buhr et 
al., 2015), S. aureus (Tang et al., 2011, Herzog et al., 2019),  and P. aeruginosa (Mulcahy et 
al., 2010, Cherny and Sauer, 2019).   
Several functions have been linked to extracellular DNases. For example, many of 
these enzymes have been considered important for bacterial virulence through their ability to 
digest DNA-rich neutrophil extracellular traps (NETs), which are complex networks of DNA 
and extracellular proteins produced by neutrophils as a part of host immune action to kill 
bacteria (de Buhr et al., 2015, Herzog et al., 2019, Jhelum et al., 2018). Thus, DNases are 
particularly important for pathogenic microorganisms to digest NETs and escape their 
potential antimicrobial activity. It has been also shown that the ability of isogenic nuclease-
deficient strains of S. aureus to digest and escape NETs was significantly reduced compared 
to the wild-type parent strain (Berends et al., 2010). Additionally, the efficacy of 
Streptococcus agalactiae NucA to digest NETs was disrupted by substituting alanine with 
histidine at the active site (Derre-Bobillot et al., 2013). 
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Extracellular DNases have been shown to play important roles in regulating microbial 
biofilm formation. For example, in Shewanella oneidensis, deletion of extracellular nuclease 
genes exeM and exeS was associated with a significant increase in biofilm formation and 
eDNA accumulation within the biofilm matrix (Godeke et al., 2011). Similar findings have 
been reported in strains of Vibrio cholerae disrupted in the xds gene encoding extracellular 
DNase (Seper et al., 2011a) and in nuc1 and nuc2- deficient strains of S. aureus (Beenken et 
al., 2012, Kiedrowski et al., 2011). However, other extracellular DNases of Vibrio cholerae 
and S. oneidensis have been shown to have functions other than controlling biofilm formation. 
For instance, disruption of endA affected the ability of S. oneidensis to scavenge eDNA as a 
phosphorus source (Heun et al., 2012b). Extracellular nuclease Dns of V. cholerae has been 
associated with genetic transformation. In addition, extracellular nucleases, Dns and Xds of V. 
cholerae, have been shown to play important roles in the degradation of NETs (Seper et al., 
2013).  Extracellular DNA is considered an important nutrient source for microorganisms in 
hostile environments, and therefore its degradation by extracellular DNases can provide 
nucleotides to be reused by bacteria as a source for phosphorus, carbon, and nitrogen 
(Mulcahy et al., 2010, Pinchuk et al., 2008, McDonough et al., 2016) . Furthermore, eDNA 
digestion by extracellular DNase likely impairs chelation of cations such as Mg+2, and Ca+2 by 
eDNA and  enhances scavenging of these cations by bacterial cells within the biofilm while 
also protecting cells from chelation-mediated lysis (Mulcahy et al., 2010). There is a strong 
association between the roles of extracellular DNases in bacterial nutrient scavenging and 
genetic transformation. Cell wall-associated  nucleases, such as EndA in S. pneumoniae 
(Lacks and Neuberger, 1975, Bergé et al., 2013) have been shown to degrade eDNA into 
single-stranded DNA, which is a substrate for cellular DNA uptake systems involved in 
genetic transformation. Membrane associated  nucleases in S. oneidensis also allow other 
enzymes such as extracellular phosphatases to scavenge DNA as a phosphorous source 
(Mulcahy et al., 2010, Heun et al., 2012a).  
In conclusion, bacterial extracellular nucleases play a potential role in several 
functions including enhancing NETs digestion, using DNA as a nutrient source, regulating 




1.7 Extracellular DNase enzymes as a potential anti-biofilm approach 
Since eDNA is a key structural component within the matrix of many microbial 
biofilms, it is a promising target for biofilm control by DNase enzymes. As previously 
described, DNases are released by wide range of biofilm-forming microbial species that can 
naturally inhibit or eradicate the biofilms of other microorganisms (Rendueles and Ghigo, 
2012). A good illustration of this is the extracellular nuclease NucB, which is released by a 
strain of B. licheniformis isolated from the surface of seaweed. It has been proposed that B. 
licheniformis naturally uses NucB to eradicate the biofilms of its competitors. Interestingly, 
exogenous addition of NucB to pre-established biofilms formed by E. coli, Micrococcus 
luteus and B. subtilis led to almost complete dispersal of these biofilms (Nijland et al., 2010). 
Moreover, the addition of NucB to monospecies in vitro biofilms formed by a wide range of 
bacteria freshly isolated from patients with chronic rhinosinusitis resulted in significant 
disruption of biofilms formed by 50% of these clinical isolates (Shields et al., 2013). 
Extracellular nuclease, Nuc1, of S. aureus has also been shown to disrupt biofilms formed by 
Haemophilus parasuis, Actinobacillus  pleuropneumoniae, and P. aeruginosa (Tang et al., 
2011). Consistent with the critical roles of eDNA in biofilm formation and maintaining the 
structural stability of mature biofilm, the exogenous addition of DNases can potentially 
inhibit biofilm formation, disperse pre-established biofilms, or increase the susceptibility of 
biofilms to antibiotics (Okshevsky et al., 2015). Different species appear to have different 
requirements for eDNA in biofilm formation and stability, and DNases could potentially 
interfere with any of the key functions of eDNA. For example, the DNase could digest eDNA 
associated with the microbial cell wall that serves as an adhesin for initial adhesion of 
microbial cells to biotic or abiotic surfaces. This would inhibit the initial stages of biofilm 
formation. Alternatively, the DNase enzyme could hydrolyse eDNA within the matrix of 
established biofilms, and degrade the adhesive network holiding the biofilm together. This 
would compromise the structural role of eDNA and promote biofilm dispersal. Furthermore, 
DNases have also been shown to enhance the sensitivity of bacteria within established 
biofilms to the killing action by various antibiotics or biocides, possibly by preventing the 
eDNA from sequestering the antibiotics (Kaplan et al., 2012, Tetz et al., 2009). Therefore, the 
ability of these enzymes to degrade eDNA within the matrix of biofilms makes them an 
excellent strategy for biofilm control.   
Different types of DNases have been used as a tool to assess the role of eDNA in 
biofilm development. In vitro biofilms of many bacterial species and fungi have been shown 
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to be sensitive to nucleases when they were included during the early stages of biofilm 
formation or when they were added to pre-established mature biofilms (Table 1. 1). A number 
of studies have investigated the potential clinical application of DNase enzymes in treating 
biofilm-associated human diseases. Exogenous addition of bovine DNase I to dual-species 
biofilms formed by P. aeruginosa and S. aureus resulted in a substantial decrease in biofilm 
thickness (Yang et al., 2011). In addition, B. licheniformis NucB efficiently promoted the 
release of microorganisms from mixed-species biofilms on tracheoesophageal speech valves 
(Shakir et al., 2012). Together these data indicate that DNase enzymes can potentially be 
applied to control clinically relevant polymicrobial biofilms. Furthermore, DNases such as 
recombinant human DNase I (rhDNase I), also known as Dornase alfa, and Varidase ®   have 
been used clinically in treating patients with cystic fibrosis and chronic wound infections, 
respectively, before the structural roles of eDNA in microbial biofilms were discovered. The 
application of inhaled Dornase alfa in patients with cystic fibrosis has been associated with 
increased pulmonary function through reducing the viscosity of DNA-rich bronchial 
secretions (Shak et al., 1990, Yang and Montgomery, 2018). More recently, a study has 
demonstrated that Dornase alfa can be used as an adjuvant therapy to increase the 
susceptibility of pulmonary biofilms to antibiotic therapy (Manzenreiter et al., 2012, 
Frederiksen et al., 2006). Varidase ®, which is a combination of a DNase (streptodornase) and 
a tissue plasminogen activator (streptokinase), has previously been used in vivo to enhance 
wound healing (Smith et al., 2011). However, due to doubts about its purity and its activity, 
Varidase ® has been withdrawn from the market in most countries (Steed, 2004). Dornase alfa 
is clinically being applied as an inhaled mucolytic agent in patients with cystic fibrosis and 
there is some evidence that Dornase alfa efficiently disrupted in vitro biofilms formed by S. 
pneumoniae and S. aureus (Hall-Stoodley et al., 2008, Kaplan et al., 2012). However, data 
confirming its anti-biofilm activity in vivo are scarce. Recently, it has been shown that 
Dornase alfa is potentially non-ototoxic in experimental animal models, and in a clinical trial, 
Dornase alfa showed an ability to unclog tympanostomy tubes in 59% of children with 
clogged tympanostomy tubes. However, this effect was not significantly different when 
compared with the treatment with antibiotics (Chan et al., 2018). One of the critical 
disadvantages of mammalian DNases, such as Dornase alfa, is that they require glycosylation 
for full activity and thermal stability, and therefore, it is difficult to produce them cheaply at 
scale using bacterial expression systems (Fujihara et al., 2008). This significantly increases 
the costs of production and limits potential medical and biotechnological applications. 
Nevertheless, different recombinant DNases including glycosylated mammalian DNase and 
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DNase I have been produced in a modified yeast Picia pastoris expression system which may 
reduce the cost of producing mammalian DNases (Cho et al., 2012).  
 Purified bacterial nucleases such as NucB from a marine strain of B. licheniformis 
(Rajarajan et al., 2013) have been successfully produced in large quantities and have been 
shown to be more effective than bovine DNase I in dispersing and inhibiting monospecies  
bacterial biofilms (Nijland et al., 2010, Shields et al., 2013). Furthermore, the onset of biofilm 
dispersal by NucB was much faster than DNase I. Recently, Basle et al. (2018) analysed the 
biochemical properties of B. licheniformis NucB and determined its crystal structure. This 
study revealed that NucB belongs to a unique subfamily of ββα metal-dependent non-specific 
endonucleases and shares less than 12% amino acid sequence identity with its closest 
structural neighbour (endonucleases of His-Me finger family), such as Smendo, an 
endonuclease from Serratia marcescens. The NucB family of endonucleases is characterised 
by its small size. For example B. licheniformis NucB contains only 110 amino acid residues, 
approximately 50% shorter than the length of the crystallized secreted endonucleases 
from Anabaena and Serratia marcescens, and half the size of the Dornase alfa used for the 
treatment of patients with cystic fibrosis (Horton N.C.Rice PA, 2008). As previously 
described, NucB has shown a potent ability to disrupt bacterial biofilms by degradation of 
eDNA (Nijland et al., 2010). Consistent with this behaviour, it has been shown that NucB is a 
non-specific endonuclease that can hydrolyse both single and double stranded DNA, and 
structurally complex molecules, such as supercoiled plasmid DNA. Both single- and double-
stranded DNA play roles in biofilm formation (Zweig et al., 2014), and therefore it is entirely 
consistent that the non-specific endonuclease activity of NucB will potentially enable the 
enzyme to be effective against different types of DNA in the biofilm matrix (Nijland et al., 
2010, Shakir et al., 2012, Shields et al., 2013, Rostami et al., 2017). Furthermore, NucB has 
been shown to be thermally stable enzyme that can regain significant nuclease activity after a 
heat-inactivation and cooling cycle (Basle et al., 2018). In contrast, Dornase alfa does not 
refold passively after thermal denaturation (Chan et al., 1996). Furthermore, as previously 
described, Dornase alfa requires glycosylation for full activity, thermal stability, and protease 
resistance (Fujihara et al., 2008). No data are currently available about the biological half-life 
(t1/2) of NucB, and approaches to further enhance the  in vivo biocompatibility, activity, and 
stability of NucB are required before it can be used for biofilm-associated health problems. 
Other purified bacterial nucleases include Nuc isolated from Neisseria gonorrhoeae 
(Steichen et al., 2011), and extracellular nuclease, Nuc2, from S. aureus (Kiedrowski et al., 
2014). An important step to increase the potential applications of nucleases is to scale up their 
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cost-effective laboratory production. A B. subtilis protein production system to improve the 
production of B. licheniformis NucB has been described by Rajarajan et al. (2013). 
Another therapeutic potential of DNases is to enhance the susceptibility of bacterial 
biofilms to antibiotics (Hymes et al., 2013, Kaplan et al., 2012, Martins et al., 2012, Tetz et 
al., 2009). For example, degradation of eDNA by exogenous DNases can inhibit the chelating 
activity of DNA against cationic antimicrobials such as aminoglycosides which will increase 
their permeability through the biofilm matrix (Chiang et al., 2013). An alternative approach to 
control biofilms through DNases is to stimulate the production of natural bacterial nucleases 
within the biofilm by targeting control mechanisms of bacteria that are involved in 
suppressing nuclease production. This will stimulate the natural biofilm dispersal systems of 
different biofilm-producing microorganisms, as seen in B. licheniformis and P. aeruginosa 
(Blokesch and Schoolnik, 2008, Kiedrowski et al., 2011, Nijland et al., 2010, Cherny and 
Sauer, 2019) . However, this approach requires a full understanding of the control 
mechanisms for nuclease production in a wide range of bacteria. Moreover, stimulation of the 
endogenous nucleases can also serve a variety of purposes including genetic transformation, 
escaping from NETs, and microbial nutrient scavenging which increase the difficulty of 
establishing a universal regulatory mechanism for a wide range of microbial species relying 




Table 1. 1 Examples of the effects of treatment with exogenous DNases on microbial 









DNase enzyme Reference 
Gram-negative bacteria   
  
Acinetobacter baumannii ✓ ✓ 
DNase I (Tetz et al., 2009) 
(Sahu et al., 2012) 
Actinobacillus 
actinomycetemcomitans 
 ✓ DNase I 
 
(Inoue et al., 2003) 
Bdellovibrio bacteriovorus ✓ ✓ DNase I (Medina and Kadouri, 2009) 
Bordetella pertussis  ✓ ✓ DNase I (Conover et al., 2011) 
Bordetella bronchiseptica  ✓ ✓ DNase I (Conover et al., 2011) 
Campylobacter jejuni   ✓  DNase I (Svensson et al., 2009) 
Comamonas denitrificans  ✓  DNase I (Andersson et al., 2009) 
Escherichia coli ✓ ✓ DNase I, NucB (Nijland et al., 2010, Tetz 
and Tetz, 2010) 
Haemophilus influenzae  
 
✓ ✓ DNase I (Izano et al., 2009) 
Klebsiella pneumonia 
 
 ✓ DNase I 
 
(Tetz et al., 2009) 
Neisseria meningitides  
 
✓  DNase I (Lappann et al., 2010) 
Pseudomonas aeruginosa  
 
✓ ✓ DNase I, DNase 
1L2, DNase 
EndA 
(Eckhart et al., 2007, 
Whitchurch et al., 2002, 
Cherny and Sauer, 2019) 
Shewanella oneidensis 
 
✓  DNase I (Godeke et al., 2011) 
Vibrio cholera  
 
✓ ✓ Nuclease Dns 
and Xds 
(Seper et al., 2011a) 
Gram-positive bacteria 
 
    
Bacillus licheniformis  ✓ NucB (Nijland et al., 2010) 
Bacillus subtilis   ✓ NucB (Nijland et al., 2010) 
Enterococcus faecalis   ✓ DNase I (Thomas et al., 2008, Torelli 
et al., 2017) 
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Listeria monocytogenes  ✓ ✓ 
DNase I (Harmsen et al., 2010, 
Zetzmann et al., 2015a) 
Micrococcus luteus   ✓ 
NucB (Nijland et al., 2010) 
Staphylococcus aureus  
✓ ✓ rhDNase I, 
NucB, DNase 
I 
(Kaplan et al., 2012, 
Shields et al., 2013, 
Sugimoto et al., 2018) 
Staphylococcus epidermidis   NucB (Shields et al., 2013) 
Staphylococcus haemolyticus    DNase I (Fredheim et al., 2009) 
Streptococcus anginosus  ✓ NucB (Shields et al., 2013) 
Streptococcus constellatus   ✓ NucB (Shields et al., 2013) 
Streptococcus salivarius   ✓ NucB (Shields et al., 2013) 
Staphylococcus lugdunesis   ✓ NucB (Shields et al., 2013) 
Streptococcus intermedius   ✓ NucB (Shields et al., 2013) 
Streptococcus intermedius  ✓  DNase I (Petersen et al., 2004) 
Streptococcus mutans  ✓  DNase I (Petersen et al., 2005) 
Streptococcus pneumonae  ✓ rhDNase I (Hall-Stoodley et al., 
2008) 
Streptococcus pyogenes   ✓ DNase I (Tetz et al., 2009) 
Fungi 
 
    
Aspergillus fumigatus   ✓ DNase I (Rajendran et al., 2013) 
Candida albicans ✓ ✓ 
DNase I (Martins et al., 2010, 




1.8 Human microbiome and its clinical significance 
The full range of microorganisms that live on or inside the human body is called the 
microbiota, whereas, human microbiome comprises the overall collection of microbial 
genomes that contribute to the wider genetic profile or metagenome of a human body(Rogers, 
2016). Recent analysis has shown that the number of microbial cells in the body is roughly of 
the same order as the number of human cells and their overall mass is approximately 0.2 Kg 
(Sender et al., 2016). Increasing evidence indicates that the composition of the human 
microbial population has an important contribution to human health and certain disease 
conditions (Janssens et al., 2018). Microbial communities play a number of key roles in 
human health. For example, gut microbiota were initially thought to have a role mainly in 
preventing overgrowth of pathogenic bacteria within gastrointestinal tract, however, there is 
increasing evidence indicating that gut microbiota play important roles in digestion, 
inflammation, maintaining intestinal integrity, modify the host immune response, and 
affecting the health status of human body(Mueller et al., 2015, Rowland et al., 2018).  
Human microbiome analysis has been revolutionized by the advanced culture-
independent molecular-based methods such as Illumina ® and Roche/454 pyrosequencing 
platforms that can employ complete or partial high throughput bacterial 16S or fungal 18S 
ribosomal RNA (rRNA) gene sequencing to characterise the microbial communities 
colonising different anatomical sites of the human body at a level of detail that far exceeds 
previous culture-dependent or other targeted-molecular based methods (Huttenhower et al., 
2012, Pollock et al., 2018). The 16S rRNA gene is a universal gene among all bacteria that 
contains both conserved and hypervariable genetic regions, which can be employed for 
phylogenetic classification to the species level of many complex bacterial communities. The 
eukaryotic equivalent of the 16S rRNA is the 18S rRNA, and this has been commonly used 
for fungal population analysis (Begerow et al., 2010, Johnson et al., 2019). Various internal 
transcribed spacer regions are becoming more commonly used for fungal (mycobiome) 
analysis than 18S rRNA sequencing (McTaggart et al., 2019).   
There are many advantages that favour the use of 16S rRNA (or 18S rRNA) gene next 
generation sequencing in microbiome analysis. Firstly, this method involves simultaneous 
targeted sequencing of a short region of DNA for numerous samples, therefore it is much 
cheaper than classical Sanger sequencing. Furthermore, this method can provide important 
species level information about microbial communities that may harbour a high proportion of 
fastidious and difficult to culture microorganisms without the need for cultivation (Ranjan et 
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al., 2016). Finally, culture-independent methods are also superior to culturing for microbes 
residing in biofilms (Swearingen et al., 2016). 
Human Microbiome Project (HMP), which commenced in 2007 and was run by the 
National Institute of Health, is the most well-known microbiome survey in healthy humans 
(Turnbaugh et al., 2007).The HMP conducted by Huttenhower et al. (2012) aimed to 
characterise the ecology of human-associated microbial communities of 242 healthy young 
western individuals in five different anatomical regions (skin, nose, oral cavity, 
gastrointestinal tract (GIT), and vagina), and to determine site-specific environmental factors 
that may influence the composition of gut microbiome. Samples were collected from 18 body 
habitats in women and 15 in men (excluding three vaginal sites), distributed among five major 
anatomical regions which were mentioned above.   
The HMP has shown that the microbiome in healthy young adults is individual- 
specific and site-specific over time. Interestingly, each anatomical site was dominated by a 
single or a small number of certain microbial taxa almost in all studied individuals. For 
example, in the GIT, Firmicutes and Bacteroides were the most abundant families, while, 
Proteobacteria and Actinobacteria were more abundant in skin. These differences in the 
microbial abundance support the notion of microbiome involvement in the physiological and 
molecular processes that are specific to the human body system (Huttenhower et al., 2012). 
Whilst the HMP focussed on health, many studies have investigated links between 
shifts in the microbiome at specific body sites (‘dysbiosis’) and different diseases. There have 
been so many of these studies, that a database has been created to catalogue the associations 
(Janssens et al., 2018). Association surveys have provided evidence that alteration of the 
microbiota composition can be associated with a variety of local (including recurrent 
Clostridium difficile infections, Crohn’s disease, ulcerative colitis, necrotizing enterocolitis, 
irritable bowel syndrome) and systemic diseases (diabetes mellitus, obesity, malignancy, 
bacterial vaginosis, autism and coronary heart diseases).   
In recent years a number of culture-independent studies have investigated the 
microbiome in various regions of the head and neck in health and disease. These culture-
independent analyses would be of particular importance in understanding the role of bacteria 
and biofilms in aetiopathogenesis of chronic head and neck diseases including COME and 
CRS. Ultimately, this will greatly assist in treating these diseases effectively.  
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1.9 Microbiome of middle ear and pharynx 
An early comparative microbiome study of the oropharynx and nares in seven 
individuals using 16S rRNA gene and PhyloChip sequencing analysis found that the 
oropharynx houses a much more diverse microbiota than the nose (Lemon et al., 2010). At the 
phylum level, Firmicutes were the most dominant microbes in both anatomical sites, whereas 
Staphylococcaceae and Lachnospiraceae were most abundant bacterial families in nostrils, 
and Streptococcaceae, Lachnospiraceae and an unclassified group of Clostridia were most 
dominant families in the oropharynx.  
Recently, a population-based microbiome study has analysed anterior nasal and 
oropharyngeal swabs collected from 524 participants using 16S rRNA gene sequencing 
techniques (Akmatov et al., 2017). Again, oropharyngeal microbial communities have shown 
higher species richness and diversity than the anterior nasal communities. The most dominant 
phyla in the anterior nose were Actinobacteria, Firmicutes, and Proteobacteria. 
Corynebacterium accolens/segmentosum, Propionibacterium acnes, Staphylococcus 
epidermidis, and Staphylococcus aureus were the most abundant bacterial species within 
anterior nasal communities, which collectively formed an average abundance of 47%.  In 
contrast, oropharyngeal communities were dominated by a variety of bacterial species 
(Leptotrichia sp., Fusobacterium periodonticum, Streptococcus salivarius/vestibularis, 
Veillonella atypical, Prevotella melaninogenica and Prevotella histicola) that were detected at 
an average abundance of only 3.3-5.1%. Despite the anatomical relation between the nose and 
oropharynx, these findings support the concept that each body site has its own unique 
microbiome  
As noted in section 1.3.1, the ascension of bacteria from the adenoids to the middle ear 
through the ET is thought to be important factor in the pathogenesis of AOM and COME. The 
adenoids are submucosal mass of lymphoid tissue located at the nasopharynx adjacent to the 
opening of the ET. The mucosal surface of the adenoids shows numerous depressions called 
crypts and elevations called folds which are known to house a diverse normal bacterial flora 
(Winther et al., 2009). Although adenoids are thought to play an important role in the 
pathogenesis of COME by acting as a reservoir for otopathogens, it has proved difficult to 
characterise the microbial population in enough detail to demonstrate clearly whether it is the 
primary source of bacteria that reach the middle ear space. Early surveys used traditional 
culture-based assays, which are relatively insensitive for identifying the total population of 
microorganisms, particularly fastidious, uncultivable microbes and bacteria residing in 
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biofilms (Swidsinski et al., 2007). Therefore, these studies potentially delivered partial or 
biased characterisation of the composition of the microbial communities colonising these 
anatomical niches (Ren et al., 2013). 
When the work on this project started, there were only two published studies that had 
utilised culture-independent techniques to characterise microbial communities present in the 
middle ear effusion and adenoids of COME patients (Liu et al., 2011, Stol et al., 2013). Stol et 
al. (2013) obtained microbial community profiles of nasopharyngeal swabs and middle ear 
effusion samples from patients with rAOM and those with COME using quantitative real-time 
PCR analysis. In both groups of patients, H. influenzae and rhinovirus were the most 
abundant microbial pathogens in nasopharyngeal and middle ear effusion samples, and the 
abundance of microorganisms in the middle ear effusions of these patients was not 
significantly different. This PCR-based study was targeted to three common otopathogens (S. 
pneumoniae, H. influenzae, and M. catarrhalis) and 15 different viruses, and therefore it is 
not clear which other species were present. 
Liu et al. (2011) analysed the microbiome in middle ear effusion, adenoid and tonsil 
samples recovered from a child with COME using 16S rRNA gene-based pyrosequencing. 
Pseudomonadaceae was the most abundant microbial family in the MEEF sample. Families 
of the three major otopathogens: Streptococcaceae, Pastuerellaceae (Haemophilus) and 
Moraxellaceae were also detected. There was a difference in the microbial communities in the 
three set of samples and the results indicated that the adenoid may be a potential source for 
both the middle ear and tonsil microbiota. However, differentiation at genus or species level 
and relative abundance of microorganisms were not reported. Furthermore, this study was 
restricted to samples from a single patient and its findings cannot be generalized until 
reproduced in a larger study population.  
During the course of this project, several studies utilising culture-independent 16S 
rRNA gene sequencing methods to characterise the members of the microbiota associated 
with MEEF, adenoid, nasopharynx of COME children, were published and these are 
summarised in Table 1. 2. 
The three common otopathogens were the most frequently detected genera in the 
MEEFs of children with COME; however, Alloiococcus otitis was the most predominant 
bacterial species in several microbiome studies (Ari et al., 2019, Boers et al., 2018, Chan et 
al., 2017a, Chan et al., 2016, Jervis-Bardy et al., 2015). A. otitis was not frequently cultured 
from the MEEFs before the widespread utilisation of PCR due to its fastidious growth 
requirements. However, since the use of culture-independent methods including 16S rRNA 
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gene sequencing, it has been shown to be the most abundant organism detected in MEEFs of 
children with COME, but not in those with AOM (see Table 1. 3). Turicella otitidis has also 
been reported as a dominant bacteria within middle ear microbiota of children with COME 
(Ari et al., 2019, Boers et al., 2018, Krueger et al., 2017).  
The roles of adenoids or the nasopharynx as a reservoir for bacterial pathogens 
implicated in the pathogenesis of COME and AOM has been investigated in several studies 
which are summarised in Table 1. 2 and Table 1. 3. Differences in the cohort of patients 
studied, methods of DNA extraction, the region of 16S rRNA gene sequenced, and 
bioinformatics analysis pipelines can make the comparison of these microbiome studies 
difficult. However, there are some common patterns in what have been found. Overall, it has 
been demonstrated that the nose and nasopharynx of children with otitis media are more 
commonly colonised by the three major otopathogens compared with healthy controls, 
supporting the hypothesis that otopathogen colonisation of the nasopharynx is an important 
risk factor for the development of otitis media. Some of these microbiome studies have also 
observed that commensal genera, particularly Corynebacterium and Dolosigranulum, are 
more prevalent in the nose or nasopharynx of healthy children than children with otitis media 
(Pettigrew et al., 2012a, Man et al., 2019). These observations suggest that an imbalance in 
the composition of the nasopharyngeal microbiota as a result of the arrival of new pathogens, 
concomitant viral infection or other factors such as antibiotic treatment or exposure to 
cigarettes smoke, could be critical for otitis media. These microbiome studies have also 
observed that the microbial profiles of the nose or nasopharynx in children with otitis media 
are less diverse than those of healthy controls, and that the microbiome of the nasopharynx is 
more diverse than that of MEEFs (Jervis-Bardy et al., 2015, Man et al., 2019). 
 An important challenge in microbiome studies involving low microbial biomass 
clinical samples such as MEEFs of patients with COME, is contamination with DNA from 
exogeneous sources such as nucleic acid extraction kits, laboratory reagents or the skin of 
people handling the samples. This contaminating DNA can obscure the signal from the 
bacterial population present in these samples during the sequencing process (Salter et al., 
2014, Eisenhofer et al., 2019). Thus, it is of particular importance to include negative 
sequencing controls concurrently with samples for low biomass microbiome analyses. There 
are also several challenges in the analysis of 16S rRNA gene sequencing data. Techniques 
have been developed to uncover hidden biases in sequencing, annotation, and bioinformatics 
analysis to overcome these limitations (Tripathi et al., 2016, Eisenhofer et al., 2019). 
39 
 
Even the best currently available methods for culture-independent microbiome analysis 
have a number of limitations. One key issue is that the identification of microbial DNA 
sequences does not necessarily indicate the presence of viable bacteria. For detection of viable 
bacteria, it is necessary to employ improved culture techniques or use RNA analysis methods 
to identify short-lived microbial transcripts in clinical samples (Wolk, 2016). Therefore, in 
order to provide a robust characterisation of complex microbial communities such as those 
present in MEEFs and adenoids of patients with COME, it is necessary to employ a 
combination of culture-based and culture-independent techniques. A “microbial culturomics” 
approach has been developed by incorporating the use of several culture conditions and mass 
spectroscopy microbial identification with the culture-independent molecular methods that 
enabled species-level identification of rare and new microorganisms of gut microbiota (Lagier 
et al., 2012). The key goal of this project was to characterise both the culturable and the total 
population of microorganisms in MEEFs and adenoids of patients with COME in the North 
East of England. This would then provide insights and isolates that could be employed to 




Table 1. 2 Studies utilising culture-independent 16S rRNA gene sequencing methods to characterise microbiome of middle ear effusions, 
adenoids and/or nasopharynx in children with COME.  
Microbiome study Type of sample Age of 
patients 
Number and type of 
cases 
Controls* Key findings 
Jervis-Bardy et al. 
(2015) 
MEEF, adenoid and 
nasopharyngeal swabs 
3-9 y 11 indigenous 
Australian children 
with COME 
NA ● MEEFs were dominated by A. 
otitis, followed by H. influenzae. 
● A. otitis not detected in 
nasopharynx or adenoid. 
● Microbiomes of MEEFs were less 
diverse than that of nasopharynx.  






forms of surgery  
● MEEFs were dominated by A. 
otitis, followed by H. influenzae. 
● A. otitis almost absent from 
adenoid. 
● Microbiomes of adenoids were 
similar in patients and controls, 
microbiomes of MEEFs and adenoids 
in patients were dissimilar. 
Chan et al. (2017b) MEEF, external ear 
canal (EEC) lavages 
1-14 y 18 children with 
COME 
NA ● MEEFs were dominated by A. 
otitis, followed by H. influenzae. 
● EEC dominated by A. otitis and 
Staphylococcus. Otopathogens were 
rare in EEC. 
● Both adenoid and EEC may act as 





Table 1.1 (continued) 
Microbiome 
study 
Type of sample Age of 
patients 
Number and type 
of cases 
Controls* Key findings 
Krueger et al. 
(2017) 
MEEF 3 m-14.6 
y 
55 children with 
COME 
NA ● MEEFs were dominated by Haemophilus followed by 
Moraxella and Turicella 
● Higher abundance of Turicella in children aged 
>24months, less abundant in children with hearing loss. 
● Haemophilus associated with increased mucin 
production.    









21 children with 
OM only 
● MEEFs were dominated by Alloiococcus and Turicella 
● Gastroesophageal reflux had no obvious impact on 
middle ear and nasopharyngeal microbiomes  




1.5-9 y 25 children with 
OME 
NA ● MEEFs were dominated by Alloiococcus, followed by 
Turicella 
● Abundance of predominant bacteria was significantly 
different between MEEFs and adenoids microbiome  
Johnston et al. 
(2019) 
MEEF, adenoid 
and tonsil swabs 
3 m-14.6 
y 
50 children with 
COME 
NA ● Fusobacterium, Haemophilus, Neisseria, and 
Porphyromonas were most abundant genera in all sites. 
● Haemophilus and Moraxella were most abundant in 
adenoid than in MEEFs. 
● Tonsil and adenoid microbiomes similar to one 
another, adenoid and MEEF microbiomes less similar. 
Kolbe et al. 
(2019) 
MEEF 3 m-14.6 
y 
50 children with 
COME (13 with 
lower respiratory 
illness and 37 
without) 
NA ● Haemophilus, Moraxella, and Turicella were most 
abundant genera. MEEF microbiome less diverse in 
COME patients with lower respiratory illness than in 
patients without. 




Table 1. 3 Studies utilising culture-independent 16S rRNA gene sequencing methods to characterise microbiome of middle ear and/or 
nasopharynx in patients with AOM.  
Microbiome study Type of sample Age of 
patients 
Number and type 
of cases 
Controls* Key findings 








but with URTI 
and 73 healthy 
controls 
● Colonisation with otopathogens associated 
with lower diversity of URT commensals 
● High abundance of Lactococcus, 
Propionibacterium, Corynebacterium and 
Dolosigranulum less likely to develop AOM.  
Sillanpää et al. 
(2017) 
MEEF 5 m-3.5 y 79 children with 
AOM 
NA ● S. pneumoniae most dominant bacteria 
● A. otitis, T. otitidis and Staphylococcus 
auricularis detected less frequently than classical 
otopathogens.  
● No novel pathogens were detected. 








● Colonisation of otopathogens positively 
associated with higher URTI frequencies  
● High abundance of Staphylococcus and 
Sphingobium associated with reduced risk of 
AOM complicating URTI 
● Abundance of Corynebacterium reduced in 
AOM but had no effect on UTRI/AOM 
progression.  





< 5 y 94 children with 
AOM and 
tympanostomy tubes 
NA ● Paired nasopharynx and MEF greatly 
correlated  
● Microbiome of nasopharynx much more 
diverse than that of MEF 
● Abundance of Corynebacterium and 
Dolosigranulum associated with shorter duration 
of otorrhoea   
*NA= not applicable; URTI= upper respiratory tract infection.
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1.10 Aim and objectives of the study 
       Evidence from previously published studies points to a clear deficiency in the 
current treatment of COME. Many clinical criteria for the diagnosis of COME are consistent 
with biofilm infections. The complex microbial community associated with COME is not well 
understood and there is pressing need to develop novel therapeutic approaches to improve 
treatment outcomes of this disease. The main aim of this thesis was to investigate the potential 
of the bacterial nuclease, NucB from Bacillus licheniformis, to improve the diagnosis and/or 
management of COME.    
The objectives of the study were as follows: 
1. To optimise methods for quantification of biofilm formation and to evaluate the 
potential of NucB for biofilm control.  
2. To characterise and isolate bacterial population present in MEEFs and adenoids of 
patients with COME by a combination of culturing and 16S rRNA gene sequencing. 
3. To study the sensitivity of in vitro biofilms formed by representative COME isolates 







Chapter 2. Materials and Methods 
2.1 Reagents and equipment 
2.1.1 Reagents  
Reagents are described in the text with their manufacturers and are abbreviated 
subsequently if needed. 
2.1.2 List of equipment used in the study 












Sigma Centrifuges, Osterode am 
Harz, Germany. 
Beckman Coulter Ltd., High 
Wycombe, UK 
Bench-top Centrifugation MiniSpin® Eppendorf UK Ltd., Stevenage, UK 
Static Incubator 30°C /37°C LTE Scientific Ltd., Oldham, UK 
Anaerobic Incubator 
 
Bug Box Plus Ruskinn Technology Ltd., 
Bridgend,UK 
Incubation Water bath Grant instruments, Cambridge, UK 









NanoDrop® ND-1000 Thermo Fisher Scientific Ltd, 
Loughborough, UK 
Measuring optical density Libra S11 Biochrom Ltd., Cambridge, UK 
Light/ Phase contrast 
Microscopy 
Leica DM 750 Leica Biosystems Newcastle Ltd, 
Newcastle upon Tyne, UK 
Fluorescence microscopy Eclipse Ti-E Nikon, Surrey, UK. 






Nikon, Surrey, UK. 
Bead beater Tissuelyzer LT Qiagen, Manchester, UK 






2.2 Ethical approval  
Ethical approval for this project was sought from the NHS National Research Ethics 
Service Committee (North East Newcastle and North Tyneside 2). Initially an online 
application was prepared via the Integrated Research Application System (IRAS) and 
submitted to the Research Ethics Service Committee electronically. The application form and 
the supporting documents of the study were prepared by me with regular review and editing 
by the supervisors. These documents included the research protocol (Appendix A), five age-
specific participant information sheets (Appendix B) (for parents/carers, for younger children 
aged 3-6 years, children aged 6-11 years, young persons aged 12-15 years, and young persons 
aged 16 years), two participant consent forms (for parents/carers, and for younger persons 
aged 16 years), two age-specific assent forms (children aged 6-11 years, and young persons 
aged 12-15 years) (Appendix C), and in addition to other documents including research 
project insurance (Appendix D), letter of sponsorship review (Appendix E), and a letter from 
the project funder (Appendix F). All documents that were submitted to Research ethic 
committee (REC) are listed in the REC checklist (Appendix G).  
Two rounds of amendments and revisions were required by NHS Research Ethics 
Service Committee (North East- Newcastle and North Tyneside 2) before ethical approval 
was granted for this study (no.15/NE/0225) titled “Investigation of biofilms associated with 
chronic otitis media with effusion and adenoids hypertrophy” (Appendix H (1)). Prior to the 
start of the study, it was necessary to obtain management permission or approval from all 
NHS organisations involved in this study in accordance with NHS research governance 
arrangements. Therefore, another application was submitted to the NHS host organisation 
(Newcastle upon Tyne Hospitals NHS Foundation Trust Research and Development) to 
obtain their management approval. This application also involved completing the relevant 
online application forms such as NHS Research and Development (R&D) form and NHS site 
specific information (SSI) form from IRAS and providing the supporting documentation 
listed in R&D valid submission checklist (see Appendix I). A full Newcastle upon Tyne 
Hospitals NHS Foundation Trust R&D approval (no. 7514) for the present study was obtained 
(Appendix H (2)) and patient recruitment was started. 
The recruitment target of this project for the middle ear effusion samples of patients 
with COME was at least 60, whereas the sample size for adenoids tissue was 60 in total 




During the collection of clinical samples, I approached patients fulfilling inclusion 
criteria of the study and their parents/carers on the surgery day. Relevant information about 
the aims of the research project, methodology, and potential outcomes were explained to 
patients and their parents/carers in simple language. Parents and patients were given plenty of 
time to read the study participant information sheet. Any questions or concerns from the 
patients or their parents were answered by me. Parents/carers and patients who agreed to 
participate in the study were asked to sign the relevant consent form prior to enrolment in the 
study. 
2.3 Sample collection   
2.3.1 Middle ear effusion fluids 
A total of 59 middle ear effusion fluid (MEEF) samples were collected from 34 
patients aged less than 16 years, who were recruited in the Freeman and Royal Victoria 
Infirmary Hospitals, Newcastle upon Tyne, during the period between November 2015 and 
December 2016. Patients were listed for myringotomy and grommet tube insertion according 
to the standard clinical practice, for the treatment of persistent symptomatic COME for at 
least 3 months duration. Patients with previous history of grommet insertion, middle ear 
surgery, congenital craniofacial malformations, recurrent AOM, or those who did not have 
any visible MEEF in both ears during the operation were excluded from the study. Detailed 
instructions for the collection of samples were given to the operating surgeon to minimise the 
risk of contaminating MEEF samples by external ear canal flora. During the operation, wax 
and other debris was atraumatically removed from the ear canal using crocodile forceps or a 
separate suction catheter. Myringotomy (a small surgical incision in the eardrum) was 
performed using standard aseptic technique without prior ear canal sterilisation, and the 
MEEF aspirated through the myringotomy using a sterile suction catheter. Stringent 
precautions were taken to avoid contact with the external ear canal, and a new sterile set of 
suction catheter was used to aspirate MEEF from each ear. The MEEF was collected into a 
sterile mucous trap by aspiration of 2 ml of 0.9% saline solution through the suction catheter 







2.3.2 Adenoid tissue  
A total of 10 adenoid tissue specimens were collected from patients who were listed 
for either adenoidectomy plus grommet tube insertion (5/10), or adenotonsilectomy (5/10) 
according to standard clinical practice, for the treatment of persistent symptomatic COME of 
at least 3 months duration, or obstructive sleep apnea, respectively. Adenoidectomy was 
performed using the standard curette technique. The surgically removed adenoids tissue was 
immediately placed into a sterile collection tube containing 20 ml of a sterile reduced 
transport fluid (RTF) (Syed and Loesche, 1972). RTF contained per litre the following 
mineral salt mix (0.6 g K2HPO4, 1.2 g NaCl, 1.2 g (NH4)2SO4, 0.6 g KH2PO4 and 0.25 g 
MgSO4), 0.1 M EDTA, 8 g Na2CO3 and 1 g dithiothreitol. Specimens were transported on ice 
to the Oral Microbiology laboratory, Newcastle University and stored at -20°C. All specimens 
were processed within 24 h.  
2.3.3 Processing of middle ear effusion fluid samples 
MEEF samples were divided into 3 equal portions using a pipette and 50 μl portions 
were inoculated on each blood, chocolate, and Fastidious anaerobe agar (FAA) agar plates 
(see section ). Pipetting was not possible for some very thick tenacious mucoid MEEF 
samples (see Figure 2. 1). In these cases, the sample was placed in a sterile petri dish and 
divided by surgical scalpel and a pipette into 3 equal portions, in the biological safety cabinet. 
The first portion of the sample was treated with NucB (see section 2.8.3), Recombinant NucB 
from B. licheniformis DSM13 was produced and purified as described in section 2.6.4. The 
second portion of the sample was used as a negative control (incubation control) for NucB 
treated portion (section 2.8.3). The last portion of MEEF underwent microbial DNA 
extraction for 16S rRNA gene sequencing (see section 2.6.1). 
2.3.4 Processing of adenoid tissue samples  
Adenoid tissue samples were thawed on ice. After thawing, 300-500 mg of tissue for 
each sample was transferred to a sterile petri dish and diced with a sterile surgical scalpel in 
the biological safety cabinet. This was transferred to a 2 ml disposable tube containing 0.5 ml 
of sterile phosphate buffer saline (PBS) and homogenized for 2 min using a cordless plastic 
pistol motor (Sigma Aldrich, UK). An additional 1 ml of PBS was added to the homogenate, 
vortexed briefly at high speed and filtered through a 40 µm cell culture strainer to dissociate 
cells from tissue clumps. The residual tissue from the filtration was washed three times with 1 
ml PBS and filtered again. In selected samples, the filtered tissue homogenate was divided 
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into 2 equal portions using a pipette. The first portion was used to culture and isolate bacteria 
present in adenoid samples (see section 2.4.3). Microbial DNA was extracted from the second 




Figure 2. 1 A photograph of Middle ear effusion sample. 
Shows yellowish orange coloured thick tenacious middle ear effusion fluid (21R) from patient 
number 21 placed in a sterile petri dish (47 mm in diameter) in a Class I biological safety 




2.4 Microbiological methods 
2.4.1 Culture media and chemicals  
All growth media (broth or agar) were sterilised by autoclaving at 121˚C for 20 min. 
For the solidified media, 15 g/L of agar granules (Melford Laboratories Ltd, Suffolk, UK) 
were included prior to autoclaving. All growth media containing agar were allowed to cool in 
water bath at 45-50˚C before being poured into petri dishes. Chemicals were purchased from 
Sigma Aldrich, Dorset, UK unless stated otherwise. 
Brain heart infusion with yeast extract (BHYE) was prepared by dissolving 37 g brain 
heart infusion (Melford, Suffolk, UK), and 5 g yeast extract (Melford, Suffolk, UK) in 1 L of 
distilled water (dH2O). 
Blood agar contained 5% (v/v) defibrinated horse blood (TCS Biosciences, 
Buckingham, UK) in pre-cooled BHYE agar. 
Chocolate agar was prepared using the same ingredients as blood agar except that, 
following the addition of defibrinated horse blood, the medium was incubated in a water bath 
at 75-80˚C for 10-15 min until it turned a chocolate brown colour. 
Fastidious anaerobe agar (FAA) was prepared by mixing 46 g of fastidious anaerobe 
broth (Lab-M, Lancashire, UK) and 15 g of agar granules in 1 L of dH2O. Following 
autoclaving, 5% (v/v) defibrinated horse blood was added to the pre-cooled medium before 
being poured into petri dishes. 
Tryptone soya broth (TSB) was used as a rich nutrient medium to culture 
Staphylococcus aureus strains. This was prepared by dissolving 30 g Trypto soya broth 
powder (Melford, Suffolk, UK) in one litre of dH2O and autoclaved as described above. 
Cation adjusted Mueller Hinton broth (CAMHB) was used for testing antibiotic 
sensitivity of both planktonic and biofilm cultures of Staphylococcus aureus. The medium 
was prepared by adding 17.3 g Casein acid hydrolysate (Oxoid, Hampshire, UK), 3 g Beef 
extract (Lab-Lemco broth, Oxoid, Hampshire, UK) and 1.5 g Soluble Starch to 1 L of dH2O. 
The mixture was dissolved completely by heating in an oven at 70°C and, after cooling, the 
pH was adjusted to 7.3 +/- 0.2 before being autoclaved for sterilisation. Prior to use, Mg+2 
stock solution (prepared by dissolving 8.36 g of MgCl2•6H2O in 100 ml of dH2O; the final 
concentration is 10 mg ml-1 Mg+2) was added to a final concentration of 10 mg L-1 Mg+2. 
Calcium stock solution (prepared by dissolving 3.68 g of CaCl2 •2H2O in 100 ml of dH2O; the 
final concentration is 10 mg ml-1 Ca+2) was also added to a final concentration of 20 mg L-1 
Ca+2.   
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Tryptone yeast extract glucose (TYEG) is an enriched growth medium used to culture 
streptococci and Actinomyces odontolyticus. TYEG was prepared by adding 10 g Bacto 
tryptone (Melford, UK), 5 g Yeast extract (Melford, UK), 3 g K2HPO4 (VWR International 
BVBA, Leuven, Belgium) and 2 g of glucose (Sigma, UK) to 1L of dH2O. The pH was 
adjusted to 7.5 before autoclaving.   
Todd Hewitt Yeast Extract (THYE) is a non-selective medium that was prepared by 
mixing 37 g of Todd Hewitt (Melford, UK) with 5 g of Yeast Extract (Melford, UK) per L of 
dH2O before autoclaving. 
Supplemented BHYE medium was used to culture Haemophilus influenzae strains. It 
was prepared by adding 1% (v/v) of Difco™ Supplement VX (Becton, Dickinson and 
Company, Sparks, USA) to pre-cooled sterile BHYE broth or agar.  
2.4.2 Culture and isolation of chronic otitis media with effusion microbial population   
To culture and isolate the microbial population present in MEEF samples, each sample 
was gently mixed and 50 μl was plated on blood agar, chocolate agar, and FAA in duplicate. 
Blood and chocolate agar plates were incubated at 37˚C with 5% CO2 for 10-14 days and the 
cultures were checked for growth daily. Pre-reduced FAA plates were incubated anaerobically 
(Bug Box Plus, Ruskinn, Bridgend,UK) under a mixture of gases consisting of 10% CO2, 
10% H2 and 80% N2  for 7-14 days. The cultures were read at >40 hr, at 5 day, and at 14 day.  
2.4.3 Culture and isolation of adenoid microbial population 
Selected samples of adenoid tissue were cultured in an attempt to isolate and identify 
bacteria colonising paired adenoid and MEEF samples collected from the same patients. Ten 
microlitres of the filtered adenoid tissue homogenate was plated on non-selective blood agar, 
chocolate agar, and FAA in duplicate. Blood and chocolate agar plates were incubated at 37˚C 
with 5% CO2 for up to 7 days and the cultures were checked for growth daily. Pre-reduced 
FAA plates were incubated anaerobically under a mixture of gases consisting of 10% CO2, 
10% H2 and 80% N2 for 7-14 days. The cultures were read at >40 hr, at 5 days, and at 14 
days.    
2.4.4 Glycerol stocks of bacteria 
During examination of the agar plates, individual colonies were picked, and sub-
cultured three times to establish a pure culture. Colonies were suspended in 20 ml BHYE 
broth and incubated for 24-48 h at 37˚C with 5% CO2. The cultures were checked for 
contamination using a light microscope (Leica DM 750) prior to centrifugation (3,600 g) for 
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10 min at 4˚C. The pellet was suspended in 1 ml of BHYE medium and diluted by the 
addition of one volume of glycerol (Sigma Aldrich, UK) before being stored at -80˚C. 
2.4.5  Routine culture of bacterial strains used in this study  
Staphylococcus aureus SB14, SB17, NCTC 6571, 38, 35, and Staphylococcus 
auricularis 29, 33 were routinely grown in TSB medium overnight at 37˚C aerobically. 
Turicella otitidis 24, 28, 42, 43, 44, 45, 47 were grown in THYE medium for 48 h at 37˚C 
aerobically (see Table 2. 2 for more details about strains’ names). Haemophilus influenzae 38, 
52, SB11BBAII were cultured in SBHYE medium overnight at 37˚C with 5% CO2. 
Streptococcus pneumoniae 28, 51, 11, Streptococcus pyogenes 28, Streptococcus oralis 31, 
37, and Streptococcus mitis 37 were cultured in TYEG medium overnight at 37˚C with 5% 
CO2. Actinomyces odontolyticus 31 was grown in TYEG medium for 48 h anaerobically at 
37˚C. 
2.4.6 Total viable count 
The total viable count of bacterial cells was determined by preparing ten-fold serial 
dilutions of bacterial suspensions in PBS and placing triplicate 20 μl drops of each dilution 
(103 -106) on organism specific agar medium. The agar plates were incubated in air, 5% CO2, 
or anaerobically at 37˚C for various time periods. At the end of incubation, plates were 
photographed using a Canon IXUS 22HS camera and the number of colonies was counted 
using ImageJ (1.48v) computer software (http://imagej.nih.gov/ij/). Taking into account the 
dilutions, the colony forming units (CFU) per millilitre were then calculated. 
2.4.7 Biofilm formation in a 96-well microtitre plate model 
Bacterial stock cultures (5 μl) were added to triplicate wells of a sterile 96-well plate 
(Greiner Bio-One GmbH, Germany) containing 200 μl of organism specific culture media. 
The plate was covered, sealed with parafilm, and incubated statically for 24-48 h in 
appropriate growth conditions in a humid environment. At the end of incubation period, the 
OD600 was read in a microplate reader (BioTek Synergy HT) to quantify total growth. Biofilm 
formation was quantified using crystal violet (CV) staining assay (refer to section 2.8.1).  
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2.4.8 Bacterial strains used in this study  
Table 2. 2 Bacterial strains used in this study 
Strain NU 
number* 
Details Source or Reference 
Staphylococcus aureus   
  
SB14  NU118 Wild type CRS project (Shields et al., 
2013) 
SB17 NU119 Wild type CRS project  
NCTC6571 N/A Wild type NCTC 
18 NU85 Isolated from MEEF 18L   This project 
21 NU84 Isolated from MEEF 21L   This project 
Staphylococcus auricularis  
  
12 NU83 Isolated from MEEF 12L   This project 
16 NU82 Isolated from MEEF 16L   This project 
Turicella otitidis   
  
8 NU95 Isolated from MEEF 8R   This project 
11 NU69 Isolated from MEEF 11R   This project 
18 NU96 Isolated from MEEF 18L This project 
19 NU105 Isolated from MEEF 19L This project 
24 NU62 Isolated from MEEF 24L This project 
25 NU109 Isolated from MEEF 25R   This project 
26 NU106 Isolated from MEEF 26R   This project 
27 NU107 Isolated from MEEF 27R   This project 
29 NU108 Isolated from MEEF 29R   This project 
Haemophilus influenzae  
  
21 NU79 Isolated from MEEF 21L   This project 
33 NU78 Isolated from MEEF 33L   This project 
SB11BBAII N/A Wild type CRS project  
Streptococcus pneumoniae   
  
11 NU75 Isolated from MEEF 11R   This project 
32 NU77 Isolated from MEEF 32R   This project 
B10BBAI N/A Wild type CRS project  
SB11BBAI N/A Wild type CRS project  
Streptococcus pyogenes     
11 NU86 Isolated from MEEF 11R   This project 
Streptococcus oralis   
  
14 NU88 Isolated from MEEF 14L   This project 
20 NU39 Isolated from MEEF 20L   This project 
Streptococcus mitis     
20 NU90 Isolated from MEEF 20L   This project 
Actinomyces odontolyticus     




Table 2.2 (continued) 
Strain NU number* Details Source or Reference 
Moraxella catarrhalis    
22 NU74 Isolated from MEEF 
22L   
This project 
SB11BBAIV N/A Wild type CRS project  
*A new nomenclature that recently has been adopted for the clinical isolates in Newcastle 
Oral Microbiology laboratory. These were included to avoid future confusion about the 
bacterial strains used in this thesis. ‘N/A’ – ‘not applicable’.  
 
2.5 Microbial identification 
2.5.1 Conventional microbiological identification 
During culturing of clinical isolates, the agar plates were examined for the presence of 
contaminant growth by employing conventional microbiological techniques such as checking 
microbial cell morphology under light microscope, Gram stain, and growth in anaerobic 
conditions. Furthermore, the characteristic morphology of colonies on agar medium was also 
utilised as a guide for isolation of the correct microorganism.     
2.5.2 Microbial identification by Matrix Assisted Laser Desorption/Ionization Time-of-
Flight Mass Spectrometry ((MALDI-TOF MS) 
The screened clinical isolates were further identified to species-level using MALDI-
TOF MS, Bruker Daltonik MALDI Biotyper (Bruker UK Ltd., Coventry, UK). The clinical 
isolates were grown on blood or chocolate agar, incubated at appropriate growth conditions 
for various time periods and transferred to Dr Michael Ford at the Pathology Department in 
the Freeman Hospital, Newcastle upon Tyne for identification.    
2.5.3 Microbial DNA next generation sequencing 
The composition of microbial communities present in MEEF and adenoid samples was 
further characterized using culture-independent 16S rRNA gene sequencing. DNA was 
extracted from MEEFs and adenoids (see sections 2.6.1 and 2.6.2). The 16S rRNA gene V1-
V3 variable region amplification, sequencing, and bioinformatics analysis were performed by 
Dr. Scot E. Dowd (www.mrdnalab.com, Shallowater, TX, USA) as previously described by 
Rostami et al. (2017) in the supplemental appendix of the paper. 
55 
 
2.5.4 Microbial full genome sequencing    
To investigate whether similar bacterial strains colonising both adenoid and middle ear 
of COME patients are genetically identical, full genome sequencing of the similar bacterial 
species isolated from matched adenoid and MEEF samples of COME patient was performed 
by MicrobesNG in Birmingham University. Briefly, two putative Streptococcus oralis and 
Streptococcus parasanguinis strains (identified on the basis of MALDI-TOF) that were 
isolated from different sites of the same patient (patient 20) were grown overnight on blood 
agar at 37˚C with 5% CO2. A single colony of the strain to be sequenced was taken from an 
overnight culture plate and mixed in 100 μl sterile PBS buffer. The strain was plated on blood 
agar from the 100 μl bacterial suspension. Around 1/3 of the plate was made as a lawn of 
bacteria and then the rest was streaked out to check that the culture was pure. A large sterile 
loop was used to harvest the bacterial culture from the plate and mix into the barcoded bead 
tube supplied by MicrobesNG. This included the 1/3 plate lawn of bacteria. The tube was 
mixed by inverting 10 times. The tube was sealed and sent at room temperature to 
MicrobesNG for DNA extraction and full genome sequencing 
(https://microbesng.uk/microbesng-faq/). The sequencing data of the similar bacterial species 
that were obtained from MicrobesNG were compared using Mauve multiple genome 
alignment software version 2.4.0 (http://darlinglab.org/mauve/download.html) and the 
numbers of different single nucleotide polymorphisms (SNPs) between the two similar 
bacterial genome were determined as one of the indications for genetic compatibility of these 
bacterial strains. Genome sequences were submitted to GenBank under BioProject ID 
PRJNA454893. 
2.6 Molecular biology methods 
2.6.1 Extraction of microbial DNA from middle ear effusion fluid samples 
 To characterise microbial community members present in MEEFs of COME patients, 
at least 250 μl of each sample underwent DNA extraction using QIAamp® DNA Microbiome 
Kit (Cat. No. 51704) (Qiagen,UK) according to the manufacturer’s instructions for Next 
generation DNA sequencing. Initially the sample was centrifuged at 14,000 g for 10 minutes 
to pellet the cellular components. The pellet was resuspended in 500 μl of Buffer AHL in a 2 
ml tube and incubated for 30 min at room temperature with end-over-end mixing at 18 rpm 
using Dynal sample mixer (Model MXICI, UK). The sample was then centrifuged at 10,000 x 
g for 10 min and supernatant was removed carefully. A 190 μl aliquot of Buffer RDD and 2.5 
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μl of Benzonase were added, mixed well and incubated at 37°C for 30 min at 600 rpm in a 
water bath to digest host DNA. The microbial genomic DNA was extracted and purified as 
per manufacturer’s protocol (QIAamp® DNA Microbiome Handbook, version May 2014).  
The concentrations and purity of DNA were measured using a Nanodrop® ND-1000 
spectrophotometer (ThermoFisher scientific Ltd, Loughborough, UK). The eluted DNA 
samples were stored in 1.5 ml microcentrifuge tubes at -80°C until they were sent for 16S 
rRNA next generation sequencing by Dr. Scot E. Dowd (www.mrdnalab.com, Shallowater, 
TX, and USA).   
2.6.2 Extraction of microbial DNA from adenoid tissue samples 
DNA extraction were performed using the PowerLyzer® PowerSoil® DNA Isolation Kit 
(Cat. No. 12855-50) (MO BIO Laboratories, Inc, Germany). The cellular pellet was re-
suspended in 750 µl of Bead Solution, vortexed briefly, and transferred to the Power Bead 
Tubes before being vortexed briefly again. The tubes were placed in a Tissue Lyser LT 
(Qiagen, Manchester, UK) for 10 min at 50 Hz. Genomic DNA was extracted and purified as 
per the manufacturer’s protocol (PowerLyzer® PowerSoil® DNA Isolation Kit instruction 
manual, version 07272016). The eluted DNA samples were stored in 2 ml microcentrifuge 
collection tubes at -80°C. 
2.6.3 Agarose gel electrophoresis 
The digestion products of NucB-treated calf thymus DNA samples were separated and 
visualised using 1% agarose gel electrophoresis. To prepare 1% agarose gels, 1 g of 
Molecular Biology Grade Agarose (Melford,UK) was dissolved by boiling in 100 ml of TAE 
buffer consisting of 40 mM Tris, 20 mM glacial acetic acid (Fisher Scientific), and 1 mM 
ethylenediaminetetraacetic acid (EDTA) (Sigma Aldrich), pH 8.0. The solution was allowed 
to cool for approximately 20 min before the addition of 5 μL of GelRed™ Nucleic Acid Gel 
Stain (10 000x in DMSO) (Cambridge Bioscience Ltd, UK). The solution was poured into a 
gel tray with comb and allowed to set. Solidified gel was then submerged in 1x TAE buffer in 
a gel tank. DNA samples were mixed with 5x DNA Loading Buffer (1:5 ratio) (Bioline 
Reagents Ltd., London, UK) before loading. To determine the molecular weight of DNA 
products, 5 μL of HyperLadder 1 kb Plus (250-12,007 bp) (Bioline, UK) was compared 
against DNA samples. Gel electrophoresis was undertaken for 90 min at 100 V using a Bio-
Rad Power Pac 300 and then transferred to a G:BOX Transilluminator (Syngene, Cambridge, 
UK) to visualise DNA bands and capture images using GeneSnap software (Syngene, UK). 
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2.6.4 Production and purification of NucB 
Recombinant NucB from B. licheniformis DSM13 was produced in Bacillus subtilis 
NZ8900 using the SURE expression system as previously described (Nijland et al., 2010) and 
purified as previously described (Rostami et al., 2017) by Professor Alastair Hawkins. 
Briefly, secreted NucB was precipitated from cell-free spent growth medium by making it 
65% saturated with ammonium sulphate and incubating for 15 h at 6°C. NucB pellet was 
recovered by 4 serial centrifugation steps at 10,000 g for 60 min at 4°C. A minimal volume of 
50 mM potassium phosphate pH 7.2, 1 mM dithiothreitol (buffer 1) was used to dissolve the 
NucB-containing pellet. All subsequent chromatography steps were performed at 6°C. 
Following clarification by centrifugation at 10,000 g for 60 min at 4°C, the soluble protein 
was dialyzed against buffer 1 at 6°C and loaded onto a Q sepharose column previously 
equilibrated with buffer 1. Following a wash with buffer 1, the sample flow through and 
column wash were collected as individual fractions and assayed by SDS PAGE (12% 
separating gel) for the presence of NucB. NucB-containing fractions were pooled 
appropriately and loaded onto a hydroxyapatite column previously equilibrated with buffer 1. 
The column was washed with buffer 1 and the sample flow through and column wash were 
collected as individual fractions. Following assay of individual fractions by SDS PAGE (12% 
separating gel) and UV absorbance spectroscopy, NucB-containing fractions were pooled 
appropriately. Using this procedure 50 mg of NucB at >95% purity was routinely recovered 
from a starting cell culture volume of 10 L. The purity of NucB was assessed using multiple 
independent and complementary methods. The presence of any nucleic acid contamination 
was assessed by measuring the UV absorption spectrum from 400 – 240 nm. Preparations had 
a typical A260/A280 ratio of 0.57 (+/- 0.2) indicating an absence of nucleic acid contamination. 
Purity in terms of protein content was assessed by overloading an SDS PAGE gel and by 
differential scanning calorimetry analysis. A further indication of purity of NucB was 
provided by the observation that purified NucB crystallized under defined conditions thereby 
facilitating determination of its structure (Basle et al., 2018).   
2.7 Measurement of NucB activity  
2.7.1 Measurement of NucB nuclease activity in the optimal buffer solution  
The main aim of this method was to monitor NucB DNase activity and ensure adding a 
consistent amount of active NucB in each experiment. The DNase activity of NucB was 
determined using the method developed by Kunitz (1950) with a slight modification. Each 
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assay contained the following: 25 μL of 50 mM Tris-HCl pH 8.0 (stock 500 mM), 12.5 μL of 
5 mM MnSO4  (stock 100 mM), 168.9 μL equivalent to  125 μg  Calf thymus (CT) DNA 
(Sigma Aldrich D1501 - 1G, UK)(Stock 0.74 mg ml-1), 2.5 μL equivalent to  10 ng NucB 
(Stock 1 μg ml-1), and  41.1 μL of sterile dH2O. The final reaction volume was 250 μL. The 
buffer and DNA mixture were incubated at 37oC for 10 min before the reaction was started by 
addition and gentle mixing of NucB followed by further incubation for 15 min, 30 min, and 
60 min intervals at 37oC. A negative control made up with buffer and CTDNA with no 
enzyme was included. 
 For analysis by agarose gel (1% w/v) electrophoresis, 50μl of the reaction was halted 
by the addition and mixing of 50 μl of phenol/chloroform/isoamyl alcohol mixture (Sigma 
Aldrich, UK) for both enzyme and control. The mixture was shaken vigorously for 30 sec to 
form an emulsion. The sample was centrifuged at 13,000 rpm at 4oC for 3 min in a benchtop 
microcentrifuge (Prism R, Labnet International Inc, New Jersey, USA) forming two layers. 
The DNA was carefully removed from the upper layer and stored at 4oC until all time 
intervals were processed.  
Gel electrophoresis was performed as described in section 2.6.3. For spectroscopic 
measurement, at the end of 60 min incubation, the reaction was stopped and the high 
molecular weight CTDNA was precipitated by the addition and mixing of 250 μl of cold 
(4oC) 4% (v/v) perchloric acid (Sigma Aldrich, UK). The mixture was incubated on ice for 40 
min before being centrifuged at 13,000 rpm at 4oC for 3 min in a benchtop microcentrifuge to 
precipitate the residual high molecular weight CTDNA and to recover low molecular weight 
CTDNA in the supernatant. After this, 250 μl of the supernatant was transferred into a new 
microcentrifuge tube, and the amount of low molecular weight CTDNA produced by NucB 
was determined by reading the absorbance at 260 nm using Nanodrop® ND-1000 
spectrophotometer.  
In subsequent experiments, a range of NucB concentrations (0.25, 1, 5, 10, 25, 50, 100 
ng) was used to generate a line graph for NucB activity which included the absorbance 
readings at 260 nm (A260) against NucB concentration. This approach in conjunction with gel 
electrophoresis analysis enabled us to determine the optimal concentration of NucB to be used 
in measuring the unit of activity. A unit of NucB activity was defined as a production of 
perchloric acid soluble low molecular weight CTDNA that generated an absorbance of 1.0 at 
260 nm, per hour at 37oC in 50 mM Tris pH 8.0, 5 mM MnSO4 buffer. Since 1 ml of DNA 
with A260 of 1.0 contains 50 µg of DNA, one unit of activity is equivalent to the production of 
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50 μg of perchloric acid soluble low molecular weight CTDNA per hour at 37oC in 50 mM 
Tris pH 8.0, 5 mM MnSO4 buffer. 
2.7.2 Measurement of NucB nuclease activity in culture medium and saline solutions 
Experiments investigating the anti-biofilm activity of NucB against different microbial 
biofilms involve addition of NucB into different culture media and solutions. It was important 
to ensure that ingredients of these solutions would not inhibit the nuclease activity of NucB. 
Therefore, the nuclease activity of NucB was measured in the representative solutions such as 
TSB and 0.9% saline solution.       
For both solutions, each assay contained the following: 12.5 μL of 5mM MnSO4 (stock 
100mM), 168.9 μL equivalent to 125 μg CTDNA (Stock 0.74mg/ml), 2.5 μL equivalent to 
10ng NucB (Stock 1μg/ml), and 66.1 μL of either 0.9% normal saline solution or TSB. The 
final reaction volume was 250 μL. The mixtures were incubated at 37oC for 10 min before the 
reaction was started by addition and gentle mixing of NucB followed by further incubation for 
15 min, 30 min, and 60 min intervals at 37oC. A negative control made up with the same 
ingredients with no enzyme was included. A standard NucB activity assay in the optimal 
buffer was performed as previously described in section 2.7.1 under the same conditions. The 
NucB activity was then determined using both spectroscopic measurement and gel 
electrophoresis as described previously in section 2.6.3. 
2.7.3 Nanodrop spectrophotometry 
DNA concentrations and purity were measured using a Nanodrop® ND-1000 
spectrophotometer. The device was blanked using 2 μL of elution buffer loaded on the 
NanoDrop stage. Following this, 2 μL of the DNA sample was placed on the stage to measure 
DNA concentration. To estimate DNA purity, the ratio of A260 to A280 was determined and a 
ratio of 1.8-2.0 was deemed acceptable.   
2.8 Anti-biofilm activity of NucB against bacterial biofilms 
2.8.1 Quantification of biofilm formation by crystal violet staining assay 
Crystal violet assay was employed to quantify both the ability of bacterial strains to 
form biofilms and to determine the anti-biofilm efficacy of NucB against monospecies 
biofilms using the method described by Shields et al. (2013)  with some modifications. 
Biofilms were grown in 96-well microtitre plates (see section 2.4.7). At the end of the 
incubation, the supernatants were discarded, and the extent of biofilm formation was 
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determined by staining with 100 μL 0.5 % (w/v) crystal violet (per well). The plate was 
incubated for 15 min at room temperature (20-25°C), before the wells were rinsed 3 times 
with PBS. The microtiter plate was turned upside down in the oven at 60°C to dry for 5 min. 
The residual stain was dissolved in 100 μL 7 % acetic acid (v/v) and the A570 was measured 
using a microplate reader (Synergy HT). The A570 values of a negative controls (stained and 
washed wells with no bacterial cells) were subtracted from sample absorbance values. Each 
assay was performed independently at least three times. 
2.8.2  Assessing the sensitivity of in vitro biofilms to DNase enzymes 
To quantify the efficacy of DNase enzymes (NucB, Bovine DNase I (catalogue no. 
04716728001, Roche Diagnostics, Mannheim, Germany) to disperse pre-formed bacterial 
biofilms, bacterial biofilms were established in 96-well microtitre plates, treated with nuclease 
enzyme (DNase I at 5 μg ml-1, NucB at 10-1000 ng ml-1) for 1 h at 37°C, and biofilm biomass 
was quantified using CV staining method. When assessing the efficacy of DNase enzymes to 
inhibit biofilm formation, the filter-sterilised enzyme was added with growth media and 
bacterial inoculae at the beginning of biofilm formation. Again, the biofilm biomass was then 
measured using CV staining assay. These were compared with control biofilms that had been 
treated with enzyme buffer only. Each assay was repeated at least three times independently.  
2.8.3 Assessing efficacy of NucB for improving culturing recovery of bacteria from MEE 
fluids 
The efficacy of NucB for improving the recovery of microorganisms from MEEFs of 
COME patients was assessed by incubating MEEF with or without NucB. Initially, two 
aliquots of MEEF were placed in separate sterile microcentrifuge tubes. The first was treated 
with 100 units of NucB and the second left without treatment as a control. Samples were 
incubated for 1 h at 37°C in air. Following the incubation period, 50 μl inoculum from each 
sample was spread evenly on blood agar, chocolate agar, and FAA in duplicate. Blood and 
chocolate agar plates were incubated at 37˚C with 5% CO2 for 10-14 days and the cultures 
were checked for colony growth daily. Pre-reduced FAA plates were incubated anaerobically 
for 7-14 days. The cultures were checked for growth at >40 hr, at 5 days, and at 14 days. 
Plates were photographed periodically using a Canon IXUS 22HS camera and the number of 
colonies was counted using ImageJ (1.48v) computer software. Taking into account the 
dilutions, the colony forming units (CFU) per millilitre were then calculated for both NucB 
treated and control samples. Only plates containing 1-400 colonies were counted.  
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2.9 Antibiotic susceptibility of bacterial biofilms 
2.9.1 Determination of minimum inhibitory and minimum bactericidal concentrations of 
planktonic bacterial cultures 
Before assessing antibiotic susceptibility of bacterial cells within biofilms, the 
minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of 
planktonic cultures were determined using the broth microdilution method as previously 
described (Andrews, 2001). MIC represents a standard parameter used in clinical practice to 
determine the sensitivity and resistance of free-living bacterial cells to antibiotics. Co-
amoxiclav (Amoxicillin + Clavulanic acid 5:1, Duchefa Biochemie, Netherland) was selected 
for use in antibiotic susceptibility assays of S. aureus strains in planktonic cultures and within 
biofilms. 
 Co-amoxiclav stock solution was prepared at 40 mg ml-1 in sterile dH2O, filter 
sterilised and stored at -80°C. The working solution of Co-amoxiclav was prepared at twice 
the maximum concentration to be tested in the challenge plate to compensate for the addition 
of an equal volume of inoculum. To prepare antibiotic challenge plates, twofold dilutions of 
Co-amoxiclav were made in CAMHB. A suitable range of antibiotic concentrations was 
chosen (0.0625-16 mg L-1). Each well contained 100 μL of Co-amoxiclav, and triplicate wells 
were used for each concentration. Growth (no antibiotics) and sterility (uninoculated) controls 
were included in each plate. Following this, the inoculum was prepared by suspending 3-4 
large or 6-8 small isolated colonies selected from an overnight culture on agar plate (a 
nonselective medium, such as blood agar) in 5 ml of PBS. The suspension was adjusted to 
achieve a turbidity equivalent to a 0.5 McFarland standard. This results in a suspension 
containing approximately 1 to 2 × 108 CFU ml-1 that was validated by determination of the 
total viable counts on TSA plates. This solution was diluted 1 in 20 with CAMHB and it was 
used within 30 min. An equal volume of the adjusted bacterial inoculum (100 μL of 106 CFU 
ml-1) was added to each well except the sterility control wells. The plate was covered with the 
lid, sealed with parafilm and incubate aerobically overnight at 37°C. The MIC endpoint was 
recorded as the minimum concentration of antibiotic at which there was no visible growth. 
Each experiment was repeated three times independently. 
2.9.2 Minimal Biofilm Eradication Concentration (MBEC) assay 
Bacterial biofilms can tolerate high concentrations of antibiotics in comparison to their 
planktonic counterparts. Thus, it was important to determine minimal biofilm eradication 
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concentration (MBEC) of Co-amoxiclav for S. aureus strains before assessing the effects of 
NucB on this susceptibility. 
 MBEC™ Biofilm Inoculator (peg lid with 96-well microtiter plate base) (Innovotech 
Inc., Canada) was used to measure MBECs for S. aureus strains according to the 
manufacturer’s instructions with minor modifications. An overnight culture was prepared by 
streaking out from a -80°C cryogenic stock of desired S. aureus strain on a blood agar plate. 
The culture was checked for purity the next day. The inoculum was prepared as previously 
described in section 2.9.1. The subsequent steps were carried out in a biological safety 
cabinet. Each well of the MBEC plate was inoculated with 150 μl of the adjusted inoculum, 
the peg lid was placed onto the plate and sealed by Parafilm. The device was placed on an 
orbital shaker (IKA KS 4000i control, IKA® England LTD., Oxford, UK) at 100 rpm in a 
humid environment at 37°C for 18- 24 h in air. A sample of the inoculum was validated by 
determination of the total viable counts on TSA plates to verify the starting cell number for 
biofilm formation.  
At the end of the incubation period, the peg lid was removed from the plate and pegs 
were submersed in the wells of a pre-prepared PBS rinse plate (200 μl in each well) for 1 to 2 
min to remove loosely adherent cells. Using flamed sterilised pliers, three pegs were removed 
from different points on the lid, placed in microcentrifuge tubes containing 200 μl of TSB, 
and sonicated with an Aquasonic sonicating water bath (Decon FS200 frequency sweep, 
Decon Ultrasonics Ltd, Sussex, UK) for 30 min at energy of 44 kHz frequency, 10 kPa rms 
pressure, and 67 w/m2 intensity as calculated using a calibrated Hydrophone. Viable counts 
were determined on TSA plates to establish the number of CFU per peg prior to exposure to 
Co-amoxiclav. 
The antibiotic challenge plate was prepared as previously described in section 2.9.1. A 
suitable range of Co-amoxiclav concentration was chosen (0.25-1024 mg L-1). The final 
volume of Co-amoxiclav solution in each well of the challenge plate was 200 μl. This was to 
ensure complete submersion of the biofilm in the antibiotic solution. Each plate included 
growth and sterility control wells in triplicate. 
 The peg lid of the MBEC™ device was transferred to a standard 96-well plate in 
which desired dilutions of Co-amoxiclav were prepared in CAMHB. Antibiotic plates were 
incubated for 20-24 h at 37°C in air. After 24 h, the challenge plate was removed from the 
incubator. In the laminar flow hood, the lid was removed, rinsed in PBS for 1-2 min, and 
placed in a second 96-well plate containing 200 μl of CAMHB in each well. The biofilm was 
removed from the peg lid of the MBEC™ device by sonication for 30 min, and a new cover 
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was placed over the plate. The biofilm recovery plate was incubated overnight at 37°C in air. 
To determine the MIC values, the wells of the challenge plate were examined for turbidity. 
Alternatively, a plate reader was used to measure A650. The MIC is defined as the lowest 
concentration of antibiotic that inhibits growth of the organism. Wells with A650 < 0.1 were 
considered to be growth-inhibited. To determine the minimum biofilm eradication 
concentration (MBEC) values, the wells of the recovery plate were examined for turbidity. 
Alternatively, a plate reader was used to measure A650. Wells with A650 < 0.1 were considered 
to be evidence of biofilm eradication. 
2.9.3  Colorimetric tetrazolium salt XTT viability assay  
Another method used to assess the susceptibility of bacterial biofilms to antibiotics 
treatment was the tetrazolium salt XTT viability assay. The assay is based on the ability of 
viable and metabolically active cells to reduce the tetrazolium salt XTT into a highly-coloured 
water soluble formazan salt which can be measured spectrophotometrically. Dead or damaged 
cells will rapidly lose the ability to produce formazan salt. There is a proportional relationship 
between the amount of formazan produced and the number of live cells present in the culture.  
The bacterial inoculum for XTT assay was prepared and verified as described 
previously in section 2.9.1. Each well of a 96-well plate was inoculated with 150 μL of the 
adjusted bacterial inoculum. Plates were incubated statically for 18-20 h at 37◦C in humid 
environment to allow biofilm formation.  
At the end of the incubation period, the supernatants were discarded, and biofilms were 
washed once with 200 μL of PBS. Biofilms were then treated in triplicate with 200 μL of Co-
amoxiclav solution prepared in CAMHB for 18-20 h at 37◦C in air. Growth with no antibiotic 
and sterility controls were included. The applied concentrations of the Co-amoxiclav solution 
were 32-8192 mg L-1. After incubation, the antibiotic solution was removed, and each well 
was rinsed three times with 200 μL of PBS. To quantify the antibiotic susceptibility of 
biofilms with XTT staining, the method described by Koban et al. (2012) was used with some 
modifications. Biofilms in each well were incubated with 200 μL of XTT solution (Cell 
proliferation kit II (XTT), version 17, Roche Diagnostics GmbH, Mannheim, Germany) in the 
plate chamber of the plate reader for 1 h at 37◦C and A450 was measured every 10 min. The 
rate of XTT reduction (MAX V (A450 test- A450 blank)) per min was calculated over the time 
period. The XTT solution was prepared freshly in 10% TSB as per the manufacturer’s 
instructions. The mixture contained 0.2 mg ml-1 XTT, and 0.02 mg ml-1 phenazine 
methosulphate (PMS). Each experiment was repeated three times independently.    
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2.10 Assessing effects of NucB on the antibiotic susceptibility of bacterial cells  
2.10.1 Assessing effects of NucB on antimicrobial sensitivity of planktonic bacterial 
cultures 
The XTT viability assay was used to determine effects of NucB on MICs and cell 
viability of planktonic bacterial cultures. The challenge plate containing treatment groups 
(NucB alone, NucB+ Co-amoxiclav, Co-amoxiclav alone) was set up.  
The antibiotic challenge plate was prepared as previously described in section2.9.1. A 
suitable range of Co-amoxiclav concentration was chosen (0.0625- 8 mg ml-1). Each well 
contained 100 μL of either Co-amoxiclav alone, Co-amoxiclav plus NucB (0.5 µg ml-1), or 
NucB (0.5 µg ml-1) alone in triplicate. Each plate included growth and sterility (uninoculated) 
controls. The bacterial inoculum was prepared as previously described in section 2.9.1. An 
equal volume of an adjusted inoculum of the test microorganism (100 μL) was added to each 
well except the sterility control wells. Wells containing Co-amoxiclav only received buffer 
solution equivalent to the volume of NucB added to wells containing either NucB alone or 
NucB plus Co-amoxiclav. The plate was covered with the lid, sealed with parafilm and 
incubated at 37◦C for 18- 20 h in air.  
The MIC endpoint was recorded as the minimum concentration of Co-amoxiclav or 
Co-amoxiclav plus NucB (0.5 µg ml-1) at which no turbidity was observed. To determine 
effects of NucB on planktonic bacterial cell viability and MIC, 80 μL of each treatment group 
solution were transferred onto a new sterile 96-well plate in triplicate and 20 μL of XTT 
solution (0.2 mg ml-1 XTT, and 0.02 mg ml-1 PMS) prepared in PBS were added to each well. 
Absorbance at 450 nm was measured using a plate reader. Each experiment was repeated 
three times independently.    
2.10.2 Assessing effect of NucB on antibiotic sensitivity of in vitro S. aureus biofilms  
The XTT viability assay was also used to assess effect of NucB on antibiotic 
susceptibility of in vitro biofilms of S. aureus clinical isolates. Biofilms of the tested S. aureus 
strains were grown in a 96-well microtitre plate for 18-20 h as previously described in section 
2.4.7. At the end of the incubation, the supernatants were discarded, and biofilms were 
washed once with 200 μL of PBS to remove loosely attached bacterial cells. Biofilms were 
then treated in triplicate with 200 μL of either NucB (1 µg ml-1) alone, or NucB (1 µg ml-1) 
plus Co-amoxiclav (512 µg ml-1 or 1024 µg ml-1) or Co-amoxiclav (512 µg ml-1 or 1024 µg 
ml-1) alone for 18-20 h at 37°C in air. The treatment solutions were prepared in CAMHB. 
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Negative (no treatment) and sterility (no cells) controls were included. Following the 
treatment period, all solutions were discarded and biofilms were washed three times with 200 
μL of PBS. Each well then received 200 μL of freshly prepared XTT solution in 10% TSB 
and the plate was incubated in the microplate reader for 1 h at 37°C. Absorbance at 450 nm 
was measured every 10 min. The rate of XTT reduction (MAX V (A450 test- A450 blank)) per 
min was calculated over the time period. Each experiment was repeated at least three times 
independently. 
2.11 Investigation of NucB toxicity for bacterial and human respiratory epithelial cells 
2.11.1 Human bronchial epithelial cell culture   
BEAS-2B (obtained from ATCC; LGC Standards, Teddington, UK) is a human 
bronchial epithelial cell line derived from normal human epithelial cells immortalised using a 
hybrid of adenovirus 12 and simian virus 40. Using a Costar™ 12-well flat bottom cell 
culture plate (Thermo Fisher Scientific, UK), BEAS-2B cells were seeded at a density of 6-7 
× 105 cells ml-1 and allowed to adhere and grow in 500 μL of bronchial epithelial growth 
medium (BEGM) (Lonza, Cambridge, MA, USA) on 5% CO2 at 37◦C. BEGM was 
supplemented with 2 mL bovine pituitary extract (0.004 mL−1), 0.5 mL insulin (5 μg mL−1), 
0.5 mL hydrocortisone (0.5 μg mL−1), 0.5 mL retinoic acid (0.1 ng mL−1), 0.5 mL transferrin 
(10 μg mL−1), 0.5 mL tri-iodothyronine (6.7 ng mL−1), 0.5 mL adrenaline (0.5 μg mL−1), 0.5 
mL recombinant epidermal growth factor human (10 ng mL−1), 2 mM L-glutamine, 100 
U mL−1 penicillin G and 100 μg mL−1 streptomycin (Sigma, Gillingham, UK). 
 
2.11.2  CellTiter-Blue® cell viability assay  
The effect of NucB on human bronchial cell viability and proliferation was assessed 
using a fluorometric CellTiter-Blue® viability assay according to the manufacturer 
instructions.  This assay utilises the ability of cells to convert dark blue resazurin reagent into 
highly fluorescent and pink colour resorufin as an indicator for their viability and active 
metabolic status. Compromised or non-viable cells rapidly lose this ability to reduce resazurin 
dye, and therefore do not produce a florescent signal.  
BEAS-2B cells were cultured as previously described in section 2.11.1. At the end of 
incubation, the culture medium was removed and  cells were challenged with a range of NucB 
concentrations (final concentrations: 1, 10, 50, 100 μg ml-1), NucB buffer (50 mM Tris pH 
8.0) or Dornase alfa (100 μg ml-1) (from Dornase Alfa stock concentration of 2.5 mg ml-1, 
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Roche, UK), that were prepared in 500 μl of BEGM, or left untreated with BEGM only  and 
incubated for 24–48 h in 5% CO2 at 37°C. Following each treatment period, 100 μl of thawed 
CellTiter-Blue® reagent was added into each well and shaken gently before being incubated 
for 2 h on 5% CO2 at 37°C. Positive controls in triplicate were treated with 500 μl of absolute 
methanol (Sigma Aldrich, Dorset,UK) for 2 min at room temperature before the addition of 
CellTiter-Blue® reagent. The plate was shaken for 20 sec and the fluorescence at 560/590 nm 
was recorded using the plate reader (Infinite® 200Pro, Tecan Life Sciences, UK). Each 
experiment was repeated three times independently.  
2.11.3 Assessing effects of NucB on bacterial cell viability within biofilms  
 To assess the potential toxicity of NucB against cells in pre-formed S. aureus 
biofilms, 6-well tissue culture plates containing 3 ml of BHYE were inoculated with 50 μl of 
stock bacterial cultures per well and incubated statically in air at 37◦C for 18-20 h. Medium 
was carefully removed after 24 h and wells were washed once with PBS to remove loosely 
attached bacterial cells. Biofilms were treated with 1 ml of NucB solution (0.5 μg ml-1) for 1 
hr at 37ºC, and the control treated with 1 ml of PBS. The NucB, and PBS were aspirated and 
collected in sterile tubes separately. Biofilms were rinsed twice with 2 ml of PBS and the 
rinsing PBS from each well was collected and pooled to give a final volume of 5 ml. This was 
labelled ‘Planktonic cells’. After addition of 2 ml PBS, the residual biofilms were scraped 
using a tissue scraper (Greiner bio-one GmbH, Germany). The PBS containing scraped 
biofilm cells was collected in a separate sterile tube of 2 ml final volume. The harvested cells 
(planktonic & biofilm phases) were serially ten-fold diluted in PBS and spot plated on 
organism specific agar plates using the method of Miles et al, (1938). After incubation at 
37°C for 24 h aerobically, colonies were enumerated and total viable counts in initial samples 
were calculated.  
2.12 Imaging 
2.12.1 Quantification of NucB effects on biofilm structure using confocal laser scanning 
microscopy (CLSM) 
Confocal laser scanning microscopy (CLSM) was used to visualise and quantify the 
structural alterations within biofilms grown on glass surfaces and treated with NucB as 
previously described by Shields et al. (2013) with some modifications. The acquired stacks of 
each image were further analysed using 3D imaging software (Imaris 8.0, Bitplane) and the 
COMSTAT2 plugin for ImageJ (Heydorn et al., 2000). 
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Sterile 13 mm coverslips were placed in wells of a 12-well tissue culture plate (Greiner 
Bio-One GmbH, Germany). When testing for biofilm dispersal, wells containing 2 ml of 
organism-specific culture medium were inoculated with 40 μL of -80oC bacterial stock 
cultures equivalent to 5-10 x 106 CFU. The plate was incubated statically at the appropriate 
growth conditions in humid environment for 24-48 h. Culture medium was carefully removed 
after 24 h and replaced with fresh medium. At the end of incubation period, medium removed, 
coverslips were rinsed with PBS to removed loosely attached cells. Then 0.5 ml of NucB (0.5-
1 μg ml-1) was added to each well for 1 h at 37°C. This was compared with control biofilms 
that had been treated with NucB buffer only. Coverslips were rinsed again with PBS and then 
submerged in 300 μl of LIVE/DEAD® BacLightTM stain solution (Molecular Probes) and 
incubated at room temperature in the dark for 15 min. 
LIVE/DEAD® BacLightTM stain consists of a combination of two fluorescent dyes, 
SYTO® 9 and propidium iodide (PI), which are employed to assess microbial cell viability 
(Boulos et al., 1999). Both stains can selectively bind to DNA but SYTO® 9 specifically 
stains intracellular genomic DNA, whereas PI binds to both intracellular and extracellular 
DNA. In intact cells, SYTO® 9 outcompetes and excludes PI from cells. In membrane-
damaged cells,  PI can enter the cells more easily and outcompetes the SYTO® 9 for DNA 
binding. These features allow the application of LIVE/DEAD® BacLightTM stain for assessing 
the viability of bacterial cells, and for visualising eDNA within biofilms. 
Excess stain was removed by careful washing in PBS twice. Coverslips were inverted 
onto adhesive Gene Frame® (Thermo Fisher Scientific, UK) that had been placed on a 
microscope slide and filled with 25 μl PBS. Biofilms were examined using a Leica confocal 
microscope (Leica TCS SPE) with an argon/neon laser for visualisation of SYTO 9 
(excitation 485 nm, emission 519 nm), and PI (excitation 536 nm, emission 617 nm). For 
biofilm inhibition, NucB was included (with the culture media and inoculae) during biofilm 
formation and processed using same protocol described above. Each experiment was repeated 
three times independently.     
2.12.2 Testing antibiotic susceptibility of bacterial biofilms using combined microfluidic 
biofilm system and Live/Dead CLSM imaging 
  To assess effects of antibiotics on biofilm structure and viability, a combination of 
BioFlux microfluidic system (BioFlux200 system, Fluxion Biosciences Inc., San Francisco, 
USA), with  LIVE/DEAD® BacLightTM staining and a Nikon A1R (invert) CLSM imaging 
was used (Nance et al., 2013). A forty-eight-well BioFlux plate (Biosciences Inc., San 
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Francisco, USA) was pre-conditioned with Tryptone soya broth (TSB) to enhance cell 
adhesion and biofilm formation. One hundred microlitres of TSB were added to each outlet 
well then flowed towards the inlet well at 1.0 dyn/cm2 for 2 min at room temperature. Flow 
was stopped and the plate was incubated for 20 min at room temperature. At the end of pre-
conditioning incubation, the residual growth medium in the outlet wells was transferred to 
matching inlet wells. The outlet wells were inoculated with 100 µl of adjusted inoculum (20x 
diluted and filtered overnight culture). The inoculum was flowed again towards the inlet at 1.0 
dyn/cm2 for 6 sec at 37°C to insert bacterial cells into BioFlux channel for biofilm formation. 
The plate was then incubated at 37°C for 45 min cell attachment and early growth. When 
bacterial seeding was confirmed with a Nikon Eclipse TCS-100 inverted light microscope, the 
inoculum was removed from each outlet well and 750 µl of growth medium was added into 
each inlet well. The plate was then incubated at 37°C for 18-20 h at 0.2 dyn/cm2 for biofilm 
formation. 
 At the end of incubation, the remaining growth medium and culture were removed 
from each inlet and outlet well. Biofilms were challenged in triplicate with a range of Co-
amoxiclav concentrations diluted in CAMHB (2048, 512, 128, 32, 8, 2 µg ml-1) at 37°C for 
18-20 h at a flow rate of 2.0 dyn/cm2. Growth controls with no antibiotics were included. 
Following overnight incubation, all wells were aspirated and rinsed with 100 µl of PBS at 
room temperature for 20 min at a flow rate of 0.2 dyn/cm2 to remove residual antibiotics 
solution. Following this, biofilms were stained with LIVE/DEAD® BacLightTM stain. The 
stain solution was prepared according to the manufacturer instructions by mixing 3 µl of 
SYTO 9 and 3 µl of PI per ml of PBS and flowed at room temperature, in dark for 45 min at 
0.2 dyn/cm2. 
 Following biofilm staining, the stain solution that remained in each inlet well were 
aspirated and followed by washing with 100 µl of PBS in each inlet at room temperature for 
20 min at a flow rate of 0.2 dyn/cm2 to remove excess stain in the channel. Biofilms in the 
channels were imaged using Nikon A1R (invert) CLSM.    
2.12.3 Assessing effects of NucB on human cell apoptosis using Dual acridine 
orange/ethidium bromide staining and Microscopy 
Effects of NucB on epithelial cell viability and the morphology of their nuclei were 
assessed using dual acridine orange (AO)/ethidium bromide (EB) staining technique in 
conjugation with microscopic imaging as described previously (Shin et al., 2015). Both AO 
(Sigma-Aldrich, St Louis, USA) and EB (Sigma-Aldrich, St Louis, USA) can selectively bind 
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to nucleic acid, and these dyes can be used in combination to assess cellular apoptosis and 
functional integrity of epithelial cell membrane. Using a 12-well flat bottom cell culture plate 
(Thermo Fisher Scientific, UK), cells were seeded at around 1.5- 2 × 104 cells/cm2 and 
allowed to adhere and spread over 3-4 days in 5% CO2 at 37°C. The culture medium was 
carefully removed after 48 h and replaced with fresh medium. Following 3-4 days of 
incubation, cells were treated with a range of NucB concentrations (final concentrations: 1, 
10, 50, 100 μg ml-1), NucB buffer (50 mM Tris pH 8.0), Dornase alfa (100 μg ml-1), that were 
prepared in 500 μl of BEGM, or left untreated with BEGM only and incubated for the 
following 24–48 h on 5% CO2 at 37°C. After 24 or 48 h incubation, the supernatants were 
discarded and the cells were stained with 300 μl of AO/EB stain solution for two min under 
gentle shaking. Positive control wells were treated with 500 μl of absolute methanol for 2 min 
before staining with AO/EB dye solution. The AO/EB dye solution was prepared by mixing 
100 μg ml-1 of EB with 100 μg ml-1 of AO in PBS. The dye solution was aspirated, replaced 
by PBS and the cells were imaged using an inverted fluorescence microscope (Eclipse Ti-E 
fluorescence wide field, Nikon,UK) at 40x magnification. AO and EB were excited at 488 
nm and emission detected at 525/20-nm and 635/20-nm respectively.  
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2.13 Statistical analysis 
Experimental data were analysed using statistical software IBM SPSS Statistics ver. 
23. Graphs and tables were produced using either Microsoft Excel or Sigma-plot® ver.12.5. 
Experiments were performed independently at least three times. Data values were represented 
as the mean ± standard error. Sample values were analysed for normality using Shapiro-Wilk 
test where data with a significance value of > 0.5 were considered normally distributed, 
whereas those with a significance value of < 0.5 were considered not normally distributed 
(non-parametric data). Normally distributed data were also checked for homogeneity of the 
variance by measuring the Levene statistic p value, where data with a p value > 0.5 meant that 
there was non-significant difference in the variances and data with p value <0.5 meant that 
there was significant difference in the variances and the probability that the difference is due 
to chance is very small. Student’s paired t-test was used to determine the statistical 
significance between two treatment groups with homogenic and normally distributed data 
(parametric data), whereas Mann-Whitney U test was used for non-parametric data. ANOVA 
with Tukey’s post hoc test was used to determine the statistical significance among more than 
two treatment groups with parametric data, whereas Kruskal-Wallis test was used with non-




Chapter 3. Anti-biofilm activity of marine nuclease, NucB, against 
Staphylococcus aureus biofilms 
3.1 Introduction  
Staphylococcus aureus is a major pathogen implicated in a variety of biofilm-
associated human diseases. In the head and neck region, S. aureus infections include chronic 
rhinosinusitis (CRS), chronic supportive otitis media, COME, and indwelling medical device-
related infections such as those on cochlear implants, ventilation tubes, and speech valves 
(Zheng et al., 2018). S. aureus is one of the most common members of the microbial flora 
inhabiting the human skin and anterior nasal linings. Between 9% and 37% of the population 
have their nasal mucosal surfaces persistently colonised by S. aureus and transient carriage of 
S. aureus varies between 9% and 69% in different studies (Mehraj et al., 2016) . Possible host 
factors that may be involved in carriage include ABO-/secretor status, Toll-like receptor 
(TLR) 9 polymorphisms and a range of other gene polymorphisms (Nurjadi et al., 2012, 
Nurjadi et al., 2018, Brown et al., 2015). Alternatively, the phenotypic properties of the 
strains of S. aureus that a person encounters may affect the outcome of colonisation (Jenkins 
et al., 2015). 
S. aureus can form a robust biofilm encased within self-produced extracellular 
polymeric substances (EPS). These polymers play key roles in maintaining the structure of 
biofilms through cell-cell cohesion and cell-to-surface adhesion, conserving nutrients, 
facilitating the dissemination of genetic material among biofilm cells, and shielding biofilm 
cells from harsh external environmental stresses such as heavy metals, UV light, host immune 
action and antimicrobial agents (Teitzel and Parsek, 2003, Leid et al., 2002, Flemming et al., 
2016). Furthermore, EPS plays an important role in providing a nutrient-limited 
environmental niche within biofilms which promotes the appearance of metabolically 
dormant cells and persister cells. These cells are well-known to be tolerant to high 
concentrations of antimicrobials and their presence may be a major factor in the reduced 
susceptibility of bacterial biofilms to treatment with antimicrobials that has been termed 
‘antimicrobial recalcitrance’. Other mechanisms that elicit reduced susceptibility of biofilm 
microorganisms to treatment with antimicrobials include phenotypic alteration of the biofilm 
cells trigged by cellular attachment to a surface, for example by up-regulation of efflux 
pumps, or variations in pH, nutrients, or O2 tension across the intracellular milieu of biofilm, 
which may inactivate antibiotics directly or enhance the growth of anaerobic cells toward the 
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core of biofilm (Hall and Mah, 2017). In addition, reduced permeability of certain antibiotics 
through the biofilm EPS matrix may protect cells in the inner regions of the biofilm. These 
mechanisms may act individually or collectively (Goltermann and Tolker-Nielsen, 2017). 
The EPS of S. aureus can consist of different structural compounds including poly-N-
acetyl-glutamate (PNAG), proteins, lipids and extracellular DNA (eDNA) (Fleming and 
Rumbaugh, 2017). Originally, teichoic acids and proteins derived from host and 
staphylococcal cells were considered to be ubiquitous and vital constituents of S. aureus 
biofilm EPS (Hussain et al., 1993). Increasingly, evidence indicates that eDNA is also a key 
structural component within the EPS of many microbial biofilms including S. aureus (Kaplan 
et al., 2012, Rice et al., 2007, Shields et al., 2013). The critical role of eDNA in maintaining 
the structural integrity of bacterial biofilms was first discovered in vitro by Whitchurch et al. 
(2002) when they demonstrated dramatic dispersal of P. aeruginosa biofilms treated with 
DNase I enzyme. Dornase alfa (rhDNase) is in current use as a therapeutic, and is applied to 
reduce the sputum viscosity in cystic fibrosis patients by disrupting neutrophil extracellular 
traps derived from microorganisms and host neutrophils (Manzenreiter et al., 2012). 
Subsequent studies performed in various bacterial species including S. aureus have provided 
evidence that eDNA plays a variety of roles in the biofilm matrix, such as facilitating the 
exchange of genetic material, acting as a nutrient source, maintaining structural stability in 
mature biofilms, enhancing initial adhesion of bacterial cells to the surface, and contributing 
to protection from antimicrobials and host immune actions (Kaplan et al., 2012, Mulcahy et 
al., 2008, Rice et al., 2007, Shields et al., 2013). Therefore, the addition of DNase enzymes 
could potentially inhibit biofilm formation, disperse pre-established biofilms, or increase the 
susceptibility of biofilms to antibiotics (Okshevsky et al., 2014).  
Previous studies have largely employed crystal violet staining or qualitative 
microscopy methods to characterise the effects of deoxyribonuclease (DNase) enzymes on 
bacterial biofilms, such as those formed by S. aureus. To provide more detailed information 
on the role of eDNA in biofilm structure, this section of the study focused on optimising 
quantitative image analysis tools and developing an in vitro biofilm model that could be 
employed to investigate the sensitivity of clinically relevant bacterial isolates to DNase 
treatment, and to combination therapy with DNase and antibiotics. Bacteria that had 
previously been isolated from paranasal sinuses of patients with chronic rhinosinusitis 
(Shields et al., 2013) were employed since these were readily available in the laboratory and 
could be used while the application for ethical approval was in process. While these strains 
were not from otitis media, they were recent clinical isolates that had already been isolated 
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and identified. The microbiota of chronic rhinosinusitis is similar to that of chronic otitis 
media, and both are related to species found on the adenoids (Ren et al., 2013). Therefore, it 
was felt that strains from chronic rhinosinusitis were appropriate for developing techniques to 
be employed later with isolates from COME.  
 
3.2 Aims and objectives 
The main aims of this section were to optimise methods for quantification of biofilm 
formation and to investigate the potential of NucB to be employed as a safe (non-toxic) anti-
biofilm therapy against in vitro biofilms of relevant S. aureus clinical isolates. The objectives 
were as follows: 
1. To assess the ability of clinical isolates relevant to COME to form biofilms. 
2. To develop techniques for assessing the sensitivity of in vitro biofilms of relevant 
clinical isolates to NucB treatment. 
3. To investigate the ability of NucB to enhance the impact of antibiotics against in vitro 
biofilms. 
4. To investigate the potential toxicity of NucB against bacteria, and the possible 




3.3 Efficacy of NucB against in vitro biofilm models of S. aureus 
3.3.1 Test the sensitivity of S. aureus biofilms to NucB treatment using 96-well microtitre 
plate model  
While waiting for ethical approval for isolation of COME strains, we established the 
key techniques for biofilm growth and analysis using clinically relevant strains that had 
previously been isolated from a project on chronic rhinosinusitis (CRS). A range of isolates 
derived from patients with CRS were assayed for biofilm formation in 96-well MTP using 
organism-specific media and growth conditions. The selected isolates are shown in Table 3. 1. 
Staphylococcus aureus SB14 and SB17 strains showed the greatest capability to form robust 
and consistent in vitro biofilms (Table 3. 1). Therefore, these strains were taken forward as 
model organisms for optimising the methodologies that would be employed later in the thesis.  
 
Table 3. 1 Biofilm formation of selected CRS isolates quantified by CV staining assay    
Bacterial species and strain Biofilm formation (A570 (SE))  
Haemophilus influenzae SB11BBAII 0.47 (0.08) 
Moraxella catarrhalis SB11BBAIV 0.62 (0.09) 
Streptococcus pneumoniae SB11BBAI 0.21 (0.04) 
Streptococcus pneumoniae SB10BBAI 0.50 (0.1) 
Staphylococcus aureus SB14 2.43 (0.2) 
Staphylococcus aureus SB17 1.52 (0.3) 
S. aureus SB14 and SB17 showed the highest capabilities to form in vitro biofilms among the 
assayed CRS clinical isolates.   
In order to determine the effective biofilm inhibitory and dispersal concentration of 
NucB to be used in subsequent experiments, a range of NucB concentrations (see Figure 3. 1 ) 
were either included during biofilm formation for 20 h (for inhibition assays) or incubated for 
one hour with 24 h old pre-established biofilms of S. aureus SB14 grown in a 96-well MTP 
(for dispersal assays; see Materials and Methods section 2.8.2). For the inhibitory effect of 
NucB on biofilm formation (see Figure 3. 1(A)), a statistically significant concentration-
dependent reduction in biofilm formation was observed over a concentration range of 25-500 
ng ml-1 in comparison to PBS treated controls (p<0.05; One-Way ANOVA with Tukey’s 
Honestly Significant Difference (HSD)  post-hoc test after Normality and Homogeneity of 
variances test had indicated that the data satisfied the assumptions for ANOVA test). Biofilm 
biomass was reduced by approximately 50% in the presence of 500 ng ml-1 of NucB. When 
testing the efficacy of NucB to disperse pre-formed S. aureus SB14 biofilms (see Figure 3. 1 
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(B)), similarly significant dose-dependent biofilm removal was demonstrated over a 
concentration range of 10-500 ng ml-1 NucB. Interestingly, NucB at 100-500 ng ml-1 
concentrations showed more than 50% dispersal of pre-established biofilm when compared to 
PBS treated control biofilms. For the inhibition assay, NucB at 10 ng ml-1 showed a 
borderline effect, and for both inhibition and dispersal assays NucB did not show significant 
disruption of biofilms at concentrations lower than 10 ng ml-1 (data not shown). A similar 
trend of biofilm inhibition and dispersal activities of NucB was obtained when biofilms 
formed by S. aureus SB17 strain were treated with the similar range of NucB concentrations 
(data not shown). Based on these findings, NucB at 500 ng ml-1 was selected as the most 





Figure 3. 1 NucB inhibits biofilm formation and disperses pre-formed biofilms of S. 
aureus SB14. 
A range of concentrations of NucB were incubated with preformed (24 h) S. aureus SB14 
biofilms at 37°C for 1 h (B), or included during biofilm formation for 20 h (A). Biofilms were 
stained with crystal violet, and the biofilm biomass was quantified by measuring A570. Mean 
values from three independent assays are shown and error bars represent standard error of the 
mean. Statistical significance was calculated using One-Way ANOVA test with Tukey’s HSD 
post-Hoc comparison (* p<0.05, **p <0.01). NucB showed concentration-dependent 






To validate the DNase activity of NucB against S. aureus biofilms, commercial bovine 
DNase I at 5 µg ml-1 was included during biofilm formation for 20 h (inhibition assays) or 
was added to the 24 h-old pre-established biofilms of S. aureus SB14 (dispersal assays) using 
the standard 96-well MTP crystal violet staining assay (see Material and Methods section 
2.8.2). In both biofilm inhibition and dispersal assays, DNase I showed just above 50% 
reduction in biofilm formation and around 50% removal of preformed biofilm of S. aureus 
SB14 (see Figure 3. 2). These reductions in biofilm biomass were similar to those observed 
with NucB, which is consistent with NucB acting through a DNA-degrading mechanism. 
Figure 3. 2 Effect of Bovine DNase I on S. aureus SB14 biofilms 
For biofilm dispersal, DNase I (5 µg ml-1) was added to pre-formed (24 h) S. aureus SB14 
biofilms at 37°C for 1 h or included during biofilm formation for 20 h for the inhibition assay. 
Biofilms were stained with crystal violet, and the biofilm biomass was quantified by 
measuring A570. Mean values from three independent assays are shown and error bars 
represent standard error of the mean. DNase I significantly inhibited biofilm formation and 








3.3.2 Image analysis of the structure of NucB treated S. aureus biofilms  
Having demonstrated a potent anti-biofilm activity of NucB against biofilms of 
selected S. aureus clinical isolates, it was considered important to obtain more comprehensive 
information about the structural changes within the biofilms treated with NucB. A 
combination of CLSM and LIVE/DEAD fluorescent stains were employed to study the 
typical three-dimensional architecture of biofilms. Biofilms of the chosen microorganisms 
were grown on the surface of glass coverslips, stained with LIVE/DEAD® BacLight™ stain, 
and imaged by CLSM (see Materials and Methods section 2.12.1). This assay was focused on 
the same S. aureus clinical isolates (SB14 and SB17) that had been investigated in previous 
experiments. In the absence of NucB, biofilms of S. aureus SB14 were relatively thick and 
were mainly composed of several layers of cells that covered the majority of the surface (see 
Figure 3. 3 and Figure 3. 4). In most areas, heterogeneous patches or clumps of cells 
protruded from the surface at a thickness ranging between 7-10 μm. However, biofilms of S. 
aureus SB17 were relatively thin and consisted mostly of a single layer or a few layers of 
cells that were spread widely over the surface with medium size patches or clusters of cells 
projecting from the surfaces at 3-6 μm thickness (Figure 3. 3 and Figure 3. 4 C, G). Using 
LIVE/DEAD® BacLight™ stain, we were able to visualise both live cells (green) and dead or 
damaged cells (red). The majority of cells were alive (green) in biofilms of both S. aureus 
SB14 and SB17. 
When NucB at 0.5 μg ml-1 was included during biofilm formation of S. aureus SB14 
and SB17 for 20 h, biofilm formation was significantly inhibited compared with controls 
lacking NucB (see Figure 3. 3). Biofilms grown in the presence of 0.5 µg ml-1 were less 
extensive than the untreated controls, and were composed of irregularly distributed individual 
cells or very small clumps of cells (Figure 3. 3 B, F and D, H). Red (compromised) cells were 
difficult to be see in printed images. However, visual inspection of the images on screen 
showed that the proportion of dead and live cells in biofilms treated with NucB was almost 
equal to the control biofilms, indicating that NucB had no killing effect on biofilm cells.  
Visual observation of 3D-rendered images indicated that the treatment of biofilms with 
NucB during growth altered the biofilm structure. In order to assess and quantify this 
alteration, COMSTAT 2 software was used to determine some of the key structural 
parameters of biofilms such as the biomass, average thickness and roughness coefficient of 





Figure 3. 3 Effect of NucB on biofilm formation by S. aureus SB14 and SB17, observed by CLSM 
NucB (0.5 μg ml-1) was included during biofilm formation on glass surfaces for 24 h and visualised with 
CLSM using fluorescent LIVE/DEAD® BacLight™ stain. Merged images show live cells with green 
signals(Syto9) and cells with red signals (propidium iodide) are dead or damaged cells. Note that it is 
difficult to see red signals in the printed images, however they were clearly evident when the images were 
inspected on the sceen, albeit in low numbers compared with green cells. (A, E and C, G) represent 
control biofilms with no NucB, and (B, F and D, H) represent biofilms incubated with NucB. (A-D) 
represent x–y plane, (E-H) represent an angled view of each plane (x–y–z) and the scale bars are 30 µm. 
NucB-treated biofilms are less extensive than controls, without NucB.  
 
Table 3. 2 COMSTAT analysis of S. aureus SB14 and SB17 biofilm formation in the 
presence or absence of NucB (0.5 μg ml-1). 
Data [mean (SE)] were generated from the imaging of three randomly selected areas on each 
coverslip from at least three independent experiments. NucB greatly altered the structure of S. 
aureus biofilms by significantly reducing biomass and average thickness of biofilms (p<0.05, 
regarded as statistically significant differences from no NucB controls; two samples t-test).   
 
 
Biofilm parameters  
S. aureus SB14 S. aureus SB17 
- NucB 
+ NucB 
(0.5 μg ml-1) 
P-Value  - NucB 
+ NucB 
(0.5 μg ml-1) 
P-Value 
Biomass (µm3/µm2) 2.9 (0.2) 1.3 (0.3) 0.002 3.1 (0.6) 1.1 (0.4) 0.02 
Average thickness: (µm) 4.9 (0.4) 2.2 (0.5) 0.001 4.0 (0.5) 1.2 (0.5) 0.001 
Roughness coefficient 0.5 (0.1) 0.8 (0.2) 0.27 0.6 (0.2) 1.1 (0.3) 0.2 
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For S. aureus SB14, the average biofilm biomass and thickness of the untreated 
biofilms were 2.9 μm3/μm2 and 4.9 μm, respectively (Table 3. 2). The mean biofilm biomass 
and thickness of the NucB-treated biofilms were 1.3 μm3/μm2 and 2.2 μm, respectively (Table 
3. 2). Therefore, the average biomass and average thickness of NucB treated biofilms were 
significantly reduced by more than 50% compared to untreated controls. In the case of S. 
aureus SB17, the inclusion of NucB during biofilm growth of S. aureus SB17 significantly 
decreased the average biofilm biomass and thickness by more than 70% in comparison with 
untreated controls (Table 3. 2). For both S. aureus SB14 and SB17, the roughness coefficient 
values of the biofilms incubated with NucB were increased compared with the control, 
although the differences were not statistically significant. Collectively, these data indicate that 
inclusion of NucB (0.5 μg ml-1) efficiently inhibited biofilm formation by two clinically 
relevant S. aureus strains. 
To determine the impact of NucB on the structure of pre-formed S. aureus biofilms, S. 
aureus SB14 and SB17 were cultured on glass coverslips for 48 h, and treated for 1 h (see 
Material and Methods section 2.12.1). Treatment with NucB resulted in significant reduction 
of biofilm biomass when compared to the PBS treated controls (see Figure 3. 4). From CLSM 
imaging, pre-established biofilms that were incubated with NucB had greatly reduced biomass 
than the control. No differences in the viability of biofilms cells were detected and again 
NucB-treated biofilms consisted of isolated cells or very small aggregates of cells. Further 
quantitative analysis of the images demonstrated that the mean biomass and mean thickness of 
S. aureus SB14 biofilms incubated with buffer alone were 9.5 μm3/μm2 and 12.7μm, 
respectively (Table 3. 3). The mean biomass and thickness of the preformed biofilms 
incubated with NucB at 0.5 μg ml-1 were 1.1 μm3/μm2 and 1.2 μm, respectively which were 
decreased by about 75% compared with the untreated controls. For S. aureus SB17, in the 
absence of NucB, the average biofilm biomass and thickness were 3.5 μm3/μm2 and 7.0 μm. 
The average biofilm biomass and thickness of NucB treated biofilms were 2.1 μm3/μm2 and 
2.5 μm. When compared to biofilms incubated with PBS alone, NucB treated biofilms 
showed significant reduction in average biomass and thickness by about 50%. It should be 
noted that an approximately 3-fold reduction in the average thickness of S. aureus SB17 
biofilms treated with NucB was associated with only a 1.7-fold reduction in biomass of the 
same biofilms (Table 3.3). This apparent discrepancy may have arisen because COMSTAT 2 
software includes the voids (empty spaces) within the biofilm in the measurement of the 
average thickness but excludes them in the measurement of the biomass of biofilm (Heydorn 
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et al., 2000). Similar patterns were also observed in the inhibition assays of S. aureus SB17 & 
SB14 (see Table 3. 2).     
Overnight (24 h-old) grown biofilms of S. aureus SB14 and SB17 on the glass surface, 
which were used in the inhibition assay, were much thinner than 48 h-old biofilms which 
were used in the dispersal assay (see Figure 3. 3 and Figure 3. 4). In the absence of NucB 
treatment, average biofilm biomass and average thickness were more than twofold less than 
those of untreated 48 h-old biofilms of the same strain (Table 3. 2 and Table 3. 3). 
Overall, the qualitative and quantitative outputs of CSLM imaging analysis were 
consistent with the quantitative results obtained from 96-well plate crystal violet staining 
assay, and showed that eDNA is a key structural component of the extracellular matrix (EPS) 
of the clinically relevant S. aureus biofilms. Furthermore, the addition of NucB at 0.5μg ml-1 
could efficiently inhibit biofilm formation and efficiently detach pre-established biofilms of S. 





Figure 3. 4 Effect of NucB on the structure of established biofilms of S. aureus SB14 and SB17 
observed by CLSM 
Biofilms were grown on glass surfaces for 48 h, treated with 0.5 μg ml-1 NucB for 1 h at 37°C, stained with 
LIVE/DEAD® BacLight™ stain and imaged with CLSM. Merged images show live cells with green 
signals (Syto9) and cells with red signals (propidium iodide) are dead or damaged. NucB at 0.5 μg ml-1 
substantially dispersed pre-established biofilms of S. aureus SB14 and SB17 (B, F and D, H) when 
compared to control (PBS) treated biofilms (A, E and C, G). (A-D) represent x–y plane, (E-H) represent an 




Table 3. 3 COMSTAT analysis of S. aureus SB14 and SB17 biofilms dispersal by NucB 
(0.5μg ml-1) 
Data [mean (SE)] were generated from the imaging of three randomly selected areas on each 
coverslip from at least three independent experiments. NucB substantially altered pre-
established biofilms structure by significantly reducing biomass and average thickness of 
biofilms (p<0.05 regarded as statistically significant difference from no NucB controls; two 
samples t-test).   
  
Biofilm parameters  
S. aureus SB14 S. aureus SB17 
- NucB 
+ NucB 
(0.5 μg ml-1) 
P-Value - NucB 
+ NucB 




Biomass (µm3/µm2) 9.5(1.1) 2(0.6) 0.0001 3.5(0.5) 2.1(0.2) 0.03 
Average thickness: (µm) 12.7(1.7) 2.7(0.8) 0.0001 7.0(1.1) 2.5(0.4) 0.003 
Roughness coefficient 0.26(0.1) 0.9(0.3) 0.09 0.78(0.2) 0.2(0.04) 0.006 
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3.4 Testing the antimicrobial susceptibility of S. aureus planktonic cells  
In clinical practice, the measurement of minimum inhibitory concentration (MIC) and 
minimum bactericidal concentrations (MBC) are the standards to determine the sensitivity of 
bacteria to antibiotics, and they provide important supportive information for clinicians to 
treat infections (Andrews, 2001). MIC and MBC represent the sensitivity of bacteria in a free-
living state. However, in infections such as otitis media, bacteria are present in a biofilm, and 
may be significantly more tolerant than planktonic cells to antimicrobial agents. To compare 
the level of antimicrobial tolerance of S. aureus biofilms with planktonic cells, it was 
necessary to assess antimicrobial sensitivity in both biofilm and planktonic cultures. Initially 
the standard MICs and MBCs of S. aureus SB14 and SB17 clinical strains for Co-amoxiclav 
(clavulanic acid/amoxicillin) were determined using the standard micro-dilution method (see 
Material and Methods section 2.9.1). Co-amoxiclav was selected because of its well-known 
action against S. aureus which was the focus of the in vitro experimental investigations 
outlined in this chapter. Moreover, Co-amoxiclav is also effective against the three most 
common pathogens associated with COME (Haemophilus influenzae, Streptococcus 
pneumoniae, and Moraxella catarrhalis), and has been used for the treatment of CRS and 
otitis media. To validate the method, the MIC and MBC of S. aureus NCTC 6571 reference 
strain were also determined (see Table 3. 4). The MIC and MBC obtained for S. aureus 
NCTC 6571 was similar to the quality control (QC) value for this organism (0.12 μg ml-1) 
(Andrews, 2001). Measurement of the Co-amoxiclav susceptibilities of the planktonic 
cultures of these clinical strains enabled us to estimate the concentration range to be used in 
measuring the antimicrobial sensitivity of biofilms. 
Table 3. 4 MICs and MBCs of S. aureus strains for Co-amoxiclav determined by 
standard microdilution method. 
S. aureus strains MIC (μg ml-1) MBC (μg ml-1) 
SB14 1 4 
SB17 1 4 
NCTC6571 0.125 0.25 




3.5 Investigating the antibiotic susceptibility of S. aureus biofilms   
Following determination of MICs and MBCs of the selected planktonic S. aureus 
cultures for Co-amoxiclav, the sensitivities of these bacterial biofilms to Co-amoxiclav 
treatment were investigated using a range of assays that had been described in the literature.  
 
3.5.1 Testing the susceptibility of S. aureus biofilms to antibiotics using MBEC assay.  
The minimum biofilm eradication concentration (MBEC) assay is a quick and 
reproducible high-throughput technique developed for measuring the antimicrobial sensitivity 
of microbial biofilms. Thus, MBEC™ (HTP) microtitre plates with peg inserts attached to the 
lids were used to determine MBECs of S. aureus SB14, SB17, and NCTC6571 for Co-
amoxiclav. Initially, the time of sonication required to dislodge biofilms cells attached to pegs 
were optimized using a combination of total viable counts and crystal violet (CV) staining to 
determine release of cells. Biofilms of S. aureus SB14 were grown on pegs in MBEC™ 
(HTP) plates for 24 h according to the manufacturer’s instructions (see Materials and Methods 
section 2.9.2). After 24 h, the peg lid was rinsed for 1-2 min and three pegs from randomly 
selected places were removed. The extent of biofilm formation was assessed by CV staining 
which represented the ‘0’ sonication time point (see Figure 3. 5). Following this, the peg lid 
was placed in fresh 96-well plate containing 200 μl of TSB and sonicated for different time 
periods (10, 20, 30, 60 min). After each sonication time, 3 pegs were removed, and biofilm 
biomass was quantified by CV (see Figure 3. 5 (B)). At the same time, the bacterial 
suspension released from each peg was serially diluted and spot plated to calculate total viable 
count (see Figure 3. 5(C)). A sonication time of 30 min released the majority of cells from 
biofilm formed on the peg surface (see Figure 3. 5). Longer sonication times dislodged greater 
numbers of cells, which was evident by reduced biofilm biomass in comparison to other time 
points. However, this increase in bacterial release was associated with a negative impact on 





Figure 3. 5 Optimisation of biofilm removal from MBEC pegs using 
sonication. 
S. aureus SB14, SB17, and NCTC6571 biofilms were grown on MBEC pegs 
for 24 h. The pegs were sonicated for 10-60 min. (A) The number of cells 
released from biofilm, determined by plating and calculating mean total 
viable counts of released bacteria (CFU per peg); ‘ND’ = ‘not determined’. 
(B) Extent of biofilm remained per peg, quantified by CV staining assay. (C) 
Mean numbers of S. aureus CFU released from biofilms by sonication for 30 
min. In all panels, bars represent means and standard deviations from 3 
independent repeats are shown. The majority of cells were released from 
biofilm formed on peg by sonication for 30 min without negative impact on 





To assess the reproducibility of biofilm formation on each peg, biofilms of each S. 
aureus strain were grown for 24 h (see Materials and Methods section 2.9.2). The peg lid was 
sonicated for 30 min and the suspensions of at least 3 randomly selected wells were 
individually serially diluted and spot plated. There were no significant differences in biofilm 
formation among the selected pegs for each strain, and the mean biofilm formation for each S. 
aureus strain is shown in Figure 3. 5(A). 
Following these optimisation steps, the determination of MBECs of S. aureus SB14, 
SB17 and NCTC6571 for Co-amoxiclav was performed. One of the well-recognized features 
of bacterial biofilms is a reduced susceptibility to antimicrobial treatment compared with their 
planktonic counterparts. Hence, a higher range of Co-amoxiclav concentrations, up to 1000 
fold greater than their MICs, was used to challenge preformed biofilms of these S. aureus 
strains in order to determine the concentration of antibiotics necessary to eradicate bacterial 
cells within biofilms. Pre-established 24 h biofilms of S. aureus SB14, SB17, and NCTC6571 
were formed on the peg lids of MBEC plates (see Materials and Methods section 2.9.2), and 
treated with a range of Co-amoxiclav concentrations (0.25-1,024 μg ml-1 for SB14 and SB17 
and 0.25- 256 μg ml-1 for NCTC6571) for 24 h. Biofilms were removed from the peg lid by 
sonication and placed in a fresh 96-well plate containing recovery medium (CAMHB), and 
the MBEC values were determined following 24 h of incubation at 37°C in air by checking 
for turbidity in the wells and measuring OD650 using a microtitre plate reader. Also, it was 
possible to determine the MICs of these bacteria from MBEC device by reading OD650 in 
wells of the challenge plate following 24 h incubation of the isolates in Co-amoxiclav. 
The MICs of Co-amoxiclav for the tested S. aureus strains (SB14, SB17, and 
NCTC6571) determined by MBEC device were similar to those obtained by standard 
microdilution methods (see Table 3. 4). However, despite several attempts, it was not possible 
to obtain consistent and reproducible readings for the MBEC values for all tested strains (see 
Figure 3. 6). An inability to obtain reproducible MBEC values could be due to the step of 
overnight incubation of biofilm cells released from pegs by sonication in the recovery 
medium (CAMHB) according to the manufacturer’s instructions following 24 h antibiotic 
challenge. Low numbers of surviving cells such as persisters would potentially lead to growth 
in samples that had been almost eliminated by antibiotic treatment. Survival of even a single 
bacterial cell could eventually produce heavy bacterial growth during overnight incubation 
resulting in inconsistent and non-reproducible MBECs. Furthermore,  minor modifications in 
the method employed such as using an incubator with a rotating shaker rather than tilting one 
during biofilm formation could also influence the reproducibility of the MBEC assay, as has 
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been reported in other studies (Dall, 2013). The MBECs of Co-amoxiclav for S. aureus SB14, 
SB17, and NCTC6571 were greater than the highest concentration of antibiotic in all attempts 
and were at least 100-1000 fold greater than the MICs for planktonic culture of these strains. 
 
Figure 3. 6 Determination of MBECs of Co-amoxiclav for S. aureus biofilms.  
Biofilms of S. aureus (SB14 and NCTC6571) were grown in MBEC plates as described in 
Materials and Methods, challenged with a range of Co-amoxiclav concentrations for 24 h at 
37°C  and biofilms were recovered from peg lids by sonication. MBEC values were 
determined by measuring OD650 following 24 h incubation at 37°C in air. (A) and (B) are 
examples of many experiments performed showing inconsistent MBECs of co-amoxiclav 
determined for S. aureus SB14 and NCTC6571 biofilms. MBEC values for S. aureus 
NCTC6571 were 0.5 and 128 μg ml-1 in the two different assays. The MBEC values of S. 
aureus SB14 were 8 and 16 μg ml-1, with significant growth in cultures at concentrations 
higher than the estimated MBEC values. Therefore, overall the MBEC data must be treated 




3.5.2 Testing antibiotic susceptibility of S. aureus biofilms using combined microfluidic 
biofilm system and Live/Dead CLSM imaging 
As an alternative to the MBEC device and for illustration purposes, a medium-
throughput microfluidic biofilm system was used to assess the susceptibility of S. aureus 
SB14 biofilms to a range of Co-amoxiclav concentrations using combined LIVE/DEAD 
BacLight stain and CLSM imaging. Biofilms were grown within the channels of 48-well 
plates (24 channels) for 24 h according to the protocol described in Materials and Methods 
section 2.12.2 and challenged with Co-amoxiclav ranging from 2- 2048 μg ml-1 ml for up to 
24 h. Negative (no antibiotics) and positive (treated with 70% ethanol) controls were included 
and samples were stained using LIVE/DEAD BacLight stain and imaged by CLSM. One of 
the drawbacks observed using this system was the inability to obtain uniform biofilm 
formation in all channels despite several attempts at optimisation, which included using 
different dilutions of organism specific broth, bacterial inoculae, and using different flow 
rates for biofilm formation.          
Visual inspection of the preliminary 3D-rendered images showed that the treatment of 
biofilms with different concentrations of Co-amoxiclav caused an increased cell death which 
was proportional to the increased Co-amoxiclav concentrations (see Figure 3. 7). The vast 
majority of biofilm cells were dead/damaged at Co-amoxiclav concentrations ranging from 
128-2048 μg ml-1. By contrast, the majority of cells in the negative control remained viable. 
In conclusion, the preliminary results obtained using the microfluidic biofilm system 
combined with LIVE/DEAD staining and CLSM imaging showed that the concentration of 
Co-amoxiclav required to kill the vast majority of cells within S. aureus SB14 biofilm was 
about 128-fold greater than the MIC for Co-amoxiclav (compare with the MIC of Co-




Figure 3. 7 Confocal laser scanning microscopy of S. aureus SB14 biofilms treated with a range of Co-amoxiclav concentrations 
A Bioflux microfluidic plate was inoculated with S. aureus SB14 and fed with 25% TSB for 20 h at 37°C. Biofilms were treated with Co-
amoxiclav (2-2048 μg ml-1) for 24 h at 37°C, stained with LIVE/DEAD® BacLightTM stain and examined using CLSM and 3D imaging software 
(Imaris, Bitplane). Merged images are shown; green signal indicates viable live cells (Syto 9), red signal indicates damaged/dead cells 
(propidium iodide). Negative (no Co-amoxiclav) and positive (Ethanol 70% - ‘70%eth’) controls were also shown. The majority of S.aureus 
SB14 cells were compromised (red) at Co-amoxiclav concentrations of 128 μg ml-1 and above. Scale bars are 30 µm.
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3.5.3 Antibiotic susceptibility of S. aureus biofilms using colorimetric tetrazolium salt 
(XTT) assay 
Due to the limitations of the previous assays in providing consistent and reproducible 
data about the antibiotic susceptibility of S. aureus biofilms, a colorimetric tetrazolium salt 
(XTT) assay was used. The XTT assay is a quick method which measures the vitality and the 
metabolic activity of eukaryotic and prokaryotic cells based on lactate dehydrogenase enzyme 
activity of the viable and metabolically active cells, which causes a reduction of a yellow 
color XTT salt to a soluble orange coloured formazan derivative. The degree and the rate of 
color changes are proportional to the number of live and metabolically active cells present in 
biofilms.  
Biofilms of S. aureus SB14 and NCTC6571 were formed in 96-well MTPs for 24 h 
(see Material and Methods section 2.9.3), and challenged with a range of Co-amoxiclav 
concentrations (32-4096 μg ml-1) for 24 h. The viability of biofilms was quantified by the 
addition of XTT solution and measuring A450 after incubation for 2 h at 37°C aerobically. 
Despite several attempts, it was not possible to obtain end-point readings for the biofilm 
eradication concentrations for S. aureus SB14 and NCTC6571 (see Figure 3. 8), even though 
extremely high concentrations of Co-amoxiclav (up to 4,000 fold greater than the MICs for 
planktonic cells) were used. 
Therefore, as an alternative to a simple endpoint measurement, the rate of XTT 
reduction over one hour of incubation was measured. Over this time, there was a linear 
increase in XTT reduction (data not shown). Biofilms of S. aureus SB14 and NCTC6571 
were grown in 96-well MTPs for 24 h (see Method and Materials section 2.9.2) and processed 
as previously described. The range of Co-amoxiclav concentrations used in this assay was 
250-16,384 µg ml-1 for S. aureus SB14 and 128-8,192 µg ml-1 for S. aureus NCTC6571. 
Biofilm cell viability was quantified by obtaining A450 every 10 min for 1 h at 37ºC following 
the addition of XTT solution, and calculating the increase in Relative Light Units per min 





Figure 3. 8 Testing antibiotic susceptibility of S. aureus biofilms by XTT assay. 
Biofilms of S. aureus (SB14 and NCTC6571) were grown in 96-well MTPs for 24 h, 
challenged with a range of Co-amoxiclav concentrations for 24 h at 37ºC, and bacterial cell 
viability within biofilm was determined by XTT staining assay through measuring endpoint 
A450. Even at high Co-amoxiclav concentrations, colour was observed in S. aureus SB14 and 
NCTC6571 cultures, indicating that XTT had been reduced.    
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 Using the kinetic assay, there was statistically significant concentration-dependent 
reduction in the rate of XTT conversion over the whole concentration range assayed for both 
S. aureus SB14 & NCTC6571 biofilms in comparison with controls without Co-amoxiclav 
(One Way ANOVA and Dunnett Multiple Comparison with control) (see Figure 3. 9). For S. 
aureus SB14, there was more than 50% reduction in the rate of XTT conversion at the 
concentration range 4,096-16,384 µg ml-1 when compared with no antibiotic controls (see 
Figure 3. 9 (B)). Co-amoxiclav at 2,048 µg ml-1 produced approximately a 50% decrease in 
XTT reduction rate. There was approximately 30-40% decrease at Co-amoxiclav 
concentrations between 512-1,024 µg ml-1. For S. aureus NCTC6571, again there was 
statistically significant reduction (>50%) in the rate of XTT conversion at concentrations 
4,096-8,192 µg ml-1 in comparison with controls lacking Co-amoxiclav (see Figure 3. 9 (A)). 
There was an approximately 45% decrease in XTT reduction rate at 2,048 µg ml-1 of Co-
amoxiclav, whereas, XTT reduction was decreased by approximately 27-35% at 
concentrations ranging from 512-1,024 µg ml-1. Co-amoxiclav at concentrations less than 512 
µg ml-1 showed minimal effects on XTT reduction rate within biofilms of both S. aureus 
SB14 & NCTC6571 (decreased by ≤ 25%). Co-amoxiclav concentrations of 512 and 1,024 µg 
ml-1 demonstrated statistically significant moderate impacts on cell viability (represented by 
XTT conversion rate) within the biofilms of both S. aureus SB14 & NCTC6571 which were 
between the highly effective concentrations (4,096-16,384 µg ml-1) and minimally effective 
concentrations (128-256 µg ml-1).  On the basis of these observations, it was decided to use 
concentrations of 512 and 1,024 µg ml-1 for the next series of experiments, investigating the 




    
 
Figure 3. 9 Antibiotic susceptibility of S. aureus biofilms determined by XTT 
assay 
 Biofilms of S. aureus (NCTC6571 (A) and SB14 (B)) were grown on 96-well 
MTP plates for 24 h as described in Materials and Methods, challenged with a 
range of Co-amoxiclav  concentrations for 24 h at 37ºC, and bacterial cell 
viability within biofilms was determined by measuring the rate of XTT reduction 
at 450 nm for 1 h (RLU.min-1). Asterisks indicate a significant difference from 
the control (ANOVA, post-hoc Dunnett’s test). There was a significant dose-
dependent decrease in cell viability (RLU.min-1) within biofilms of both S. aureus 




3.6 Investigating effects of NucB on antibiotic susceptibility of in vitro biofilms of S. 
aureus 
3.6.1 Effects of NucB on the antimicrobial sensitivity of planktonic bacterial cultures of S. 
aureus 
To investigate the effects of NucB on MICs of planktonic cultures of the same S. 
aureus clinical isolates (SB14 & SB17), an adjusted planktonic bacterial suspension of S. 
aureus SB14 & SB17 in 96-well plates was challenged with a range of Co-amoxiclav 
concentrations with and without NucB (0.5 µg ml-1) for 24 h (see Materials and Methods 
section 2.10.1), and quantified by colorimetric XTT viability assay. 
The MICs of Co-amoxiclav determined for S. aureus SB14 & SB17 in the absence of 
NucB were similar to the MICs determined in the presence of NucB (see Figure 3. 10 A&B). 
Interestingly, MICs of Co-amoxiclav measured by the standard microdilution method and 
XTT viability assay were also similar for S. aureus SB14 & SB17 (1 µg ml-1). Similarly, there 
was no significant difference in the cellular viability of both S. aureus strains over the assayed 
Co-amoxiclav concentration range with or without NucB (0.5 µg ml-1). Finally, the cell 
viability in planktonic cultures of both S. aureus clinical isolates treated with NucB alone 
were almost equivalent to those of negative controls (no NucB and no antibiotics), which 
indicates that NucB has no bacteriostatic or bactericidal effect on S. aureus cells (see Figure 
3. 10 A&B). This finding confirms the previous result obtained from visual analysis of 
LIVE/DEAD stained CLSM images, which showed no killing effects of NucB on both S. 
aureus SB14 & SB17 biofilm cells. In conclusion, NucB at 0.5 µg ml-1 did not affect the 





Figure 3. 10 Effect of NucB on antibiotic susceptibility of planktonic S. aureus cells. 
Standardised bacterial cultures of S. aureus SB17 (A) and SB14 (B) were challenged 
with a range of Co-amoxiclav concentrations with or without NucB (0.5 µg ml-1) in 96-
well MTPs for 24 h at 37ºC. NucB alone and untreated controls were included. Bacterial 
cell viability was determined by measuring endpoint A450 using XTT assay. NucB had no 
effect on cell viability and antibiotic susceptibility of both S. aureus SB17 and SB14 







3.6.2 Effect of NucB on antimicrobial susceptibility of in vitro S. aureus biofilms  
After assessing the effects of NucB on antimicrobial sensitivity of planktonic cultures 
of S. aureus, the next step was to investigate the ability of NucB to enhance the susceptibility 
of S. aureus biofilms to antibiotic treatment. Initially, the sensitivity of 24 h old pre-formed S. 
aureus SB14 biofilms to a range of NucB concentrations (0.156-1 µg ml-1) with or without 
Co-amoxiclav  (512 µg ml-1) was studied using XTT viability (see Material and Methods 
section 2.10.2) to identify an appropriate concentration range of NucB for more detailed 
investigations. There was concentration-dependent decrease in the rate of XTT reduction 
observed in biofilms treated with NucB alone in comparison with growth controls (Figure 3. 
11), which was likely due to the dispersal action of NucB on these biofilms. At the highest 
concentrations tested (0.5-1 µg ml-1) the reduction was generally more than 50% compared 
with controls lacking NucB. The pattern and the extent of XTT reduction within pre-formed 
biofilms of S. aureus SB14 mediated by NucB were consistent with the pattern of reduction in 
biofilm biomass obtained using the crystal violet staining assay (see Figure 3. 1(B)). 
Interestingly, combinations of NucB at different concentrations (0.156-1 µg ml-1) with 
512 µg ml-1 Co-amoxiclav appeared to show additional dose-dependent reduction in cell 
viability of S. aureus SB14 biofilms when compared with biofilms treated with Co-amoxiclav 
only (512 µg ml-1). However, this experiment was only performed once, and it was not 
possible to determine statistical significance. Therefore, to investigate the effects of NucB on 
antibiotic susceptibility in more detail,  experiments were repeated using Co-amoxiclav at 
512 µg ml-1 or 1,024 µg ml-1 and NucB at 1 µg ml-1. These experiments were performed on S. 





Figure 3. 11 Effects of different NucB concentrations on antibiotic susceptibility of S. 
aureus biofilms. 
Biofilms of S. aureus SB14 were grown on 96-well MTPs for 24 h as described in Materials and 
Methods, and challenged with a range of NucB concentrations with or without Co-amoxiclav  
(512 µg ml-1) for 24 h at 37ºC. Co-amoxiclav only and untreated controls were included. 
Bacterial metabolic activity within biofilms was determined by measuring the rate of XTT 
reduction at 450 nm for 1 h (RLU.min-1). NucB with or without Co-amoxiclav showed dose-
dependent decreases in cell viability within biofilms compared with biofilms treated with Co-





NucB alone at 1 µg ml-1 or in combination with Co-amoxiclav at either concentration 
significantly reduced XTT reduction rate within pre-established biofilms of all tested S. 
aureus strains compared with controls that were not treated with NucB (see Figure 3. 12). For 
S. aureus SB14, there was a significant reduction in metabolic activity of cells within biofilms 
amongst all treatment groups compared with no treatment controls (one way ANOVA, p 
<0.001). The metabolic activity in biofilms treated with NucB alone was approximately 58% 
reduced compared with the negative control and this difference was significant (Tukey’s post 
hoc test, p <0.001, see Figure 3.12A). Under similar conditions, the combination of NucB 
with Co-amoxiclav at 512 or 1,024 µg ml-1 resulted in further dose-dependent reductions in 
activity compared with biofilms treated by Co-amoxiclav only (p <0.001 in both cases). 
Similarly, addition of NucB alone at 1 µg ml-1 to pre-formed S. aureus SB17 biofilms 
significantly reduced (p <0.001) viable cells remained in biofilms by approximately 55% 
compared with no treatment controls (see Figure 3. 12 (B)). Again, NucB together with Co-
amoxiclav at 512 or 1,024 µg ml-1 produced an additional significant dose-dependent decrease 
in cell viability within biofilms by approximately >35% compared to biofilms treated with 
Co-amoxiclav alone. Finally, pre-formed biofilms of S. aureus NCTC6571 were more 
sensitive than those of the clinical isolates to NucB treatment alone. Treatment with NucB 
substantially decreased the metabolic activity within biofilms by approximately 80% 
compared with the control biofilms (see Figure 3. 12 (C)). Once again, NucB in combination 
with Co-amoxiclav at 512 or 1,024 µg ml-1 showed an additional significant reduction (p 
<0.001) in metabolic activity of S. aureus NCTC6571 biofilms by >50% compared with Co-
amoxiclav only treated biofilms.                
In conclusion, NucB at 1 µg ml-1 significantly reduced the metabolic activity of cells 
within biofilms formed by all assayed S. aureus strains by approximately 55-80%. This 
reduction in activity was likely due to the dispersal of attached cells from the biofilm. 
Importantly, when NucB was combined with Co-amoxiclav, there was an additional reduction 
in the metabolic activity of biofilms over and above Co-amoxiclav treatment alone. These 
data demonstrate that NucB has the potential to enhance the efficacy of Co-amoxiclav against 







Figure 3. 12 Effects of NucB on the antibiotic susceptibility of S. aureus biofilms. 
Biofilms of S. aureus SB14 (A), SB17 (B), and NCTC6571 (C) were grown on 96-well 
MTPs for 24 h as described in Materials and Methods. Biofilms were challenged for 24 h 
at 37 ºC with Co-amoxiclav (0, 512 µg ml-1  or 1,024 µg ml-1) in the presence or absence 
of 1µg ml-1 NucB. Bacterial metabolic activity within biofilms was determined by 
measuring the rate of XTT reduction at 450 nm for 1 h (RLU.min-1). NucB treatment 
resulted in significant reductions in metabolic activity at all Co-amoxiclav concentrations 
compared with equivalent samples without NucB treatment (**p <0.001; ANOVA with 





3.7 Investigating the toxicity of NucB against microbial and human cells 
3.7.1 Testing the effects of NucB on bacterial cell viability 
 Previous data from LIVE/DEAD microscopic analysis and colorimetric XTT assays 
indicated that incubation of NucB at up to 1 µg ml-1 with S. aureus biofilms and planktonic 
cells for 1-24 h at 37ºC did not have a negative impact on the cell integrity or metabolic 
activity of these cells. To assess the impact of NucB on cell viability, S. aureus SB14 biofilms 
were grown in a 6-well tissue culture plate for 24 h and treated with 1 ml NucB (0.5 µg ml-1) 
for 1 h at 37ºC (see Materials and Methods 2.11.3). The concentration of NucB at 0.5 µg ml-1 
is similar to that which was used in the LIVE/DEAD microscopic analysis. Non-bound or 
loosely bound planktonic cells were recovered directly from the supernatant, whereas biofilm 
cells were recovered using a cell scraper. Viability was assessed by viable cell counting. 
Treatment with NucB did not lead to an overall reduction in the total CFU/ml present in 
planktonic or biofilm cells compared to the control group (see Table 3. 5). In fact, the total 
number of cells was slightly, though not significantly, increased with NucB, as noted below. 
Treating S. aureus biofilms with NucB resulted in approximately two-fold more viable cells 
in the planktonic phase (increased from 2.0 x 108 to 4.2 x 108 CFU/ml) in comparison to 
buffer-treated controls. By contrast, the number of viable cells in the biofilm phase was 
reduced by approximately 15%. Biofilms in other wells on the same plates, which were also 
treated with NucB under same conditions and quantified simultaneously by CV staining, 
showed approximately two-fold decrease in biofilm biomass compared to control biofilms, 
confirming that NucB was effectively dispersing biofilms (Figure 3. 13). 
It is not clear why the total CFU appeared to be approximately two-fold higher 
following NucB treatment than in controls treated with PBS. It is possible that bacterial cells 
aggregates were present in control samples, and that these led to an artificially low viable 
count  (see Table 3. 5). To address this hypothesis, the harvested cells from both NucB- and 
PBS-treated biofilms (planktonic and biofilm phases) were sonicated with a high power 
sonicator to break down cell aggregates. Samples were compared with the matched non-
sonicated cell suspensions. However, in both treatment conditions, sonication for 1 or 3 min 
significantly reduced the total viable counts present in planktonic and biofilm phases from 
9.25 x 108 and 5.13 x 107 to 2.98 x 108 and 2.54 x 107, respectively. Due to this significant 
negative impact on cell viability, sonication of the harvested cells suspension was avoided. 
Nevertheless, the results overall indicate that NucB acts specifically through disruption of pre-




Table 3. 5 Total viable counts (CFU ml-1) of in vitro S. aureus biofilms following 
treatment with NucB. 




Figure 3. 13 Crystal violet quantitative analysis of the effect of NucB on pre-
formed S. aureus SB14 biofilms 
S. aureus SB14 biofilms were grown on the same 6-well tissue culture plates as 
those in table 3.5 for 24 h and treated with 0.5 µg ml-1 NucB for 1 hr at 37ºC. 
Biofilms were stained with crystal violet, and the biofilm biomass was 
quantified by measuring A570. PBS treated control biofilms were included. Mean 
values from three independent assays are shown and error bars represent 
standard error of the mean. NucB treated biofilms had approximately two-fold 




Bacterial phase Control CFU ml-1 ± SE NucB (0.5 µg ml-1) CFU ml-1 ± SE 
Planktonic (P) 2.0x108 (1.9x108) 4.2 x108 (3.8x108) 
Biofilm (B) 2.8 x107 (7.5x106) 2.4 x107 (1.3x107) 
Total (P+B) 2.3 x108 (2.0x108) 4.4 x108 (3.8x108) 
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3.8 Investigation of NucB toxicity for human respiratory epithelial cells  
Following the in vitro evaluation of the anti-biofilm activity of NucB against clinically 
relevant S. aureus biofilms, it was important to assess the safety of NucB on human cells 
relevant to the epithelial lining of the middle ear as a mandatory preliminary stage in the 
process of developing new drug for medicinal use. Human bronchial epithelial cells (BEAS-
2B) were treated with different concentrations of NucB (1-100 µg ml-1) and cell viability and 
morphology were quantified using fluorometric CellTiter-Blue® cell viability assay and Dual 
acridine orange(AO)/ethidium bromide (ED) staining apoptosis assay respectively. 
3.8.1 Assessing NucB safety on human cells using CellTiter-Blue® cell viability assay   
To assess the effects of NucB on human cell viability, BEAS-2B cells were seeded in 
12-well tissue culture plate (see Materials and Methods section 2.11.2) and allowed to grow in 
a 5% CO2 atmosphere at 37ºC. Cells were challenged with different concentrations of NucB 
(1-100 µg ml-1) and Dornase alfa (rhDNase I) at 100 µg ml-1 for 24-48 h. Positive (absolute 
methanol treated) and negative (media treated) controls for cell death were included. 
Subsequently, cell viability was quantified using the CellTiter-Blue® cell viability assay. The 
CellTiter-Blue® cell viability assay is a quick high-throughput fluorometric method that 
utilises resazurin dye as an indicator to monitor the metabolic activity of viable cells. Live and 
metabolically active cells can reduce dark blue resazurin into fluorescent pink resorufin. 
However, damaged or non-viable cells lose their capability to convert the indicator dye and 
therefore fluorescent signals will not be generated by these cells. 
At the end of both incubation time points (24-48 h), the epithelial cells exhibited 
normal cell viability with the addition of  NucB at concentration up to 100 µg ml-1 and 
Dornase alfa at 100 µg ml-1 compared with cells incubated with growth medium only (see 
Figure 3. 14). There was essentially no metabolic activity (<5% reduction of dye) in positive 
controls that were treated with absolute methanol for 2 min. Cells treated with Dornase alfa at 
100 µg ml-1 for 24-48 h, displayed similar proportions of viability and metabolic activity as 
those treated with medium alone (>99%). Treatment of cells with up to 50 µg ml-1 NucB had 
no significant effect on their viability (approximately 95% activity remained). Only a slight 
reduction in the activity of cells (to 86.3% of levels in untreated controls) was observed after 
24 h treatment with NucB at 100 µg ml-1. However, the activity of cells was slightly higher at 
93% after 48 h treatment with 100 µg ml-1 NucB. Again, no significant differences in 
metabolic activity were observed following 48 h incubation of bronchial cells with NucB at 
concentrations up to 100 µg ml-1 compared with negative controls. After 24-48 h, the viability 
of cells treated with NucB at an anti-biofilm concentration (1 µg ml-1) was generally remained 
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unaffected (93-98%) in comparison to control cells. Overall, NucB at concentrations up to 
100-fold greater than those required for anti-biofilm activity was not toxic to human bronchial 
epithelial cells.  
  
Figure 3. 14 Effects of NucB on viability of human bronchial epithelial cells. 
Using a 12-well plate, BEAS-2B cells were grown at a density of 6-7 × 105 cells ml-1 and 
incubated for 24–48 h in the presence of NucB (1–100 μg ml-1), and Dornase alfa (100 μg ml-
1). Positive (100% methanol) and negative (no treatment) controls were included. At 24 and 
48 h time points, cell viability were assessed using CellTiter-Blue® Cell Viability assay by 
measuring florescence (560Ex/590Em). Mean values from three independent assays are 
shown and error bars represent standard error of the mean. Addition of NucB and Dornase 
alfa at concentrations up to 100 µg ml-1 for 24-48 h had no significant effects on the viability 





3.8.2 Effects of NucB on the apoptosis of human cells using Dual acridine orange 
(AO)/ethidium bromide (EB) apoptosis assay   
To obtain more detailed information about the effects of NucB on the viability and 
nuclear morphology of human cells, AO/EB DNA binding fluorescent stains coupled with 
microscopic imaging were employed as described in Materials and Methods section 2.12.3. 
Again, human BEAS-2B cells were treated with a range of NucB concentrations (1-100 µg 
ml-1) and Dornase alfa (100 µg ml-1) for 24-48 h. Cells were then stained with AO/EB and 
imaged using fluorescent microscopy. A combination of AO/EB and microscopic imaging can 
quickly and accurately assess nuclear apoptotic alterations and cytoplasmic membrane 
integrity simultaneously. At both time points (24-48 h), in the absence of NucB, almost all 
cells were alive with intact cell membranes and appeared green by AO. In these cultures, a 
negligible number of cells were orange-stained apoptotic or red-stained necrotic cells stained 
by EB. It was possible to recognise bright green stained spindle, oval or kidney shape shaped 
cellular nuclei with smooth outline in the majority of live cells (see Figure 3. 15). Under cell 
death-inducing conditions (positive controls), the majority of the epithelial cells were either 
apoptotic or necrotic. Apoptotic cells showed abnormal shape nuclei contained condensed and 
fragmented chromatin (green or orange colour), whereas necrotic cells had red or orange-
stained nuclei which were similar in shape to those of live cells with the absence of condensed 
chromatin.  
At both time points, qualitative observation of images showed that cells exhibited 
tolerance to high concentrations of NucB and Dornase alfa. After 24 h treatment with Dornase 
alfa at 100 µg ml-1 and NucB of up to 100 µg ml-1, the majority of cells were viable with a 
normal nuclear morphology. Minimal apoptotic changes were observed in a small proportion 
of cells at 100 µg ml-1 NucB (see Figure 3. 15 white circles).  However, under similar 
conditions these nuclear apoptotic changes were absent in cells treated with the same 
concentration of NucB for 48 h. Similarly, the vast majority of cells were alive with normal 
morphological features after 48 h of treatment with NucB at concentrations 1-100 µg ml-1 and 
Dornase alfa at 100 µg ml-1. Once more, cells at anti-biofilm concentrations of NucB (1 µg 
ml-1) exhibited normal viability and nuclear morphology in comparison to negative controls. 
In conclusion, the results obtained from the morphological examination of human bronchial 
epithelial cells treated with NucB of up to100 µg ml-1 were consistent with the results derived 
using CellTiter-Blue® cell viability analysis which indicate that NucB has no toxic effect on 





Figure 3. 15 Effects of NucB on human bronchial epithelial cells morphology and apoptosis observed by fluorescence microscope. 
BEAS-2B cells were grown as described in Material and Methods and challenged with NucB (1–100 µg ml-1), and Dornase alfa (100 µg ml-1) for 24–48 h in 
5% CO2 at 37ºC. Positive (100% methanol treated) and negative (no treatment) controls for cell death were included. Cells were stained with dual AO/EB stains 
and visualised by fluorescence microscopy. Merged images show that the nuclei of cells with normal membrane integrity stained green by AO. Early apoptotic 
cells stained green but contained bright green dots in the nuclei due to chromatin condensation and nuclear fragmentation. Late apoptotic cells stained with EB 
and appeared orange, and characteristic apoptotic phenotypes were observed in some samples (white circles). Necrotic cells stained orange or red but the 
nuclear morphology resembled the viable cells with absence of chromatin condensation. Representative images from three independent experiments are shown. 
Scale bars are 20 µm. After 24-48 h incubation, NucB and Dornase alfa at concentrations up to 100 µg ml-1 had no obvious effect on cell viability and nuclear 
morphology of human bronchial cells.      
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3.9 Discussion  
Up to now, over 80% of all bacterial infections affecting humans are estimated to be 
associated with biofilm formation (Romling and Balsalobre, 2012, Davies, 2003). 
Staphylococcus aureus is among the most common pathogens isolated from human head and 
neck biofilm-associated infections including chronic rhinosinusitis and chronic otitis media 
with effusion (Daniel et al., 2012b, Shields et al., 2013). Biofilm formation by S. aureus is 
thought to be critical for infection since it provides bacterial cells with a plethora of 
advantages including, but not limited to, protection against host immunity and up to 1000- 
fold increase in resistance to antibiotics and antimicrobials (Elgharably et al., 2013, Rogers et 
al., 2010). Increasing evidence indicates that extracellular DNA (eDNA) is a key structural 
component within the matrix of many microbial biofilms including Staphylococcus aureus 
(Tetz et al., 2009, Fleming and Rumbaugh, 2017). In this section of the study, the main aim 
was to assess the efficacy of NucB, a DNase from Bacillus licheniformis, as a potential anti-
biofilm treatment against clinically relevant in vitro biofilms of Staphylococcus aureus.  
To date, many researchers have employed a variety of DNases such as bovine DNase I, 
recombinant human DNase I (rhDNase I), also known as Dornase alfa, restriction 
endonucleases, and micrococcal nuclease to control in vitro and in vivo biofilms formed by 
different Gram positive and Gram-negative bacterial species by targeting eDNA with the 
extracellular matrix of these bacterial biofilms (Fleming and Rumbaugh, 2017, Kaplan et al., 
2012, Tetz et al., 2009). In this study, among the assayed microorganisms relevant clinically 
to COME, S. aureus exhibit greatest capability to form robust and reproducible in vitro 
biofilms. Daniel et al. (2012a) also chose S. aureus as a suitable model microorganism to 
investigate eradication of biofilms with biodegradable modified-release antibiotic pellets due 
to its superior biofilm formation capability compared to other bacterial species implicated in 
COME. It follows that the species that produces the strongest biofilms will present the 
greatest challenge for approaches to eradicate biofilm-associated infections. Therefore S. 
aureus was felt to be a suitable species for developing methods to investigate biofilms and to 
assess the efficacy of biofilm control agents. It should be noted that S. aureus was among the 
species that were subsequently identified in COME patients and strains isolated from COME 
were analysed in Chapters 4 and 5.  
The next objective was to determine the best therapeutic concentration, which would 
efficiently inhibit biofilm formation and disperses pre-established biofilm of S. aureus clinical 
isolates. Results of this study showed that incubation of NucB at 25-500 ng ml-1 during 
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biofilm formation resulted in efficient dose–dependent inhibition (25-50%) of S. aureus 
biofilm formation as quantified by CV staining (Figure 3. 1 (A)). A maximum reduction of 
around 50% in the amount of attached biofilm biomass was observed in the presence of 500 
ng ml-1 of NucB. This finding is consistent with that of Kaplan et al. (2012) who found that 
the inclusion of rhDNase I (Dornase alfa) at 0.125-4 µg ml-1 under conditions similar to those 
employed in the current study caused efficient inhibition of biofilm formation by five 
different strains of S. aureus. In dispersal assays, the concentration of rhDNase I required to 
induce about 90% reduction in biofilm biomass of these S. aureus strains was approximately 
1 µg ml-1.  Bovine DNase I at 100 mg ml-1 also significantly inhibited biofilm formation by S. 
aureus strains SH1000, MRSA252 (Izano et al., 2008). Furthermore, Mann et al. (2009) 
found that inclusion of 28 units of bovine DNase I at different time-points of biofilm 
formation up to 24 h resulted in more than 50% decrease in cell attachment of S. aureus 
UAMS-1 in a static model. This study also revealed that addition of 500 mg ml-1 of 
polyanethole sulfonate (PAS), a chemical agent that inhibits cell lysis without affecting 
bacterial growth, at up to 2 h post-inoculation caused great reduction in biofilm biomass. 
Conversely, addition of PAS after 4 h of inoculation had negligible effect on cellular 
adhesion, highlighting the importance eDNA generated by cell lysis in mediating the 
attachment of bacterial cells during the early stage of biofilm formation by S. aureus which is 
consistent with the present study. There is evidence that eDNA is particularly important 
during infections. For example, a recent study found the amount of eDNA in 6 h biofilms of 
S. aureus and S. epidermidis was higher in strains isolated from infected knee and hip 
prostheses that in control isolates from the skin of healthy volunteers (Zatorska et al., 2017). 
Therefore, targeting eDNA is a promising approach to prevent the accumulation of 
staphylococcal biofilms in a variety of clinical situations.  
Data in this study also revealed  that the exogenous addition of NucB at 10-500 ng ml-1 
to 24 h pre-formed S. aureus static biofilms resulted in efficient detachment of approximately 
30-60% of biofilm biomass in comparison to the buffer treated control biofilms (Figure 3. 1 
(B)). The addition of various DNases such as NucB, rhDNase, and bovine DNase I to 
staphylococcal biofilms including S. aureus clinical isolates also exhibited significant 
biomass dispersal effect, indicating that eDNA is important for promoting the stability of 
mature biofilms (Izano et al., 2008, Kaplan et al., 2012, Shields et al., 2013, Sugimoto et al., 
2018).  Pre-established biofilms produced by many bacterial species such as E. coli, 
Micrococcus luteus, Bacillus subtilis, Haemophilus influenzae, Klebsiella pneumoniae, 
Pseudomonas aeruginosa, Streptococcus pyogenes, and Acinetobacter baumannii have also 
108 
 
been found to be sensitive to NucB or DNase I treatment (Nijland et al., 2010, Tetz et al., 
2009). Overall, the data presented here are consistent with a model in which eDNA is 
important both at the early stages of attachment and biofilm formation by S. aureus and later, 
for the stability of mature biofilms.  
It was noted in this study that NucB at 500 ng ml-1 was the best therapeutic 
concentration that dramatically inhibited and detached biofilms produced by the assayed S. 
aureus clinical isolates. Consequently, this concentration was employed in subsequent 
experiments. To validate this DNase activity, a commercial bovine DNase I at 5µg ml-1 was 
used under conditions identical to those applied for NucB biofilms inhibition and dispersal 
assays. In both assays, DNase I resulted in significant inhibition of biofilm formation and 
disruption of pre-formed biofilms of S. aureus by about 50% (Figure 3. 2). Therefore, 
bacterial DNase, NucB at 0.5 µg ml-1, has approximately 10-fold greater anti-biofilm 
(inhibitory and dispersal) activity against S. aureus biofilms than bovine DNase I (5 µg ml-1). 
The bovine DNase I used here was not highly purified, and therefore it is impossible to know 
how much DNase I was in the preparation. Although it was not possible to compare specific 
activities of NucB versus DNase I, the findings here supported the hypothesis that the 
antibiofilm action of NucB against biofilms is due to its DNase activity rather than any other 
property of the protein. One of the limitations with this study is that we did not included heat 
inactivated NucB enzyme in our control. However, a previous study found no anti-biofilm 
activity associated with the addition of heat inactivated NucB (Shields et al., 2013).This 
finding is consistent with other studies that compared the dispersal activity of different 
concentrations of two different NucB preparations with the similar range of commercial 
bovine DNase I concentrations against B. licheniformis biofilms (Nijland et al., 2010). Nijland 
et al. (2010) have found that the concentration of NucB required for efficient dispersal of B. 
licheniformis was approximately 5-fold lower than that of bovine DNase I. However, no 
previous study has compared the inhibitory activities of NucB and DNase I as reported in this 
study. 
Another objective of the present study was to assess effects of NucB on the structure of 
biofilms using CLSM imaging and LIVE/DEAD® BacLight™ staining. CLSM images of 48 h 
old S. aureus biofilms exposed to NucB were visibly reduced in comparison to control 
biofilms (Figure 3. 3 and Figure 3. 4). Shields et al. (2013) also have found that CLSM 
images of S. aureus FH7 and S. constellatus FH20 biofilms treated with 3 µg/ml NucB were 
clearly more dispersed compared to PBS treated control biofilms. To provide quantitative data 
on biofilm structure, we employed a well-developed computer software (COMSTAT 2) to 
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analyse 9 stacks of CLSM images for each treatment condition and calculated a range of 
parameters representing the spatial and three-dimensional structure of biofilms (Heydorn et 
al., 2000).        
Consistent with observational analysis, in both inhibition and dispersal studies, 
quantification of CLSM images by COMSTAT 2 software generally showed that biofilms 
treated with NucB had significantly reduced average thickness and biomass attached to the 
surface than those treated with the buffer only (see Table 3. 2 and Table 3. 3). Interestingly, in 
accordance with a previous study (Shields et al., 2013), CLSM images of biofilms grown on 
glass coverslip surface treated with NucB showed a slightly greater reduction in biomass than 
that observed in 96-well MTP model. In the MTP system, the reduction in biomass was 
approximately 50% for both assays (Figure 3. 1) compared to approximately 50-75% on glass 
coverslips (Table 3. 2 and Table 3. 3). This difference may arise from variation in the 
interactions of eDNA with the substrata, either glass coverslips or the polystyrene of MTPs. 
Alternatively, differences may have been due to the analysis techniques. It was noted that 
CLSM imaging shows microbial cells only in contrast to CV staining technique, which stains 
bacterial cells and matrix together. Consistent with our findings, CLSM imaging of 48 h old 
S. aureus UAMS-1 biofilms established in a flow-cell system and treated with 0.5 U ml-1 
DNase I for 24 h, showed significant reductions in biomass compared to control biofilms 
imaged before the addition of DNase I (Mann et al., 2009). Furthermore, S. aureus UAMS-1 
biofilms cultured for three days using a higher inoculum (1x108 CFU ml-1) were more 
sensitive to DNase I treatment. In contrast, 72-h old biofilms initiated with lower inoculum 
(5x105 CFU ml-1) were more resistant to treatment with DNase I, indicating that biofilm 
dispersal by DNases could be influenced by different growth conditions such as biofilm age 
and the amount of inoculum. In both techniques (CV staining and CLSM imaging) higher 
numbers of bacterial cells (2-5 x108 CFU ml-1) were used to grow biofilms in our study which 
may explain the observed sensitivity of these assayed biofilms to NucB treatment. However, 
further work is required to assess the sensitivity of S. aureus biofilms older than 48 h to NucB 
treatment.  
Having shown that NucB efficiently controls biofilms of clinically isolated S. aureus 
strains, the next stage aimed to assess the effects of NucB on antibiotic susceptibility of 
biofilms. To compare the level of antimicrobial tolerance of S. aureus biofilms with 
planktonic cells, it was necessary to assess antimicrobial sensitivity in both biofilm and 
planktonic cultures. Initially, MICs and MBCs of S. aureus clinical strains for Co-amoxiclav 
were determined. The rationale behind selecting Co-amoxiclav in this study was described in 
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section 3.4. Both strains were susceptible to Co-amoxiclav because their MICs were within 
MIC breakpoints according to the NCCLS criteria and methodology that separates susceptible 
organisms from intermediately susceptible or resistant organisms. A range of methods was 
attempted to measure antimicrobial sensitivity of these bacterial biofilms. Although the 
minimum biofilm eradication concentration (MBEC) assay is a well-established approach for 
determining the sensitivity of in vitro biofilms to antibiotics (Ceri et al., 1999), it did not 
perform well here. Difficulties in getting reproducible MBEC values with this device in 
addition to other disadvantages such as high cost of the device, risk of contamination when 
pegs are removed from the device’s lid for additional analysis and the possibility of 
incomplete dislodgement of biofilms cells from pegs by sonication have been reported 
previously (Dall, 2013). These limitations in the MBEC assay indicate that more 
standardization of the methods are required in order to be confidently introduced in clinical 
practice to guide clinicians’ decisions about treatment of biofilm infections (Coenye et al., 
2018). 
As an alternative, a colorimetric tetrazolium salt (XTT) assay was used to assess 
effects of antibiotics on metabolic activity of S. aureus biofilms. The principle of this assay 
was described in section 3.5.3. There are many advantages to the XTT assay. Perhaps the 
most important is the ability to be automated with a microplate reader for a quick processing 
of multiple biofilm samples without sample manipulation as biofilm removal from the surface 
is not required. However, there are also some limitations which should be considered in this 
assay, such as the difference in the metabolic rate of bacteria between biofilm and planktonic 
states and the susceptibility of the assay to bacterial growth rate and biofilm thickness 
(Bueno, 2014). The relationship between the time required by XTT reagents to reach the core 
of biofilms and biofilm thickness requires further investigation.  Here, the MICs of Co-
amoxiclav measured for planktonic S. aureus SB14 & SB17 cells using colorimetric XTT 
assay were similar to those determined using the standard microdilution method. Assessment 
of bacterial viability in this study showed that cells within biofilms of S. aureus SB14 & 
NCTC6571 were not susceptible to killing even when the concentrations of Co-amoxiclav 
reached as high as 4000 times greater than their MICs (Figure 3. 8). Since the metabolic 
activity of bacterial cells has been shown to be in linear relationship with the production of 
orange water-soluble formazan (Alonso et al., 2017, Peeters et al., 2008), we assumed that 
measuring the rate of tetrazolium salt conversion over the incubation time of 1 h (at 10 minute 
intervals) would provide greater sensitivity to determine differences in cell viability among 
the treatment groups of the assay. This approach revealed a significant dose-dependent 
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reduction in bacterial viability (represented by the rate of XTT salt reduction during the 
incubation period) in biofilms associated with S. aureus SB14 & NCTC6571 (Figure 3. 9). 
The MBEC values obtained in this assay were extremely elevated and they were more than 
8000- fold greater than the established MIC breakpoints. This finding broadly supports 
previous studies demonstrating that bacterial cells within biofilms are highly tolerant to very 
high concentrations of antibiotics in comparison to their free-living counterparts (Fleming and 
Rumbaugh, 2017). A recent study has also shown that biofilms of 11 staphylococcal clinical 
isolates including three S. aureus strains were resistant to wide range of antibiotics including 
Penicillin and Oxacillin at the highest concentration assayed (256 µg ml-1) when compared 
with their sensitive planktonic bacteria (Brady et al., 2017). Assessment of bacterial viability 
also showed that Co-amoxiclav at 512 and 1,024 µg ml-1 demonstrated borderline killing 
efficacy against biofilms of both S. aureus SB14 and NCTC6571, and these concentrations 
were used for investigating the effect of NucB on the antibiotic sensitivity of these S. aureus 
biofilms. 
 An important goal of this study was to assess the effects of NucB on susceptibility of 
S. aureus planktonic cells and biofilms to antibiotic treatment. Incubation of NucB at 0.5 µg 
ml-1 with S. aureus planktonic cultures in the presence of a range of Co-amoxiclav 
concentrations did not enhance their susceptibility to killing by Co-amoxiclav ( Figure 3. 10) ,  
indicating that eDNA possibly do not have a role in protecting S. aureus cells from Co-
amoxiclav action at the planktonic state phase. This observation agrees with that of Tetz and 
Tetz (2010) who showed that cultivation of E.coli and S. aureus planktonic cells in nutrient 
media in the presence and absence of DNase I (5 µg ml-1) had no effect on the susceptibilities 
of these bacteria to Ampicillin and Levofloxacin. Moreover, NucB showed no effect on the 
cell viability of these planktonic S. aureus cultures when compared with the growth controls 
without NucB. This finding was also observed in the bacterial cells within biofilms quantified 
by total viable counts (CFU ml-1) in parallel with CV staining where NucB was shown to be 
acting specifically through degradation of the pre-formed biofilms rather than by affecting 
cell viability itself (Table 3. 5 & Figure 3. 13). These findings are in agreement with Shields 
et al. (2013), who showed that incubation of NucB at 5 µg ml-1 for an hour had no effect on 
the cell viability of S. aureus FH7, S. constellatus FH20, S. salivarius FH29 and M. 
catarrhalis FH4 planktonic cultures in comparison to controls lacking the enzyme. 
Furthermore, previous studies carried out on in vitro S. aureus biofilms also have shown that 
addition of DNase I and rhDNase I for up to 24 h did not exhibit significant effects on 
bacterial growth and viability (Kaplan et al., 2012, Mann et al., 2009, Rice et al., 2007).         
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 The next stage was to use a combination of 1 µg ml-1 of NucB with Co-amoxiclav at 
512 and 1,024 µg ml-1 to assess the effect of NucB in enhancing antibiotic susceptibility of the 
selected S. aureus biofilms. Our results showed that addition of NucB alone at 1 µg ml-1 to 
pre-formed S. aureus biofilms significantly reduced the viability of bacterial cells within these 
biofilms by approximately 55-80% (Figure 3. 12). This reduction most likely owing to its 
dispersal action on these pre-formed biofilms without having a killing effect on bacterial cells 
within these biofilms. Importantly, when NucB was combined with Co-amoxiclav at either 
concentration (512 or 1,024 µg ml-1), there was an additional reduction in the metabolic 
activity of biofilms by approximately >35% compared to Co-amoxiclav treatment alone. 
These data demonstrate that NucB has the potential to enhance the susceptibility of S. aureus 
biofilms to Co-amoxiclav treatment. Furthermore, these data also show that anti-biofilm 
activity of NucB was not compromised when it was used in combination with Co-amoxiclav. 
Additional investigation of the compatibility of NucB with other antibiotics is required. In 
accordance with present findings, previous studies showed that bovine DNase I effectively 
disrupted in vitro biofilms formed by many bacterial species and enhanced their susceptibility 
to various antimicrobial agents (Kaplan, 2009, Tetz et al., 2009, Waryah et al., 2017). 
Similarly, rhDNase I has been demonstrated to inhibit biofilms produced by S. aureus and S. 
epidermidis and increase the sensitivity of bacterial cells within biofilms to biocide treatment 
(Kaplan et al., 2012).  
Finally, another important aim of this section was to investigate the safety of NucB on 
human cells relevant to the middle ear and nasal cavity. Data in this study demonstrated that 
human bronchial epithelial cells were highly tolerant to high concentrations of NucB up to 
100 µg ml-1 when compared with negative controls. Incubation of human bronchial epithelial 
cells for up to 48 h with NucB at concentrations >200-fold greater than the minimum 
concentration for anti-biofilm activity (0.5 µg ml-1) did not demonstrate significant effect on 
the viability of these cells (Figure 3. 14) . Consistent with the cell viability assay, when these 
cells were incubated in direct contact with NucB at 1-100 µg ml-1 for 24-48 h, apoptosis was 
almost absent (Figure 3. 15). These data, while preliminary, show that in vivo application of 
NucB, even at high concentrations possibly would be safe. Kaplan et al. (2012) have shown 
that treatment of the in vivo model of S. aureus infection with a combination of tobramycin 
and rhDNase I (2.5mg/l) successfully extended the survival of C. elegans in comparison to the 
control treated with antibiotic only. Moreover, in many clinical trials, daily administration of  
rhDNase I (Dornase alfa) inhalational solution, which also had no effect on cell viability and 
apoptosis in this study, has proven to be effective in slowing down the deterioration of 
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pulmonary function and reducing the frequency of lung infections in young and elderly 
patients with mild to advanced cystic fibrosis by reducing the viscosity of bronchial secretions 
(Parsiegla et al., 2012, Pressler, 2008). In conclusion, the key techniques to quantify in vitro 
biofilm formation were successfully developed and have shown that NucB effectively disrupts 
biofilms both alone and in combination with antibiotics. It was also shown that NucB is 
potentially non-toxic for in vivo use. Next, it will be important to determine whether NucB is 
effective against isolates from COME. In order to do this, representative fresh clinical isolates 









Chapter 4. Characterisation of microbial populations associated with 
COME patients  
4.1 Introduction  
Chronic otitis media with effusion (COME) is a chronic inflammatory condition of 
multifactorial cause, characterised by the persistence of middle ear fluid behind an intact ear 
drum for more than 12 weeks, typically without clinical manifestations of acute inflammation. 
It is the most common cause of acquired hearing loss and elective surgery in childhood. It is 
estimated that 80% of children have had at least one episode of COME by the age of 10 years 
(Kubba et al., 2000, NICE, 2016). Most cases of COME are self-limiting and may undergo 
spontaneous resolution. However, unfavourable consequences are not uncommon. Long-
standing hearing loss due to COME at this critical stage of young children development may 
significantly deteriorate speech and language development in addition to negative impacts on 
older children’s social skills and progress at school (Rosenfeld et al., 2016, NICE, 2016). The 
aetiopathogenesis of COME is still not well understood. In the past, middle ear effusion fluids 
from COME patients were considered sterile because a high percentage of them were culture 
negative. However, subsequent studies conducted using culture-independent approaches such 
as targeted PCR have demonstrated the presence of pathogenic bacterial DNA co-existing 
with bacterial-specific mRNA in more than 80% of culture-negative cases, indicating the 
presence of metabolically active microorganisms in these effusions (Rayner et al., 1998, 
Kubba et al., 2000). This discrepancy between high culture-negative rate and high PCR-
positive rate in middle ear effusions of COME patients was later attributed to the presence of 
surface associated bacterial communities known as biofilms (Fergie et al., 2004). Biofilms of 
otopathogens were frequently observed on middle ear mucosa and effusions of patients with 
COME (Daniel et al., 2012b, Hall-Stoodley et al., 2006, Thornton et al., 2011, Van Hoecke et 
al., 2016, Kania et al., 2019, Novotny et al., 2019), strongly supporting the important role of 
biofilm infection in the aetiology of COME. 
The most commonly cultured bacterial pathogens from middle ear effusions of children 
with COME are Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, 
Staphylococcus aureus, and coagulase-negative staphylococci. All of these have the capability 
to develop biofilms in vitro and in vivo (Hall-Stoodley and Stoodley, 2009, Starner et al., 2006, 
Van Hoecke et al., 2016, Daniel et al., 2012b, Silva and Sillankorva, 2019). Studies suggest that 
biofilms on adenoids may be essential for the initiation and development of biofilms in the 
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middle ear, and that adenoids potentially act as a reservoir for biofilm-forming otopathogens 
(Hoa et al., 2009, Hoa et al., 2010, Van Hoecke et al., 2016, Kania et al., 2019, Nistico et al., 
2011). 
 Traditional culture-based surveys generally underestimate the total population of 
fastidious, uncultivable microbes and bacteria residing in biofilms because they tend to detect 
only dominant bacterial species that can grow efficiently and are present in high numbers in 
the samples (Swidsinski et al. 2007a; Stol et al. 2013). Therefore, these studies potentially 
delivered partial or biased characterisation of the microbial community composition (Ren et 
al. 2013). The development of advanced culture-independent molecular-based techniques 
such as 16S rRNA gene sequencing now enables characterisation of microbial communities 
present in different anatomical sites of human body, especially those that reside in biofilms, at 
a level of detail that far exceeds previous culture-dependent or other targeted-PCR based 
molecular methods (Ari et al., 2019, Boers et al., 2018, Chan et al., 2017b).  Culture-
independent methods are also biased to some extent. There are biases in DNA extraction, 
PCR amplification, DNA sequencing, and bioinformatics analysis (Fouhy et al., 2016, 
Eisenhofer et al., 2019). Detection of microbial DNA also does not necessarily indicate the 
presence of viable bacteria. Even so, the culture independent analysis still provide a new and 
detailed understanding of microbial community composition. Recent microbiome studies 
utilising 16S rRNA gene sequencing have shown that Alloiococcus otitis is the most 
predominant bacteria in the MEEFs of children with COME, followed by three common 
otopathogens genera (Haemophilus influenzae, Streptococcus pneumoniae, Moraxella 
catarrhalis) (Ari et al., 2019, Boers et al., 2018, Chan et al., 2016, Chan et al., 2017b, Jervis-
Bardy et al., 2015). Furthermore, Turicella otitidis has also been reported as a dominant 
bacteria within middle ear microbiota of children with COME (Ari et al., 2019, Boers et al., 
2018, Krueger et al., 2017). To our best knowledge, there are no published studies on the 
identification of bacterial population present in middle ear effusion fluids (MEEFs) of patients 





4.2 Aims and objectives  
The aims of this section were to characterise microbial populations present in MEEFs 
and adenoids of patients with COME using combined culturing and culture-independent 16S 
rRNA gene sequencing methods, and to investigate the efficacy of NucB enzyme in improving 
the recovery of bacteria from middle ear effusions. The objectives were as follow: 
1. To culture and identify microorganisms present in MEEFs collected from patients 
undergoing myringotomy and grommet tube insertion to obtain representative clinical 
isolates that can be used in the subsequent experiments.  
2. To measure the potential efficacy of NucB to disperse putative bacterial biofilms present 
in MEEFs. 
3. To analyse the microbiome of selected MEEFs and adenoids of COME patients 
including uncultivable species and estimate the efficacy of traditional culture methods 




4.3 Patients and samples 
In total, 39 patients were recruited in this study. Thirty-four of these were listed for 
myringotomy and grommet tube insertion for the treatment of COME, seven with 
adenoidectomy, and 27 without adenoidectomy. Control adenoid samples were also collected 
from 5 patients who were listed for adenotonsillectomy for the treatment of obstructive sleep 
apnoea (OSA) without clinical features of COME. From 34 patients, a total of 59 MEEF 
samples were collected. Twenty-five (73.5%) of 34 patients had bilateral COME, whereas 9 
had unilateral COME. There was significant variation in MEEFs consistency, colour, and 
volume. 
4.4 Isolation and identification of microbial populations associated with COME 
To characterise microbial populations associated with COME, a portion of MEEF was 
inoculated on a range of growth media such as blood, chocolate, and fastidious anaerobe agars 
using methods adopted from the UK Standards for Microbiology Investigations for ear 
infections and associated specimens (UKSMI )(PHE, 2014)(see Materials and Methods 2.4.2). 
Initially, a pilot isolation and identification of microorganisms from 12 MEEFs of 6 
COME patients was performed using the standard operating procedure for the investigation of 
ear infections. The plates were inoculated in duplicates with 20 µl of thawed MEEF that had 
been stored overnight at -80˚C. Blood and chocolate agars were incubated at 37˚C with 5% 
CO2 for 40-48 h, whereas FAA was incubated anaerobically for 7-14 days. To monitor the 
development of different colony types, plates were inspected for growth daily. Microbial 
colonies with different morphologies, colours, or sizes were sub-cultured three times on agar 
to establish axenic cultures. This approach was also employed for samples that produced 
abundant microbial colonies (> 400 colonies) (Figure 4. 6). All samples were plated in 
duplicate on each type of agar, and the total number and type of colonies were similar on each 
duplicate. In total, 8 strains of bacteria were isolated from 6 patients, consisting of 2 different 
genera and 6 separate species (Table 4. 1). In total, 7 (58.3%) out of 12 MEEFs were culture 




Table 4. 1 Bacteria isolated from MEEFs of 6 patients with COME in the pilot sample 
set 
Species  Number of MEEFs Number of patients  
Staphylococcus auricularis 4 2 
Staphylococcus epidermidis 1 1 
Staphylococcus pastueri  2 2 
Staphylococcus spp. 2 1 
Staphylococcus caprae 2 1 
Micrococcus luteus 1 1 
Staphylococcus spp. (CoNS) were most frequently isolated bacteria from pilot set of MEEFs 
 
Table 4. 2 Bacteria isolated from MEEFs of patients with COME in a follow-up set of 16 
patients, using an improved culture method 
Species  Number of MEEFs Number of patients  
Turicella otitidis 5 4 
Alloiococcus otitis 2 2 
Staphylococcus auricularis 4 3 
Staphylococcus epidermidis 3 2 
Staphylococcus aureus 2 2 
Staphylococcus simulans 2 1 
Staphylococcus schleiferi 1 1 
Staphylococcus pastueri  1 1 
Staphylococcus sp. 1 1 
Streptococcus oralis 2 2 
Streptococcus parasanguinis 1 1 
Streptococcus pneumoniae 1 1 
Streptococcus pyogenes 1 1 
Streptococcus mitis 1 1 
Haemophilus influenzae 1 1 
Moraxella catarrhalis 1 1 
Neisseria sp. 1 1 
Actinomyces odontolyticus 1 1 
Pseudomonas nitroreductans 2 1 




Coagulase-negative staphylococci (CoNS) including Staphylococcus auricularis and 
Staphylococcus pastueri were the most commonly isolated bacteria that were present in 
almost all culture positive MEEFs. These data in combination with the early culture 
independent 16S rRNA gene sequencing data obtained from these MEEF samples (see section 
4.8) clearly showed that the culturing methods used needed improvement as they failed to 
isolate most of the potential middle ear colonisers identified by 16S rRNA gene sequencing. 
Therefore, the methods used to culture and isolate microorganisms from the subsequent 26 
MEEFs collected from 16 patients (10 with bilateral COME, 6 with unilateral COME) were 
optimised. Modifications included (i) transferring MEEF samples quickly (within 30-60 min) 
following collection for immediate processing, (ii) inoculating the plates with 50 µl of MEEF 
instead of 20 µl, and (iii) incubating blood and chocolate agars at 37˚C with 5% CO2 for a 
longer duration (10-14 days instead of 40-48 h; see Materials and Methods section 2.4.2).  
Following these optimisation steps, 32 strains of bacteria were isolated from the 16 
patients, comprising 9 different genera and 19 different bacterial species (Figure 4. 2). 
Fourteen (53.8%) of the 26 MEEFs were culture positive, and 12 (46.2%) MEEFs were 
culture negative. The most prevalent bacterial species present in MEEFs of COME was 
Turicella otitidis, which was isolated from 19.2% of the samples. Colonies of T. otitidis 
started to appear on culture media (blood, chocolate, FA agars) after 72 h. Coagulase-negative 
staphylococci (CoNS) were still the most frequent microorganisms associated with COME 
and were isolated from 12 of 26 MEEFs (46.2%). S. auricularis (15.4%), Staphylococcus 
epidermidis (11.5%), and Staphylococcus simulans (7.7%) were the most frequently isolated 
species among CoNS. Alloiococcus otitis was isolated from 7.7% of samples. Colonies started 
to appear on growth media after around 5-7 days of incubation. S. aureus, Streptococcus 
oralis, and Pseudomonas nitroreductans were each isolated from 2 MEEFs (7.7%). Other 
bacterial species that were less frequently isolated from MEEFs included H. influenzae, M. 
catarrhalis, S. pneumoniae, Streptococcus pyogenes, Streptococcus mitis, and Actinomyces 
odontolyticus. The modifications adopted in culture methods significantly improved the 
isolation of many bacterial species associated with COME, particularly fastidious 
microorganisms such as T. otitidis, A. otitis, H. influenzae, M. catarrhalis, S. pneumoniae, S. 
mitis, Streptococcus parasanguinis, and A. odontolyticus.  
However, an extended incubation of a significant number of samples was associated 
with an increase in the rate of contamination, which started to appear on blood and chocolate 
agars as patches of fungal growth with an appearance resembling cotton wool following 72-96 
h incubation at 37˚C with 5% CO2. These patches occasionally covered most of the surface of 
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the agar, which made the visualisation of bacterial growth impossible and interfered with 
attempts to obtain axenic cultures (Figure 4. 1). Therefore, further optimisation was required 
to prevent contamination during long incubation of the growth media. Initially, this work 
focussed on determining the source of contamination. Blood agar plates were prepared as 
described in Materials and Methods section 2.4.1. Plates were poured on the bench and left 
uncovered to solidify, or were poured in the Class 1 biological safety cabinet and either left 
uncovered to solidify or covered immediately. Empty (uninoculated) control blood agar plates 
were incubated at 37˚C with 5% CO2 for up to 10 days and checked for growth daily. At the 
end of incubation, plates that were left uncovered to solidify on either the bench or in the 
biological safety cabinet showed patches of growth similar to those that had appeared on 
culture plates during the extended incubation. By contrast, no growth was observed on plates 
that were covered immediately after being poured in the biological safety cabinet (see Figure 
4. 2). These results were consistent with contamination being introduced to the plates from the 
air during growth media preparation. To minimise the risk of airborne contamination by 
fungal spores or bacteria, the biological safety cabinet was cleaned and thoroughly 
decontaminated using both antibacterial and antifungal disinfectants. The benchtop incubator 
and the candle jars were also disinfected, and plates were always covered immediately after 
pouring from this point forward. Overall, these steps dramatically reduced the levels of 





Figure 4. 1 Appearance of contamination on growth media. 
(A) Chocolate agar from MEEF 20L, (B) blood agar from MEEF 17L. The growth of white 
patches of fungal contamination (black arrows) are visible on both blood and chocolate agars. 
Occasionally, these patches covered a large area of the plate’s surface. Alloiococcus otitis 
small colonies are also visible (black circle), covering the agar surface following 5-7 days of 
incubation at 37˚C with 5% CO2. 
Figure 4. 2 Outcomes of an extended incubation of empty (control) blood agar plates 
Blood agar was prepared as described in Materials and Methods before being poured into 
petri dishes and either left uncovered to solidify on the bench or in the biological safety 
cabinet or covered immediately in the biological safety cabinet. Empty (uninoculated) plates 
were incubated for up to 10 days at 37˚C with 5% CO2. Patches of white growth were 
observed on plates that were left uncovered on the bench (A) or in the biological safety 
cabinet (B) at the end of the incubation time. No growth was observed on plates that were 
covered immediately after the growth medium was poured in the biological safety cabinet (C). 
These results show that contamination was likely introduced from the air during growth 
media preparation.       
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Following these additional optimisation steps, a total of 21 MEEF samples from 12 
patients (9 with bilateral COME, and 3 with unilateral COME) were analysed. Nineteen 
(90.5%) MEEFs were culture positive for at least one microorganism, whereas only 2 (9.5%) 
MEEFs were culture negative. Forty-five microbial strains were identified in total from 12 
patients, including 10 different genera and 16 separate species (Table 4. 3). Each MEEF 
contained between 1 to 6 microbial species, and an average of 2.3 (SE 0.5) bacterial species 
were identified per MEEF sample. There was no significant difference (p= 0.47; unpaired two 
samples t-test) in the number of bacterial species isolated from both ears in patients with 
bilateral COME. T. otitidis again was the most common microorganism detected in MEEFs 
and was isolated from 11 of 21 samples (52.4%). A. otitis was the second most common 
bacterial species and was identified in 38.1% of samples. CoNS were isolated from 76.2% of 
samples including S. epidermidis (28.6%), S. auricularis (19%), Staphylococcus capitis 
(14.3%), and in addition to other CoNS, which were isolated from 14.3% of samples. H. 
influenzae, M. catarrhalis, and S. pneumoniae have previously been shown to be the most 
frequently isolated pathogens. These microorganisms were isolated from 4 of 21 MEEFs 
(19%), and they frequently co-existed with other bacterial species. Other microbial species 
such as Propionibacterium acnes, Streptococcus salivarius, Neisseria flavescens, Kocuria 
rhizophila, and Candida parapsilosis were also identified, although less frequently. The vast 
majority of microbial isolates were facultative anaerobes. However, obligate aerobes (such as 
N. flavescens and M. catarrhalis) and obligate anaerobes (P. acnes) were also identified. In 
conclusion, adoption of the optimised culture techniques significantly improved culturing and 
isolation of microorganisms associated with COME. Moreover, a significantly higher number 
of culture positive MEEF samples were identified using the optimised culture methods in 











  Table 4. 3 Bacteria isolated from middle ear fluids of 12 patients with COME 
Species  Number of MEEFs Number of patients  
Turicella otitidis 11 6 
Alloiococcus otitis 8 5 
Staphylococcus epidermidis 6 4 
Staphylococcus auricularis 4 3 
Staphylococcus capitis 3 2 
Haemophilus influenzae 2 1 
Propionibacterium acnes 2 2 
Staphylococcus simulans 1 1 
Staphylococcus hominis 1 1 
Staphylococcus pettenkofen 1 1 
Streptococcus pneumoniae 1 1 
Streptococcus salivarius 1 1 
Moraxella catarrhalis 1 1 
Neisseria flavescens 1 1 
Kocuria rhizophila 1 1 
Candida parapsilosis 1 1 
Most of MEEFs were culture positive when the modified “improved” culture method was 
used. High proportion of fastidious species such as Turicella otitidis and Alloiococcus otitis in 




4.5 Efficacy of NucB for improving culturing recovery of microorganisms from a pilot 
set of MEEF samples 
Bacteria residing in biofilms are often difficult to culture. In Chapter 3, it was shown 
that NucB from Bacillus licheniformis can disperse biofilms formed by clinically relevant S. 
aureus strains. I hypothesised that NucB can disperse biofilms present in MEEFs and boost 
recovery of microorganisms from these biofilms. Initially, 12 MEEFs collected from 6 
patients with COME were used to optimise methods. These samples were divided into two 
portions. The first portion was stored at -80˚C until microbial DNA extraction for 16S rRNA 
gene sequencing could be performed. The second portion of MEEF was used for culturing 
cells and was either processed immediately or stored at -80˚C for processing the next day. 
Twenty microliters of MEEF were inoculated on blood agar, chocolate agar, and FA agar in 
duplicate (see section 4.4) before being treated with NucB (1 µg ml-1) for 1 h at 37°C 
aerobically. Following the incubation, 20 µl from NucB-treated MEEF were plated on each 
growth medium and incubated under the same conditions as described in section 4.4. The 
colony forming units (CFU) per millilitre were then calculated for NucB-treated and control 
samples. Of the 12 MEEFs, 6 were excluded from analysis because 5 were culture-negative, 
and one produced heavy growth (>400 colonies) that was impossible to count accurately.  
Overall, MEEFs treated with NucB a showed 2-fold or more increase in the number of 
CFU ml-1 of microorganisms in 3 out of 6 MEEFs cultured on blood agar plate in comparison 
to negative controls (Table 4. 4), whereas only 1 out of 6 MEEFs showed greater counts of 
bacteria in the absence of NucB, which could be due to uneven distribution of microbial cells 
across the MEEF samples. By contrast, in 2 out of 6 MEEFs there were at least two-fold 
greater CFU ml-1 on FA agar in untreated controls compared with NucB-treated cultures 
(Table 4. 5). Only one NucB-treated MEEF had more microorganisms cultured on FA agar 




Table 4. 4 Colony forming unit numbers (CFU ml-1) of microorganisms cultured from 
middle ear fluids, in the presence and absence of NucB (1 µg ml-1), on chocolate agars.   
Patient No.a Control   (+) NucB (1 µg ml-1 )* 
1L 2400 150 
2R 0 12550 
3R 50 200 
3L 100 200 
4R 100 100 
6L 500 400 
 
Table 4. 5 Colony forming unit numbers (CFU ml-1) of microorganisms cultured from 
middle ear fluids, in the presence and absence of NucB (1 µg ml-1), on FA agar. 
Patient No. a  Control   (+) NucB (1µg ml-1 )* 
1L 450 150 
2R 0 0 
3R 1600 100 
3L 0 300 
4R 0 0 
6L 250 150 
a MEEF 1R,2L,4L,5R,5L, and 6R were excluded from analysis. 
*  Values in bold and underlined indicate NucB increased CFU ml-1 by 2-fold or more, 
whereas values that are underlined only indicate 2-fold or more CFU ml-1 were cultured in the 
absence of NucB. The CFU numbers represent the averages of CFU ml-1 calculated from two 
plates. In general, NucB did not consistently increased the recovery of bacteria from MEEFs 
that were cultured on both blood and FA agars.     
 
The results obtained from these initial experiments showed an inconsistent efficacy of 
NucB at improving the recovery of bacteria from MEEF samples. It is likely that microbial 
cells were unevenly distributed across the MEEF samples, resulting in a great deal of inherent 
variability in the assay. These problems may have been compounded by inconsistent levels of 
NucB activity, since NucB was standardised based on mass rather than activity, and different 
preparations were used for different assays. To eliminate issues arising from inconsistent 
levels of NucB activity, it was important to develop methods to measure NucB nuclease 





4.6 Measurement of NucB enzymatic activity 
4.6.1 Measurement of NucB specific activity in the optimal buffer solution 
In order to be able to add a consistent amount of active NucB to each experiment, the 
specific activity of NucB in the optimal buffer (50 mM Tris pH 8.0, 5 mM MnSO4) was 
measured using both spectroscopic and gel electrophoresis techniques (see Materials and 
Methods section 2.7.1). It should be noted that in Chapter 3 the inhibition and dispersal of S. 
aureus biofilms by NucB was demonstrated to be dose-dependent over a concentration range 
of 10-500 ng ml-1 (see Figure 3. 1). To ensure that differences in the enzyme activity of 
different NucB preparations would not interfere with the assay, the enzyme was used in 
excess (0.5 μg ml-1) during subsequent experiments throughout Chapter 3. However, the 
continued use of high concentrations of enzyme was problematic due to the high cost of 
producing the purified enzyme. Therefore, it was important to develop an assay for measuring 
and standardising enzyme activity.    
The principle of the assay was to digest high molecular weight calf thymus DNA 
(CTDNA) with NucB for a certain time period and then quantitatively recover and measure 
the amount of perchloric acid-soluble low molecular weight DNA produced. Spectroscopic 
measurement does not provide accurate quantification of DNA degradation during early stage 
of the reaction because only DNA digestion products of less than approximately 500 bp in 
length are quantitatively solubilised by the addition of perchloric acid, whereas high 
molecular weight DNA fragments are not. Thus, the early part of the reaction was monitored 
by agarose gel electrophoresis (Figure 4. 3), which showed that maximum degradation of high 
molecular weight CTDNA into low molecular weight DNA was reached by 60 minutes in 
comparison with the negative controls. The spectroscopic analysis of the digestion of CTDNA 
(125 µg) by NucB revealed that on average 10 ng of NucB generated an A260 of 5.6 
absorbance units (+/- 0.3, n=3), equivalent to 70 µg of DNA, in 1 h at 37ºC in 250 µl of Tris 
buffer containing 5 mM Mn+2 after taking into account the various dilutions made. A unit of 
NucB activity was defined as a production of perchloric acid soluble low molecular weight 
CTDNA that generated an absorbance of 1.0 at 260 nm, per hour at 37oC in 50 mM Tris 
pH 8.0, 5 mM MnSO4 buffer. Thus, the mean specific activity of NucB calculated was 1.4 x 
105 units mg-1.  
To determine the best concentration of NucB to be used in the measurement of specific 
activity, the activity of a range of NucB concentrations (0.25, 1, 5, 10, 25, 50, 100 ng) was 
measured (see Materials and Methods section 2.7.1). The extent of DNA digestion increased 
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up to 50 ng NucB, which generate an A260= 10.7 (+/- 0.3, n=3). Therefore, NucB concentration 
of 25 ng was considered as an ideal concentration for the assay work because it produced a 
large signal (A260= 8.1 (+/- 0.25, n=3), 101 µg of DNA), and it lay approximately in the middle 
of the range (see Figure 4. 4 (B)). Visualisation of the DNA digestion products using gel 
electrophoresis confirmed that NucB at 25 ng fully digested high molecular weight CTDNA 
into low molecular weight DNA products and there were no intermediate molecular weight 
DNA fragments as seen with other concentrations below 25 ng (see Figure 4. 4 (A)). 
Furthermore, 25 ng of NucB was the lowest concentration of NucB that produced an A260 
value that was approximately 80% of the overnight value when 125 µg CTDNA was digested 
to completion, using 100 ng NucB incubated overnight (A260= 10 (+/- 0.6, n=3), 125 µg). On 
the other hand, NucB concentrations above 50 ng will saturate the reaction. Moreover, 
addition of NucB at concentrations lower than 25 ng produced partial digestion products that 
would be precipitated by perchloric acid and therefore not measured as assay products. In 
conclusion, the correct incubation time and NucB concentration of the assay were determined 
and the assay was used to monitor NucB specific activity subsequently to ensure the addition 





    
 
Figure 4. 3 NucB activity against high molecular weight calf thymus DNA. 
Calf thymus DNA (125 µg) was incubated with (+) or without (-) 10 ng of NucB in Tris 
buffer containing 5 mM Mn+2 ions for 15, 30 and 60 min at 37ºC. Agarose (1% w/v) gel 
electrophoresis was used to separate the digestion products of samples and DNA visualised by 
staining with GelRed™. (M) represents a molecular weight marker (HyperLadder 1 kb Plus 
(250-12,007 bp). The CTDNA was completely digested by 60 min. The image shows total 
degradation of high molecular weight CTDNA into low molecular weight DNA in the 
presence of NucB at each time point when compared to negative controls.      
 







Figure 4. 4 The nuclease activity of NucB against calf thymus DNA. 
(A) Calf thymus DNA (125 µg) was incubated with a range of NucB concentrations in Tris 
buffer containing 5 mM Mn+2 ions for 60 min at 37ºC. CTDNA was also incubated with or 
without 100 ng of NucB overnight (ON). Agarose (1% w/v) gel electrophoresis was used to 
separate the digestion products of samples, and DNA visualised by staining with GelRed™. 
(M) represents a molecular weight marker (HyperLadder 1 kb Plus (250-12,007 bp). (B) 
Absorbance values (A260) of perchloric acid soluble DNA products generated by the digestion 
of 125 µg of CTDNA with a range of NucB concentrations in 250 µl of Tris buffer containing 
5 mM Mn2+ ions for 60 min at 37ºC were measured by Nanodrop spectrophotometry. NucB 
showed dose-dependent degradation of High molecular weight CTDNA into low molecular 
weight DNA over 60 min with the full digestion of CTDNA was obtained at 25ng compared 
to the control (A). There was also proportional correlation between the increase in the A260 of 
perchloric acid soluble DNA products and the increase in the concentration of NucB (B).         
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4.6.2 Measurement of NucB nuclease activity in growth media and normal saline  
The nuclease activity of NucB was measured in different solutions such as TSB and 
0.9% saline solution used in the experimental methods assessing the anti-biofilm activity of 
NucB against various bacterial biofilms (see Materials and methods section2.7.2). These were 
chosen because both media were used for experiments involving NucB digestion. For 
example, 0.9% saline solution was used during the collection of MEEF samples (see Material 
and Methods section 2.3.1) that were treated by NucB to assess the efficacy in improving the 
recovery of bacteria. TSB was used as a culture medium to grow S. aureus biofilms that were 
treated with NucB to investigate the capacity to inhibit biofilm formation by different S. 
aureus strains as previously described in chapter 3. Generally, the nuclease activity of NucB 
was lower in both solutions compared with the NucB buffer. The calculated specific activity 
of NucB in TSB was 6.8 x 104 units mg-1, which was approximately 2-fold less than that 
calculated in the optimal buffer (1.4 x 105 units mg-1) containing 50 mM Tris-HCl pH 8.0, 5 
mM MnSO4. In 0.9% saline solution, the findings were similar. The calculated specific 
activity of NucB was 8.0 x 104 units mg-1, which was again just 50% less than that calculated 
in NucB buffer (1.3 x 105 units mg-1). The reduced DNase activity was also observed by 
agarose gel electrophoresis (see Figure 4. 5). In conclusion, NucB was still able to efficiently 
digest high molecular weight CTDNA in both TSB and 0.9% saline solution. However, the 






Figure 4. 5 The nuclease activity of NucB against CTDNA in 0.9% saline solution 
Calf thymus DNA (125 µg) was incubated with 10 ng NucB in Tris buffer containing 5 mM 
Mn2+ (N) or in 0.9% saline solution (NS) for 15, 30 and 60 minutes at 37ºC.  Control samples 
with no NucB (-) were included. Agarose (1% w/v) gel electrophoresis was used to separate 
the digestion products and DNA visualised by staining with GelRed™. (M) represents a 
molecular weight marker (HyperLadder 1 kb Plus (250-12,007 bp)). NucB was still able to 
degrade high molecular weight CTDNA into low molecular weight DNA over 15-60 min 




4.7 Efficacy of NucB in improving culturing recovery of microorganisms from MEEFs 
of COME patients 
Having established methods for measuring NucB specific activity, subsequent samples 
of MEEFs were treated with 100 units of NucB to assess its efficacy at improving culture 
recovery of bacteria from these samples. Furthermore, it was important to include additional 
controls that consisted of samples treated exactly the same way as the NucB samples, but 
without the inclusion of NucB. This ‘incubation control’ was included in the analysis of the 
subsequent MEEF samples (see Materials and Methods section 2.8.3). 
A total of 44 MEEFs from 26 patients with COME were assessed. After plating 50 µl 
of the MEEF sample on each growth medium (blood, chocolate and FA agar) in duplicate, the 
remaining sample was divided into 3 portions and processed according to the optimised 
methods described previously in Materials and Methods section 2.8.3. Of the 44 MEEFs 
treated, 19 were excluded from statistical analysis because 14 were culture–negative in all 
conditions, 3 were lacking incubation controls, and two samples produced abundant microbial 
colonies in all conditions that could not be counted accurately (Figure 4. 6). Generally, 
addition of 100 units of NucB to MEEF did not cause a statistically significant increase (p = 
0.38; paired two samples t-test) in the total numbers of microorganisms cultured on blood and 
chocolate agar plates when compared with controls incubated without NucB for 1 h at 37°C in 
ambient air (Table 4. 6). In the presence of NucB, 5 out of 25 samples (20%) showed 2-fold 
or more CFU ml-1 on blood and chocolate agar in comparison to incubation controls with no 
NucB (Figure 4. 7). Furthermore, 5 out of 25 MEEFs (20%) treated with NucB also showed 
just below 2-fold increase in the total bacterial CFU ml-1 cultured on blood and chocolate 
agar. However, there was a statistically significant reduction (p = 0.007; paired two samples t-
test) in the total numbers of microbes cultured from MEEFs incubated without NucB for 1 h 
at 37°C aerobically on blood and chocolate agars when compared with the control MEEFs 
that were cultured immediately on these plates without incubation (see Figure 4. 8). 
Surprisingly, this reduction affected the majority of the bacterial species cultured in this study 
and it was not species-specific, though fastidious and slow growing bacteria were affected 
more than other bacteria. However, under the same conditions the total numbers of microbial 
colonies cultured from MEEFs treated with NucB was not significantly different (p = 0.08; 
paired two samples t-test) from those cultured from negative controls without incubation.  
Under anaerobic conditions using FAA, microbial cells were released in greater 
numbers when treated with NucB than the incubation controls in only 3 out of 25 MEEFs 
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(12%) ( Table 4. 7), which was not statistically significant (p = 0.8; paired two samples t-test). 
Again, 11 out of 25 MEEFs (44%) incubated for 1h at 37°C aerobically in the absence of 
NucB had 2-fold or more decrease in the total numbers of microorganisms when compared 
with the negative controls cultured on FAA without incubation (Table 4. 7). In conclusion, 
addition of 100 units of NucB to the MEEFs collected from patients with COME did not 
efficiently improved the recovery of the bacteria from these samples onto culture media, and 
the incubation of these samples for 1 h at 37°C on air without NucB had a significant negative 







Figure 4. 6 Abundant colonies isolated from COME samples on two different growth 
media. 
(12R) Sample from the right ear of patient 12 cultured on blood agar. (33R) Sample from the 
right ear of patient 33 cultured on chocolate agar. Many colonies of different morphology are 




Table 4. 6 Colony forming units (CFU ml-1) of microorganisms cultured from MEEFs, in 
the presence and absence of NucB (100 unit), on blood and chocolate agars. 
MEEF No.a Fresh control 
CFU  
(+)100 unit NucB 
CFU ml-1 b  
Incubation control CFU ml-1 
b 
9L 1845 (2385) 540 
11L 3060 2112 2340 
11R 1600 3476 3460 
12L 7880 3740 3800 
14L 580 (242) 40 
16L 8000 0 0 
19R 120 (182.4) 80 
20L 16000 14700 23870 
21L 3760 2275 1440 
22L 400 110 120 
23R 7720 5865 3000 
23L 4700 3105 3600 
24L 180 92 100 
25R 160 138 80 
25L 980 0 0 
26R 1700 1311 780 
26L 140 184 160 
27R 700 207 120 
27L 1820 (230) 80 
29R 100 0 0 
30L 12000 184 160 
32R 3180 (3837) 1560 
32L 4560 0 0 
33L 160 430 360 
34L 7640 5221 5160 
a MEEF 7R, 7L,18L were excluded from analysis because of lack of incubation controls, 12R 
and 33R were excluded because their CFU count were >400, and the rest for being culture 
negative.b * Values in bold and underlined  indicate MEEFs incubation for 1h at 37°C 
aerobically reduced total CFU ml-1 by 2-fold or more in comparison to fresh controls, whereas 
values between parentheses indicate NucB increased CFU ml-1 by 2-fold or more compared to 
incubation controls. The CFU numbers represent the averages of CFU ml-1 calculated from 
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two plates. NucB did not significantly improved culture recovery of bacteria from MEEF 
samples.  
Table 4. 7 Colony forming unit numbers (CFU ml-1) of microorganisms cultured from 
MEEFs, in the presence and absence of NucB (100 unit), on FAA agar anaerobically 
MEEF No.a Fresh control CFU  (+)100 unit NucB 
CFU ml-1 b 
Incubation control 
CFU ml-1 b  
9L 3330 (2790) 1040 
11L 2100 748 1360 
11R 1780 4532 3760 
12L 7160 4114 2460 
14L 0 0 0 
16L 10400 0 0 
19R 140 0 0 
20L 880 210 372 
21L 2860 2100 3380 
22L 0 0 0 
23R 3980 3588 3140 
23L 2120 1610 2020 
24L 0 0 0 
25R 140 92 60 
25L 660 184 220 
26R 260 (621) 280 
26L 40 0 0 
27R 260 (414) 140 
27L 1480 138 140 
29R 80 0 0 
30L 220 115 100 
32R 3300 3750 2280 
32L 0 0 0 
33L 220 344 320 
34L 3400 3312 3980 
a MEEF 7R, 7L,18L were excluded from analysis because of lack of incubation controls, 12R 
and 33R were excluded because their CFU count were >400, and the rest for being culture 
negative. 
b * Values in bold and underlined  indicate MEEFs incubation for 1h at 37°C aerobically 
reduced total CFU ml-1 by 2-fold or more in comparison to fresh controls, whereas values 
between parentheses indicate NucB increased CFU ml-1 by 2-fold or more compared to 
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incubation controls. The CFU numbers represent the averages of CFU ml-1 calculated from 




Figure 4. 7 Recovery of COME microorganisms from MEEF samples using NucB 
enzyme.  
MEEFs were incubated for 1 h at 37°C in ambient air with or without 100 units of NucB, then 
cultured on agar plates and compared with negative controls that were not subjected to 
incubation (Fresh control). This method enabled the counting of the total number of microbial 
colonies released from MEEFs. An illustration of this, on chocolate agar (19R) and blood agar 
(9R), show greater numbers of microbes recovered with the addition of NucB, in comparison 






Figure 4. 8 Effect of aerobic incubation on COME microorganisms.  
Examples of chocolate agars from MEEF No. 16L and 30L shows significantly less 
microorganisms were cultured from MEEFs incubated for 1h at 37°C aerobically with or 
without NucB in comparison to fresh controls that were not subjected to incubation. The 
microorganisms affected were Alloiococcus otitis, Propionibacterium acnes, and 




4.8  Characterisation of microbial communities associated with COME and adenoids by 
16S rRNA gene sequencing  
To verify the efficacy of the traditional culture methods for identifying the bacterial 
population present in the MEEFs of patients with COME, and to study co-occurrence of 
otopathogens in the middle ear and adenoids, the composition of the microbiota present in the 
selected MEEFs and adenoids was also characterised using culture-independent 16S rRNA 
gene sequencing. MEEF and adenoid samples underwent microbial DNA extraction as 
previously described (see Materials and Methods, section 2.6.1 and 2.6.2) and the 
concentrations of DNA extracted from the samples are listed in Table 4. 8. The sequencing of 
PCR- amplified V1-V3 (27F-519R) fragments of 16S rRNA gene using Illumina®MiSeq™ 
platform alongside with bioinformatics analysis of these DNA sequences were performed by 
Dr Scott Dowd (see Materials and Methods, section 2.5.3). The results of 16S rRNA gene 
sequencing were received in the form of text files and the processed data in the form of 
FASTA files. The numbers and percentages of OTUs that were taxonomically assigned at 
kingdom, phylum, class, order, family, genus, and species level for each sample set were 
received in a separate text file. These data were transferred into an Excel spreadsheet by me 
for further analysis including sorting OTUs according to their percentages in each sample, 
removing OTUs with relative abundance of less than 1%, removing common contaminants 
that were identified based on negative control samples and literature screening, and finally 
presenting the processed data in bar charts and graph for further observational analysis.  
Initially, a pilot sequencing of 8 MEEFs from 4 patients with bilateral COME and 5 adenoids 
(two from patients with COME, and 3 without COME (controls)) was performed. These 8 
MEEF samples in addition to 4 MEEFs from 2 other patients were also analysed using the 
traditional culture methods (see Table 4. 1). The bacterial profile identified in 8 MEEFs with 
16S rRNA gene sequencing was greatly different from that identified using standard culture 
methods recommended by UKSMI (see Table 4. 1 and Figure 4. 9). Culture-negative samples 
(2R, 2L, 6R, and 6L) appeared to have a more diverse microbial profile when compared with 
culture – positive samples. It is likely that this was due to the high proportion of the 
contaminant DNA that was detected because of the low bacterial loads in these samples (see 
Table 4. 9). Therefore, common contaminant DNA were manually identified and removed 
based on the literature (Salter et al., 2014, Eisenhofer et al., 2019). In total, 14 different 
bacterial genera consisting of 18 separate species with a relative abundance of >1% were 
identified (see Figure 4. 9). A. otitis and Pseudomonas tolaasii were the most dominant 
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bacterial species, which were present in 4 out of 8 (50%) MEEF samples. S. epidermidis and 
P. acnes were the second most common species identified in 3 out of 8 (37%) of MEEFs. H. 
influenzae and Mycoplasma pneumoniae were present in 2/8 MEEF samples. Other bacterial 
species including Prevotella spp., S. mitis, and S. petrasii were less frequently present in 
MEEF specimens. The traditional culture methods for the initial pilot set of MEEF samples 
failed to identify the majority of the microorganisms present in these samples including 
fastidious or slow-growing bacteria such as A. otitis, H. influenzae, P. acnes, M. pneumoniae, 
and others. Furthermore, when 16S rRNA gene sequencing was used, the bacterial profiles in 
the culture positive bilateral MEEFs collected from the same patients were similar. For 
example, in patient 1, 3 out of 4 bacterial species identified were detected in both samples and 
they were dominated by H. influenzae, whereas in patient 6, A. otitis was the only dominant 
species in both MEEFs. Although A. otitis, H. influenzae, and P. acnes did not appear in the 
initial “pilot culturing” for the first set of MEEFs sample, these organisms did appear in the 
other sets of MEEF samples when ‘improved’ culturing methods were used (see Table 4. 3).      
The microbiota of the adenoids consisted mainly of Haemophilus spp., Fusobacterium 
spp., Prevotella spp., Neisseria spp., Streptococcus spp., and Gemella spp. (see Figure 4. 10). 
In general, the microbial profiles of all adenoids were similar, but proportions of the microbial 
genera were different. The microbiota of adenoids was less diverse in patients with COME 
when compared with control adenoids from patients without COME, and Haemophilus, the 
classical otopathogen, was the most dominant genus with a relative abundance of about 70%. 
Interestingly, H. influenzae was detected in MEEFs of a patient (patient 1) whose adenoids 
were also concurrently colonised with an unidentified Haemophilus sp. (See Figure 4. 9 and 
Figure 4. 10). In conclusion, the pilot culture-independent analysis of MEEF samples showed 
that the traditional culture methods used here required improvement in order to improve the 
isolation of the species present. Additionally, the data showed that it is important to include 
negative controls during the process of DNA extraction from samples in order to confidently 
filter the background contaminant signals. Moreover, bilateral effusions from a single patient 
had similar microbiota. Therefore, in future the focus will be on analysing single MEEF 
samples from more patients. Finally, adenoids of patients with COME were dominated by 
otopathogens and to further investigate this, it was decided to analyse more matched adenoids 
and MEEF samples in future.  
Following this pilot analysis, 12 unpaired MEEFs from 12 patients with COME and 5 
adenoids (3 with COME, and 2 without COME (controls)) were analysed using 16S rRNA 
gene sequencing. A negative control of 1 ml of a sterile 0.9% saline solution that was 
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processed exactly the same way as MEEF samples was included. Again, culture-negative 
MEEFs and those with low microbial biomass showed high levels of contaminant sequences 
(data not shown). The negative control and common contaminant sequences were removed 
and only microbial genera or species with a relative abundance of >1% were included.  
The most commonly identified genera in the MEEF samples were Staphylococcus 
(10/12 MEEFs), Alloiococcus (8/12 MEEFs), Moraxella (6/12 MEEFs), Turicella (5/12 
MEEFs), and Haemophilus (3/12 MEEFs). Identification to the species level revealed that S. 
epidermidis was the most frequently detected Staphylococcus species, which was present in 
6/12 (50%) samples, whereas S. simulans, S. pasteuri, Staphylococcus pseudolugdunensis, 
and Staphylococcus sp. were present in 4/12 (33.3%) of samples (see Figure 4. 11). A. otitis, 
M. catarrhalis, Turicella spp. were the only species identified in their corresponding bacterial 
genera. H. influenzae was the most dominant Haemophilus species present in 3/12 (25%) of 
samples. Pseudomonas tolaasii was not identified in this set of MEEF samples though it was 
one of the dominant species identified in the pilot set of MEEFs. It was identified in MEEF 
samples that showed higher rate of contaminant DNA (60-85%) see Table 4. 9. 
Pseudomonas tolaasii is a gram-negative soil bacterium that is the most common 
causative agent of brown bacterial blotch on several species of edible cultivated mushroom 
and it is not regarded as a pathogen of humans(Lo Cantore et al., 2015). Therefore, it is likely 
that DNA from this species was a contaminant from environmental sources. In agreement 
with this hypothesis, Pseudomonas tolaasii was never cultured from clinical samples. Further 
investigations are required to determine whether it is genuinely present in human middle ear 
infections. Burkholderia pyrrocinia was also detected in 3/12 (25%) of samples with a 
relative abundance of 3-5%. The majority of MEEFs were dominated by a single species, with 
A. otitis, M. catarrhalis, T. otitidis, or H. influenzae at a relative abundance ranging between 
58-97%. Comparison of the bacterial species identified using the improved culture methods 
and 16S rRNA gene sequencing showed that the improved culture methods were successful in 
isolating the majority of the representative microorganisms present in MEEF samples (see 
Figure 4. 11). S. epidermidis, S. simulans, Staphylococcus sp. (very likely to be S. auricularis 
basing on comparison with culture results), and T. otitidis were identified using both methods. 
A. otitis was successfully cultured in 5 out of 8 MEEF samples in which A. otitis was 
identified at relative abundance of >1%. However, the improved culture failed to isolate A. 
otitis in two MEEFs (28L and 31R) where A. otitis was detected at relative abundance of less 
than 3%, possibly due to its low relative abundance in these samples. Other bacterial species 
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that were also identified with both techniques were N. flavescens (1/1 MEEF), S. pneumoniae 
(1/1 MEEF), and P. acnes (1/2 MEEFs).  
M. catarrhalis was the most common bacterial species that the improved culture 
methods failed to isolate, and it was cultured in 2 out of 6 MEEF samples, which may be due 
to low oxygen growth conditions. Other microorganisms that were not cultured with the 
improved culture methods were B. pyrrocinia, Mycobacterium brisbanense, Corynebacterium 
kroppenstedtii, S. pseudolugdunensis, Haemophilus haemolyticus, S. pasteuri, and 
Peptoniphilus asaccharolyticus. Most of these difficult-to-culture bacterial species were 
identified by 16S rRNA gene sequencing in culture-negative MEEF samples (see Figure 4. 
11). 
To study the hypothesis that adenoids act as a reservoir for otopathogens in patients 
with COME, the microbiota identified in 3 matched MEEFs and adenoid samples of patients 
with COME were compared (Figure 4. 12). In general, the microbiota of adenoids showed 
more diverse microbial profiles that included many species present in MEEFs. Again, the core 
microbiota of adenoids commonly consisted of Haemophilus spp., Prevotella spp., 
Streptococcus spp., Veillonella spp., and Porphyromonas spp. A total of 11 OTUs 
(operational taxonomic units) were identified in both sample types, of which 9 OTUs 
including H. influenzae, S. pneumoniae, P. acnes, and M. catarrhalis were detected in both 
matched sample types from 3 patients. There were 6 unique OTUs identified in these 3 
MEEFs samples. These were Staphylococcus sp., Turicella sp., S. pasteuri, S. 
pseudolugdunensis, Peptoniphilus asaccharolyticus, and Flavobacterium sp. To assess 
whether the bacterial species concurrently colonising both middle ear and adenoid of COME 
are genetically identical, matched adenoid and MEEF samples from one patient (patient 
number 20) were analysed using traditional culture methods. Bacterial species isolated from 
matched samples are listed in Table 4. 10. 
Interestingly, strains of S. oralis and S. parasanguinis were isolated from both samples 
(adenoid and MEEF) of the same patient. Unfortunately, both adenoid and MEEF samples of 
this patient were not analysed using 16S rRNA gene sequencing with the other matched 
samples mentioned in Figure 4. 12. Therefore, none of 9 OTUs, that were identified in both 
matched adenoids and MEEF samples, appeared in Table 4. 10 Bacteria isolated from 
matched MEEF and adenoid of one patient with COME.. To assess the genetic relatedness 
between these isolates, full genome sequencing was performed. Genomic comparison using 
Mauve multiple genome alignment software showed that they were not genetically identical: 
there were ~150,000 single nucleotide polymorphisms (SNPs) between the two S. oralis 
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strains and ~300,000 SNPs between the strains that were labelled ‘S. parasanguinis’. In fact, 
one of the S. parasanguinis was re-classified as Streptococcus australis on the basis of the 
genome sequence indicating that MALDI-TOF MS is good for identification of the bacterial 




Table 4. 8 Concentrations of DNA extracted from MEEF and adenoids samples. 
Sample code Concentration of DNA (ng µl-1)  
1R 45.4 (1.8) 
1L 22.7 (1.8) 
2R 3.2 (2.6) 
2L 2.1 (2.6) 
3R 8.6 (1.7) 
3L 37.7 (1.8) 
6R 1.4 (2.1) 
6L 6.8 (1.6) 
22R 103 (1.83) 
23L 100 (1.81) 
25R 12.2 (1.8) 
26L 17 (1.6) 
27R 354 (1.87) 
28L 9.2 (1.57) 
29R 120.9 (1.83) 
30L 113 (1.85) 
31R 49 (1.76) 
32R 9.2 (1.42) 
33R 83 (1.73) 
34L 75 (1.86) 
Control (NS) 10 (1.35) 
1* 115.2 (1.8) 
2 165.5 (1.8) 
3* 282.3 (1.8) 
4 149.7 (1.8) 
5 257.3 (1.8) 
6 115.2 (1.8) 
7 60.9 (1.88) 
30* 19 (1.74) 
31* 110 (1.89) 
33* 53 (1.9) 





Table 4. 9 List of contaminant microbial species identified in the sequenced set of MEEF 
samples. 
  Contaminant Species 1R 1L 2R 2L 3R 3L 4R 4L 






     
Sphingomonas paucimobilis 2.5 5.5 18.4 




















     
Riemerella columbipharyngis 
       
11.4 
Curvibacter spp. 
       
5.8 
Acetobacter senegalensis 
















   
7.2 
    
Acetobacter aceti 
       
1.7 
Paenibacillus provencensis 
       
1.0 
Reyranella spp. 




   
6.8 
    
Massilia timonae 
       
3.3 
Paenibacillus sp. 
   
4.2 
   
1.7 
Ralstonia pickettii 
   
9.8 
    
Geobacillus spp. 








       
2.3 
Halomonas sp. 
   
2.2 
    
Bacillus pumilus 
       
1.7 
Bacillus simplex 
       
2.1 
Prevotella ruminicola 1.4 
       
Corynebacterium vitaeruminis 
       
9.2 
Total (%) 8.3 17.3 85.6 61.9 0.0 0.0 65.1 62.6 
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Table 4. 10 Bacteria isolated from matched MEEF and adenoid of one patient with 
COME. 
Species MEEF Adenoid  
Streptococcus intermedius - + 
Streptococcus parasanguinis + + 
 Streptococcus salivarius - + 
Streptococcus oralis + + 
Rothia mucilaginosa - + 
Staphylococcus aureus - + 
Actinomyces odontolyticus - + 
Streptococcus anginosus group - + 
Streptococcus pneumoniae - + 
Streptococcus mitis + - 
Alloiococcus otitis + - 
Staphylococcus pastueri + - 
Various bacterial species were isolated from adenoid than that from MEEF. Similar strains of 
Streptococcus parasanguinis and Streptococcus oralis were isolated from the adenoid and 





 Figure 4. 9 The microbiota present in the pilot set of MEEF samples of patients with 
COME. 
Data represent OTUs that were present at a relative abundance (%) of ≥ 1% in at least one 
sample. Taxonomic assignment of each OTU is at species level, except in case where OTUs 
were not identified below the genus level (*). Microbial communities of bilateral MEEFs are 
similar and consisted mainly of Alloiococcus otitis, Pseudomonas tolaasii, and 








Figure 4. 10 The microbiota present in the pilot set of adenoid samples derived from 
patients with COME (*) and without COME. 
Data represent OTUs that were present at a relative abundance (%) of ≥ 1% in at least one 
sample. Taxonomic assignment of each OTU is at genus level. Microbial profiles of adenoids 
were similar, less diverse in patients with COME (*) when compared with control adenoids 




Figure 4. 11 Characterisation of bacterial populations present in MEEFs of patients with COME using both 16S rRNA gene sequencing 
and the improved culture methods. 
The bar chart shows the bacterial taxa identified per MEEF sample compared with bacterial species cultured and isolated by the improved 
culture methods. Data represent OTUs that were present at a relative abundance (%) of ≥ 1% in at least one sample. Taxonomic assignment of 
each OTU is at species level. Alloiococcus otitis, Moraxella catarrhalis, Turicella spp., and Staphylococcus epidermidis were the most 
frequently detected species from MEEFs and the “improved” cultured method was successful in isolating the majority of representative bacteria 





Figure 4. 12 Comparison of microbiota present in 3 matched MEEF and adenoids samples of patients with COME. 
Taxonomic assignment of each OTU is at species level, unless the OTU was not classified below the genus level (*). OTUs with ≥ 1% relative 
abundance in at least on sample were included in visual differentiation between both types of samples. Circle sizes and bracketed numbers 
[adenoid/MEEF] represent the number of samples that contain the presented OTU. Similar OTUs are presented in the middle and matched by a 
solid line when the identified OTU in both samples was obtained from the same patient or by a dashed line if it is derived from different patient. 
The figure shows that matched adenoids and MEEFs of patients with COME were concurrently colonised with 9 similar OTUs that were 
dominated mainly by classical otopathogens (Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis).       
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4.9 Discussion  
In this chapter, the study aimed to characterise bacterial populations present in the 
MEEFs of COME patients. Bacterial species present in the MEEFs of patients with COME 
were isolated using conventional culture methods and the potential impact of culturing 
techniques on the isolation of different types of microorganisms was explored. The efficacy of 
NucB to improve the culture of bacteria from MEEFs was also investigated and finally 16S 
rRNA gene sequencing of MEEFs and adenoid microbiota was used to verify the efficacy of 
the culture methods to capture the correct microorganisms present in MEEFs of COME 
patients and to explore the potential co-occurrence of COME-related bacteria in the middle 
ear and adenoids of the same patients. 
Initially, the pilot analysis of MEEF samples derived from 6 patients with bilateral 
COME using the standard culture methods recommended by the UK Standards for 
Microbiology Investigations (UKSMI) for ear infections and associated specimens was not 
successful in capturing most of the fastidious microorganisms, including A. otitis, H. 
influenzae, M. pneumoniae, and P. acnes that were identified in the same sample set using 
16S rRNA gene sequencing. For this reason, several modifications to culture methods were 
applied to improve capturing of fastidious and slow-growing bacterial species. These 
modifications included immediate processing of the MEEF samples within 1 h following 
sample collection, culturing larger volumes of up to 50 µl of MEEF sample per growth 
medium used, extending the incubation period of the MEEF samples culture at 37˚C with 5% 
CO2 to up to 2 weeks, and adopting stringent sterilisation precautions to reduce 
contamination. The percentage of culture positive MEEFs increased from just under 58% to 
90.5% using the improved traditional culture methods of this study. The most frequently 
isolated microorganisms were T. otitidis (52.4%), A. otitis (38.1), and CoNS (76.2%) 
including S. epidermidis (28.6%), and S. auricularis (19%).   
The exact role of T. otitidis, A. otitis, and CoNS in the aetiology of COME is still 
debated. They are thought to be part of the commensal microbiota that may be translocated 
from external ear canal to the middle ear cavity following tympanic membrane perforation 
(Chan et al., 2017b, Harimaya et al., 2006, von Graevenitz and Funke, 2014). On the other 
hand, A. otitis, and T. otitidis are the most prevalent bacterial species repeatedly identified in 
COME patients, and there is evidence that A. otitis has a considerable immune stimulating 
ability, at least in vitro (Himi et al., 2000, Harimaya et al., 2007). Furthermore, A. otitis has a 
capability to produce both single-species and polymicrobial biofilms with H. influenzae. 
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When A. otitis was co-cultured with H. influenzae in multi-species biofilms, both survival and 
persistence of H. influenzae were enhanced compared with monospecies controls (Chan et al., 
2017a). As with other studies, CoNS, S. auricularis, and S. aureus were also the frequently 
isolated microorganisms from most MEEF samples (Daniel et al., 2012b, Yoo et al., 2018). 
Most of these CoNS have an ability to produce biofilms and have a recognised pathogenic 
role in medical implant-associated infections, and possess genetic and phenotypic features 
that would allow them to form biofilms in vivo, highlighting their pathogenic potential to 
induce otitis media (Paluch-Oles et al., 2011). 
The traditionally-considered otopathogens H. influenzae, M. catarrhalis, and S. 
pneumoniae were found in only 19% of MEEF samples (9.5%, 4.8%, and 4.8% respectively). 
These pathogens have been long considered to be the most common species implicated in the 
aetiology of COME (Holder et al., 2015, Lundgren and Rundcrantz, 1976). Our findings are 
broadly consistent with the other observations that found H. influenzae in 3-9%, M. 
catarrhalis 3-3.8%, and S. pneumoniae in around 6.5% of samples (Papp et al., 2016, Daniel 
et al., 2012b). However, the findings of this study are contrary to those of Van Hoecke et al. 
(2016)  who cultured H. influenzae in 35% of samples. It is likely that the difference is due to 
the use of both aerobic and anaerobic conditions for incubation of chocolate agar in the study 
by Van Hoecke et al. This approach was not used here because it was considered more 
appropriate to employ the standard culture methods recommended by UKSMI for ear 
infections and associated specimens in choosing types of growth media and growth 
conditions. The current study used a variety of different types of agar designed to isolate a 
broad range of species. It should be noted that there is no perfect culture method that can 
accurately isolate all the representative bacteria present in MEEFs of COME patients. Indeed, 
many other microorganisms that were cultured in this study were overlooked in Van Hoecke 
et al’s paper, which exclusively employed Chocolate agar for microbial isolation. Other less 
frequently identified microorganisms including S. oralis, S. pyogenes, S. mitis, S. salivarius, 
P. acnes, A. odontolyticus and N. flavescens were also less frequently identified in most other 
studies that used traditional culture methods (Daniel et al., 2012b, Yoo et al., 2018, Poetker et 
al., 2005).  
Although only 21 MEEF samples were analysed using the improved culture methods,   
the proportion of culture positive MEEFs (90.5%) was higher compared to other studies, 
where up to 60% of samples were positive for at least one type of bacteria (Poetker et al., 
2005, Daniel et al., 2012b, Gok et al., 2001, Papp et al., 2016). Nevertheless, our finding is in 
agreement with that of Daniel et al. (2012b) who found live bacteria in more than 90% of 
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MEEF samples from children with COME using extended culture techniques and CLSM 
imaging.  Although the MEEFs were cultured in the present study for a longer duration (with 
the aim to capture fastidious and slow-growing bacteria) compared to that in the standard 
culture approach used in diagnostic laboratories, it is unlikely that these results represent 
contamination as utmost care was taken during MEEF sample collection to avoid contact with 
the external ear canal. For example, the suction catheter used occasionally to clean external 
ear canal wax was exchanged with a new sterile suction catheter to aspirate MEEFs following 
myringotomy. Furthermore, the range of bacterial species identified in this study is similar to 
those identified in the other studies where EEC was decontaminated with 70% ethanol prior to 
MEEF sample collection (Daniel et al., 2012b, Papp et al., 2016). The most likely explanation 
for the higher number of culture positive MEEFs in this study is the adoption of the improved 
culture approaches as previously described, which were successful in culturing a wide range 
of microorganisms including fastidious and slow growing bacterial species such as T. otitidis, 
A. otitis, H. influenzae, A. odontolyticus, and P. acnes. These may have been missed by other 
studies adopting a more limited conventional culturing approach. The higher culture rate here 
could also be explained by the younger age of patients included in this study (the majority 
were below 10 years old) in comparison to previous studies that also recruited adults and 
older children. It has been shown that the proportion of culture positive MEEF samples was 
much higher in younger children than those in adults with COME (Gok et al., 2001, Poetker 
et al., 2005). Furthermore, NICE guidelines in UK for the treatment of COME recommend 
drainage of MEEF and grommet tube insertion in patients with persistent COME following 6 
months of watchful-waiting during which no systemic antibiotics are used. The lack of 
antibiotic usage by these patients may also explain the greater number of culture positive 
MEEF samples compared to other studies where antibiotics were used before MEEF sample 
collection (Gok et al., 2001, Poetker et al., 2005).  
Based on the hypothesis that bacteria associated with COME are present within 
biofilms, the efficacy of NucB in disturbing these biofilms and improving the recovery of 
bacteria from MEFFs was investigated. The results obtained from the pilot set of MEEF 
samples treated with NucB showed inconsistent efficacy of NucB at improving the recovery 
of bacteria from these samples. This finding may be explained by the addition of NucB with 
inconsistent activity and also lack of appropriate control MEEF samples that were treated 
exactly the same as NucB treated samples (see Table 4. 4 and Table 4. 5). Addition of a 
constant amount (mass) of NucB to each sample does not necessarily mean addition of NucB 
with a constant nuclease activity. In this study, nuclease activity of NucB was shown to be 
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different between different preparations of NucB and was affected by storage of NucB 
including repeated freezing and thawing (data not shown). Following this, methods were 
optimised to measure NucB specific activity in order to be able to add consistent amount of 
NucB in the subsequent experiments. Consistent with a previous study, NucB was able to 
completely degrade high molecular weight CTDNA into low molecular weight digestion 
products within 60 minutes (Basle et al., 2018). However, the calculated specific activity of 
NucB in this study (1.4 x 10-5 units mg-1) was approximately 44% less than that calculated by 
Basle et al. (2018)(2.5 x10-5 units mg-1). Furthermore, semi-quantitative analysis of NucB 
nuclease activity in 0.9% saline solution and TSB medium showed that NucB had retained 
approximately 50% of its activity compared to its activity in the optimal buffer.          
Overall, NucB did not produce a significant increase in the total number of 
microorganisms recovered on blood or FA agar compared to control MEEFs with no NucB, 
even though 20% of samples treated with NucB showed a 2-fold or more increase in the 
number of bacteria cultured on blood agar in comparison with the negative controls. The 
finding in this study is contrary to that of Shakir et al. (2012) who found that NucB was 
effective in releasing higher number of microorganisms from fouled Tracheoesophageal 
speech valves (TESVs) compared to PBS treated controls. A possible explanation for this 
might be due to the low biomass of bacterial biofilms present in the MEEF compared to the 
higher load of microbial biofilms present on the surface of TESV. Another possible 
explanation is that there was a degree of sample heterogenesity when MEEFs were divided 
between different treatment groups, and so bacterial biofilms might be localised to one part of 
the MEEF. Surprisingly, incubation of MEEF samples in the absence of NucB for 1 h at 37˚C 
aerobically was associated with a significant reduction (p = 0.007) in the total number of 
viable bacteria cultured under 5% CO2 and anaerobic growth conditions compared to control 
MEEFs that were cultured immediately without aerobic incubation for 1 h. A possible 
explanation for this finding might be that a low oxygen conditions, which resemble the 
natural environment of the middle ear cavity in patients with COME, is the favourable 
environment for the survival of microorganisms present in MEEFs. Thus, incubation of 
microorganisms aerobically adversely affected their viability or their ability to regrow on 
culture media. This is consistent with clinical practice, where grommet insertion frequently 
resolves middle ear effusion in patients with COME by improving middle ear ventilation. It 
should be noted that there was no statistically significant reduction in total viable counts 
recovered from the biofilm when MEEFs were incubated in the presence of NucB for 1 h at 
37˚C compared with controls that were cultured immediately (p = 0.08). It is possible that the 
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negative impact of incubation on recovery of microorganisms was counteracted to some 
extent by the action of NucB in releasing microbial cells from biofilms. Therefore, future 
studies should focus on employing shorter incubation times with NucB to optimise the 
benefits of NucB treatment while minimising problems associated with extended processing 
times. 
To verify the efficacy of traditional culture methods in identifying the bacterial 
populations present in the MEEFs of patients with COME, 16S rRNA gene sequencing was 
also used to study microbiota present in these MEEFs. The results showed that the traditional 
culture methods recommended by UKSMI was not successful in culturing most of the 
microorganisms representing members of bacterial communities present in MEEFs compared 
to the 16S rRNA gene sequencing data of the same samples. Thus, the culture methods were 
subsequently optimised. Also results from the pilot set of samples showed that culture-
negative MEEFs, which are likely contain low microbial biomass, had higher proportions of 
DNA from environmental bacteria compared to culture-positive samples (see Table 4. 9). This 
finding is in accord with recent studies indicating that contaminanting DNA from 
environmental sources is common in microbiome studies involving low microbial biomass 
samples and have a significant negative impact on the interpretation of microbiome data 
(Salter et al., 2014, Eisenhofer et al., 2019). In general, two kinds of contamination can be 
introduced in microbiome studies: contaminant DNA and cross-contamination (Eisenhofer et 
al., 2019). Contaminant DNA can arise from different sources despite stringent precautions 
and care during sample collection and preparation, including sampling and laboratory 
environments, human commensals on laboratory workers, laboratory consumables, DNA 
extraction kits and laboratory reagents. On the other hand, cross-contamination arises when 
DNA is transferred from other samples and sequencing runs from adjacent wells or tubes, 
resulting in ‘batch-effects’ during microbiome sample processing. To date, more than 60 
common contaminant taxa have been detected in DNA extraction blank controls and no-
template controls in many microbiome studies. Most of the contaminant taxa, that were 
identified and removed in this study (see Table 4. 9), were listed within these 60 common 
contaminant taxa and the majority of these taxa were soil, water, or non-human 
microorganisms (Eisenhofer et al., 2019, Salter et al., 2014). The presence of low levels of 
microbial DNA within low microbial biomass samples including MEEF and blood can result 
in the signals generated by contaminant DNA and cross-contamination to be perceived as 
biological signals since the contaminant sequences can easily dominate the true biological 
signals within the samples. It is important to use negative sequencing controls concurrently 
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with samples in these cases.Therefore, a DNA extraction blank control (negative control) was 
included when the second set of MEEFs was processed for16S rRNA gene sequencing. The 
dominant bacterial species identified in 3 out of 4 patients with bilateral COME, were similar, 
and there was a high degree of similarity in the overall composition of the bacterial 
communities identified (see Figure 4.9). Similar findings have also been reported in another 
microbiome study of bilateral COME, although the comparison was limited to the genus level 
(Jervis-Bardy et al., 2015). Therefore, it was decided to focus on analysing unpaired MEEF 
samples from more patients. 
Species-level microbiome analysis of 12 unpaired MEEFs showed that the improved 
culture techniques adopted in this study in combination with MALDI-TOF MS were 
successful in capturing most of the representative members of bacterial communities 
identified in MEEFs by 16S rRNA gene sequencing, including A. otitis, T. otitidis, S. 
pneumoniae, H. influenzae, and most Staphylococcus spp. including CoNS. M. catarrhalis 
was the most common bacterial species that was identified by 16S rRNA gene sequencing and 
not by the improved culture methods. In the present study, MEEFs were cultured under 5% 
CO2 and anaerobic conditions only, which is not well suited to culture the obligate aerobe M. 
catarrhalis. which may explain the low number of M. catarrhalis cultured in these samples. 
Other less frequently identified bacteria such as B. pyrrocinia, M. brisbanense, C. 
kroppenstedtii, H. haemolyticus, and P. asaccharolyticus were also not cultured by the 
improved culture methods. Indeed, it has been estimated that below 2% of bacteria present on 
the environment can be cultured on the artificial culture media, though the percentage of 
culturable bacteria present in human body is higher (Wade, 2002). Nevertheless, traditional 
culture methods combined with MALDI-TOF MS are still considered a convenient 
microbiological technique to identify bacterial isolates because they are quick and cost-
effective (Navrátilová et al., 2016).  
Of 12 MEEFs analysed by16S rRNA gene sequencing, A. otitis, S. epidermidis, M. 
catarrhalis, T. otitidis, and H. influenzae were the most commonly detected bacterial species, 
and were present in 66%, 50%, 50%, 41.6%, and 25% of samples, respectively. 
Approximately 75% of MEEF samples were dominated by one of four species: A. otitis, M. 
catarrhalis, H. influenzae, and T. otitidis, which were present at 58-97% relative abundance. 
Similar bacterial profiles have also been reported in other recent microbiome studies of 
COME, such as Boers et al. (2018), who detected Alloiococcus spp., Turicella spp., 
Haemophilus spp., and Staphylococcus spp. in 63%, 57%, 47%, and 36.8% of MEEF samples 
respectively. Furthermore, Jervis-Bardy et al. (2015) also detected Alloiococcus spp., 
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Turicella spp., Haemophilus spp., Staphylococcus spp. in 63%, 27%, 63%, and 27% of 
samples respectively. In this study, bacterial communities dominated by Alloiococcus spp., or 
Haemophilus spp. were also detected at relative abundances ranging between 57-95% in 90% 
of MEEF samples from patients with COME (Jervis-Bardy et al., 2015). S. pneumoniae, the 
third most common otopathogen previously implicated in the aetiology of COME following 
H. influenzae, and M. catarrhalis, was found in only 16.7% (2 out of 12) of samples. This 
finding is consistent with the other microbiome studies of COME that detected Streptococcus 
spp. in 9-31.5% of samples. Variations in S. pneumoniae prevalence between studies could be 
due to the pattern of vaccination that has be introduced against S. pneumoniae. A recent 
systematic review, assessed the global prevalence of the three common pathogens implicated 
in otitis media, and found that patterns of S. pneumoniae colonisation have changed in 
response to the introduction of vaccination (Ngo et al., 2016). However, the microbiome 
identified in the present study was different from previous reports to some extent. For 
example, M. catarrhalis was detected in higher numbers of the MEEF samples here (50%) 
compared to other studies, where M. catarrhalis was identified in only 5-18% of samples 
(Boers et al., 2018, Jervis-Bardy et al., 2015).  
Finally, correlations between the microbiome of adenoid tissue and the microbiome 
present in the MEEFs of patients with COME was investigated. Consistent with the other 
studies, higher bacterial diversity was detected in adenoids compared to MEEF samples 
(Boers et al., 2018, Jervis-Bardy et al., 2015). In general, the core microbiota of adenoids 
from patients with or without COME consisted of mainly Haemophilus spp., Prevotella spp., 
Streptococcus spp., Fusobacterium spp., Veillonella spp., and Porphyromonas spp. This 
finding is in agreement with previous studies that showed similar bacterial profiles on 
adenoids or nasopharyngeal swabs of patients with COME (Boers et al., 2018, Chan et al., 
2017b, Jervis-Bardy et al., 2015). Comparison of the microbiome present in 3 matched 
adenoids and MEEF samples from 3 patients with COME showed both matched sample types 
were concurrently colonised with similar bacterial OTUs consistent with common paediatric 
otopathogens such as H. influenzae, S. pneumoniae, and M. catarrhalis. Other bacterial 
species including P. acnes, A. otitis, S. epidermidis, S. infantis, S. salivarius, and H. 
haemolyticus were also identified in both sample types. This finding is consistent with several 
other studies (Boers et al., 2018, Chan et al., 2017b, Jervis-Bardy et al., 2015). 
However, many bacterial species were specific to one or other anatomical site or were 
present at markedly different proportions of the total microbiome. For example, A. otitis was 
detected on MEEF and adenoid tissue of 1 patient, at a relative abundance of 90% and 1.2% 
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respectively. A. otitis has also been identified in the nasopharyngeal swabs of patients with 
COME (Harimaya et al., 2006). In a different study, Alloiococcus spp., Staphylococcus spp., 
and Pseudomonas spp. were detected in higher abundance in the EEC of patients with COME 
than in healthy volunteers but they were absent in adenoids, suggesting that the EEC can 
serve as a reservoir for middle ear pathogens (Chan et al., 2017b).  In this study, T. otitidis, A. 
otitis, and Staphylococcus spp. that were detected in higher number of MEEF samples might 
also have been introduced to the middle ear cavity from the EEC. It is estimated that around 
80% of children will have at least one attack of acute otitis media by the age of 3 years (Teele 
et al., 1989), and around 30% of these children are reported to have tympanic membrane 
rupture (Berger, 1989). This episode could be responsible for the introduction of EEC 
microorganisms shown in the present study. Patients with previous history of grommet 
insertion were excluded from our study. However, history of previous episodes of AOM and 
tympanic membrane perforation was not obtained from our patient group. Furthermore, the 
relative abundance of Alloiococcus was significantly higher in patients with a previous history 
of grommet tube insertion than those without, which increases the possibility of translocating 
EEC microorganisms to the middle ear cavity (Chan et al., 2017b). Many EEC bacterial flora 
such as S. aureus and P. aeruginosa are reported to induce middle ear infections through the 
perforated tympanic membrane in patients with chronic suppurative otitis media (Mittal et al., 
2015). In contrast to S. aureus and P. aeruginosa, the role of A. otitis, T. otitidis, and CoNS in 
the aetiology of COME remains unclear. Further investigations are needed to elucidate their 
roles in the pathogenesis of COME. Culture analysis of matched MEEF and adenoid samples 
obtained from the same patient successfully identified S. oralis and S. parasanguinis that 
were present in both the adenoid and the middle ear. Genomic comparison of these similar 
strains showed that they were not genetically identical. In fact, one of the S. parasanguinis 
strains was re-classified as Streptococcus australis on the basis of the genomic DNA 
sequence. This indicates that MALDI-TOF MS identified three of the four oral Streptococcus 
spp. correctly, but failed to identify S. australis. Accurate species identification within 
viridans group streptococci and more specifically within the mitis subgroup is traditionally 
difficult. It has also been shown that MALDI-TOF MS is not always accurate in species level 
identification of oral streptococci and specifically within the Mitis group (Angeletti et al., 
2015). Overall, there was no evidence that precisely the same strains were located in the 
adenoid and middle ear of a single patient based on the very limited sampling and analysis 
presented here. The role of adenoids as a reservoir for otopathogens needs further analysis in 
larger patient cohorts using both traditional culture methods and full genome comparisons. 
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In conclusion, the improved culture methods adopted in this study were able to detect a 
wide spectrum of representative bacterial species present in MEEFs of COME patients 
compared to the conventional culture approach. The presence of these polymicrobial species 
in the MEEFs of COME may play a crucial role in the aetiopathogenesis of COME. In 
accordance with the evidence that bacteria associated with COME are present within biofilms 
and that NucB can disrupt biofilms both alone and in combination with antibiotics, it will be 
important next to determine whether NucB is effective against in vitro biofilms of the 




Chapter 5. Efficacy of NucB against biofilms of COME isolates 
5.1 Introduction   
Bacterial biofilms have been identified in the majority of COME patients, suggesting 
that biofilms may play a key role in the aetiopathogensis of the disease (Daniel et al., 2012b, 
Hall-Stoodley et al., 2006, Thornton et al., 2011, Van Hoecke et al., 2016). The otopathogens 
clasically associated with COME are H. influenzae, S. pneumoniae and M. catarrhalis. All 
have the ability to form single and multispecies biofilms in vitro and in vivo (Hall-Stoodley 
and Stoodley, 2009, Starner et al., 2006, Bakaletz, 2012, Silva and Sillankorva, 2019). 
Biofilm is defined as surface-associated microbial communities that are embedded in a self-
produced matrix, consisting of macromolecules such as polysaccharides, lipids, proteins, and 
nucleic acids (Flemming et al., 2016). Bacteria within biofilms have evolved a range of 
complex protective mechanisms against hostile external insults. Therefore, they are often 
more resistant to antibiotics, cellular and humoral immune actions than planktonic cells of the 
same species (Gu et al., 2014, de la Fuente-Nunez et al., 2013). Increasing evidence has 
accumulated that eDNA is a ubiquitous structural component in the EPS of biofilms formed 
by many Gram-positive and Gram-negative bacteria (Jakubovics et al., 2013, Okshevsky et 
al., 2015). The eDNA plays a critical role in maintaining the structural integrity of biofilms, 
facilitating initial adhesion of bacterial cells, protecting biofilms against antimicrobial and 
immune actions, facilitating genetic material exchange, and acting as a nutrient source.  
The current treatment options for persistent COME involve myringotomy and 
grommet insertion or hearing aids in patients who are unfit for surgery. Occasionally, 
insertion of grommets is combined with adenoidectomy in patients with recurrent or persistent 
upper respiratory tract infections (NICE, 2016, Rosenfeld et al., 2016).  However, the current 
treatment options for COME are far from ideal. Several complications have been reported 
with grommet insertion such as purulent ear discharge, tympanic membrane (TM) scarring, 
and permanent TM perforation. In addition, further grommet insertion is required in about 
25% of cases within 2 years (Kubba et al., 2000, Vlastarakos et al., 2007, Rosenfeld et al., 
2013). This significant rate of recurrence is consistent with the essential role of bacterial 
biofilms in the pathogenesis of COME because grommet insertion likely will only drain 
MEEF that is produced secondary to the middle ear mucosal inflammation and will not treat 
the underlying biofilm, which may subsequently grow again following the grommet extrusion 
(Daniel et al., 2012b).  
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The possibility that biofilms are central to the pathogenesis of COME opens potential 
new avenues for the development of better treatment approaches. With the realisation that 
eDNA plays critical roles in bacterial biofilms, targeting eDNA within the biofilm matrix by 
DNases could potentially provide a new strategy to reduce the present high rate of revision 
surgery required for COME patients. 
5.2 Aims and objectives     
Work presented in the previous section clearly showed the presence of multiple species 
of bacteria in the MEEFs of patients with COME. In accordance with the increasing evidence 
that bacteria present in COME are organised in biofilms, the aim of this chapter was to 
investigate the sensitivity of in vitro biofilms of representative COME isolates to treatment 
with the DNase NucB from B. licheniformis. The objectives were as follow: 
1. Assess biofilm formation capacity of representative species isolated from 
COME. 
2. Test the efficacy of NucB to disperse and inhibit in vitro biofilms formed by 
COME isolates. 
3. Analyse changes in the structure of biofilms formed by the selected NucB- 









5.3 Biofilm formation of COME isolates  
The biofilm formation capacity of 23 bacteria, isolated from MEEFs of patients with 
COME, were investigated. These bacteria were selected as representative strains of most 
bacterial species that were isolated from MEEF aspirates including the most frequently 
detected bacterial species and the classical otopathogens implicated in COME (see Table 5. 
1). Alloiococcus otitis strains were excluded from this analysis because they did not grow on 
rich liquid culture media such as THYE or BHYE. Bacteria were cultured in a 96-well MTPs 
and the extent of biofilm formation was assessed using the CV staining assay (see Materials 
and Methods 2.8.1). The cut off absorbance (A570C) for biofilm formation was defined as the 
mean absorbance (A570) plus three times the standard deviation (SD) of a negative control 
consisting of just organism-specific growth medium with no cells (Vuotto et al., 2017). 
Bacterial strains were classified on the basis of their biofilm formation capacity into the 
following categories: no biofilm formation (A570 ≤ A570C), weak biofilm formation (A570C < 
A570 ≤ 2 x A570C), moderate biofilm formation (2 x A570C < A570 ≤ 4 x A570C), strong biofilm 
formation (4 x A570C < A570).  
In total, 21 out of 23 (91.3%) bacterial strains produced biofilms that were detectable 
by CV staining assay (Table 5. 1). On the basis of the A570C cut off = 0.2, 69.5% (16/23) of 
the isolates showed strong biofilm formation (SBF) ability, 17.4% (4/23) showed moderate 
biofilm formation (MBF) ability, 4.3% (1/23) showed weak biofilm formation (WBF) ability, 
and 8.7% (2/23) did not form biofilms (NBF) in vitro (see Table 5. 1). In general, there was 
considerable variation in the extent of biofilm formation between different species, and 
between different strains of the same species. As an example, out of 11 strains of T. otitidis 
assayed, five strains were strong biofilm producers, two were moderate biofilm producers, 
whereas T. otitidis 18 and 26 produced weak or no biofilm in vitro, respectively. All the 
classical otopathogens such as S. pneumoniae and H. influenzae were strong biofilm 
producers except M. catarrhalis 21, which did not produce detectable biofilm in vitro. 
Similarly, all Staphylococcus species showed strong ability to produce biofilms, whereas 
strains of other less frequently detected species such as S. pyogenes 11 and S. mitis 20 were 




Table 5. 1 Biofilm formation of selected isolates from MEEFs of COME patients 
quantified by CV assay      
Species  Strain c Mean A570(SE)




18 2.14 ± 0.05 SBF 
21 2.52 ± 0.16 SBF 
S. auricularis 
  
16 1.6 ± 0.15 SBF 










8 1.57 ±0.14 SBF 
11 0.35 ± 0.01 MBF 
18 0.2 ± 0.01 WBF 
19 0.4 ± 0.03 MBF 
24 1.61 ± 0.06 SBF 
25 2.82 ± 013 SBF 
26 0.16 ± 0.02 NBF 
27 2.3 ± 0.2   SBF 
29 1.82 ± 0.04 SBF 
S. pneumoniae 
  
11 2.43 ± 0.13 SBF 
32 1.01 ± 0.03 SBF 
S. oralis 
  
14 4.67 ± 013 SBF 
20 2.27 ± 0.48 SBF 
S. pyogenes 11 0.45 ± 0.06 MBF 
S. mitis 20 0.27 ± 0.1 MBF 
H. influenzae 
  
21 1.31 ±0.1 SBF 
33 1.33 ± 0.3 SBF 
M. catarrhalis 22 0.17 ± 0.01 NBF 
A. odontolyticus 14 3.18 ± 0.07 SBF 
 
aData were generated from at least three independent experiments. bSBF= strong biofilm 
formation, MBF= moderate biofilm formation, WBF= weak biofilm formation, NBF= no 
biofilm formation, SE= standard error. Most of the COME isolates were strong biofilm 





Figure 5. 1 Categories of crystal-violet stained biofilms formed by COME isolates. 
Biofilms were grown in 12-well plates for 24-48 h and stained with CV to assess biofilm 
formation capacity of COME isolates. (A) A. odontolyticus 14 represents SBF bacteria, (B) T. 
otitidis 11 represents MBF bacteria, (C) T. otitidis 18 represents WBF bacteria, (D) T. otitidis 
26 represent NBF bacteria, and (E) represents negative control (contains growth medium 
only). The intensity of CV staining was proportional to the biofilm formation capacity of the 
microorganism.        
 
5.4 Efficacy of NucB against in vitro biofilms of COME isolates 
All SBF bacteria and 2 MBF isolates were treated with NucB to assess the role of 
eDNA in promoting biofilm formation and in maintaining the structural stability of pre-
formed biofilms. 
5.4.1 Effects of NucB on biofilm formation of COME isolates 
As previously stated, eDNA plays an important role in promoting the initial attachment 
of bacterial cells to living or inert surfaces during the early stages of biofilm formation 
(Whitchurch et al., 2002). To investigate the inhibitory effect of NucB on biofilm formation, 
100 units ml-1 of NucB with a specific activity of 1.4 x10-5 units mg-1 were included with the 
culture media and the inoculum during biofilm formation for 24-48 h in the 96-well or 12-
well plate model (see Material and Methods 2.8.2). Biofilms of T. otitidis, H. influenzae, S. 
pneumoniae, and A. odontolyticus were grown for 48 h, whereas other bacterial biofilms were 
grown for 24 h in the appropriate culture media and conditions (see Materials and Methods 
2.4.5).  
In general, biofilm formation by 14 out of 18 (77.8%) COME isolates was 
significantly inhibited by NucB (p<0.05, n=3; paired two samples t-test) (see Figure 5. 2). 
Biofilm formation by all isolates of the closely related species S. aureus and S. auricularis 
was significantly reduced by NucB. The amount of reduction on average was just above 50% 
compared to control biofilms. In the presence of NucB, biofilm formation by 4 out of 6 T. 
otitidis strains was significantly impaired by 47-65% in comparison with controls. Biofilms 
formed by T. otitidis 29 were the most strongly inhibited. Interestingly, all the SBF classical 
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otopathogens of COME (H. influenzae, and S. pneumoniae strains) were sensitive to NucB 
treatment, and biofilm formation was decreased by approximately 50%. A. odontolyticus 14 
was the most sensitive microorganism to NucB treatment; biofilm formation was reduced by 
80%. S. oralis 20 was less sensitive to NucB treatment, but biofilm formation was still 
impaired significantly by 28% (p = 0.02, n=3; paired two samples t-test). However, NucB 
treatment did not significantly inhibit biofilm formation by T. otitidis 24, T. otitidis 11, S. 
pyogenes 11, or S. oralis 11.   
5.4.2 Efficacy of NucB against pre-formed biofilms of COME isolates 
 With the realisation over the past few years that eDNA within biofilm matrix of many 
microorganisms has an essential role in maintaining the structural integrity of biofilms, the 
efficacy of NucB against pre-formed biofilms of COME isolates was assessed. For these 
experiments, mature biofilms of T. otitidis, H. influenzae, S. pneumoniae, and A. 
odontolyticus were grown for 48 h, whereas other bacterial biofilms were grown for 24 h in 
the appropriate culture media and conditions (see Materials and Methods 2.5.1). These pre-
formed biofilms were again treated with 100 units ml-1 of NucB with a specific activity of 1.4 
x10-5 unit mg-1 for 1 h at 37°C in ambient air (see Materials and Methods 2.8.2). Biofilms 
formed by 14 out of 18 (77.8%) COME isolates were significantly dispersed by NucB 
compared to buffer treated controls (see Figure 5. 3). Pre-established biofilms of A. 
odontolyticus 14 were again remarkably sensitive to NucB treatment, and biofilm biomass 
was significantly reduced by more than 70% compared with control biofilms. Similarly, pre-
formed biofilms of all S. aureus and S. auricularis isolates were significantly dispersed by 
NucB treatment. On average, the amount of reduction in biofilm biomass of these species was 
approximately 50%. Biofilms formed by 5 out of 6 T. otitidis strains were significantly 
dispersed by NucB, and the extent of biofilm decreased by 31.5-62.7% compared with 
negative controls that lacked enzyme. Biofilms of all classical otopathogens were dispersed 
by more than 56% in the presence of NucB, except H. influenzae 33 biofilms in which the 
dispersal effect of NucB (37% reduction) was lower than its inhibition effect (49% reduction) 
on biofilm formation. In contrast, the dispersal efficacy of NucB was higher than its inhibitory 
efficacy on biofilm formation by T. otitidis 7, 24, 25, 27, S. pneumoniae 11, 32, and S. oralis 
20. Reductions in biomass of A. odontolyticus 14, H. influenzae 21, T. otitidis 29, and all S. 
aureus and S. auricularis isolates were broadly similar in assays of inhibition of biofilm 
formation and biofilm dispersal (see Figure 5. 2 and Figure 5. 3). As had been observed with 
assays for inhibition of biofilm formation, NucB did not significantly dispersed mature 
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biofilms formed by T. otitidis 11, S. pyogenes11, and S. oralis 11. In conclusion, NucB 
efficiently dispersed pre-formed biofilms and inhibited biofilm formation by more than 75% 





Figure 5. 2 NucB-mediated inhibition of biofilm formation by COME isolates. 
Biofilms were grown in 96 or 12 well plates in the presence or absence of 100 units ml-1 of 
NucB for 24-48 h. Biofilms were stained by crystal violet and the extent of biofilm formation 
was quantified by measuring A570. (A) Bars represent mean data from at least three 
independent experiments and standard errors are presented. (B) Representative images of 
crystal violet stained biofilms grown in 12-well plates without or with 100 units of NucB 
treatment. Biofilms formed by the majority of COME isolates were significantly inhibited by 
NucB treatment (*p < 0.05, **p< 0.01, ***p< 0.001; paired two samples t-test). T.o= T. 
otitidis, H.i= H. influenzae, S.pn= S. pneumoniae, A.od= A. odontolyticus, S.a= S. aureus, 






Figure 5. 3 Dispersal of pre-formed biofilms of COME isolates by NucB treatment. 
Biofilms of COME isolates were grown in 96- or 12-well plates for 24-48 h. Biofilms were 
treated with 100 units ml-1 of NucB for 1 h at 37°C aerobically and quantified by CV staining. 
(A) Bars represent mean data from at least three independent experiments and standard errors 
are presented. (B) Representative images of crystal violet stained pre-formed biofilms treated 
with 100 units ml-1 of NucB in Tris buffer (+) or with Tris buffer only (-) for 1 h at 37°C 
aerobically. NucB significantly reduced the biomass of pre-formed biofilms of the majority of 
COME isolates compared to controls treated with buffer only (*p < 0.05, **p< 0.01, ***p< 
0.001; paired two samples t-test). T.o= T. otitidis, H.i= H. influenzae, S.pn= S.pneumoniae, 





5.5       Effects of NucB on biofilm structure of selected COME isolates 
Crystal violet assay data provided a quantitative measure of the inhibitory effects of 
NucB against biofilms, but did not give information on the structure of the biofilms formed. 
To understand the effects of NucB on biofilm structure, biofilms of selected bacteria were 
grown on the surface of glass coverslips and analysed using LIVE/DEAD® BacLight™ stain 
and CLSM imaging (see Materials and Methods section 2.12.1). As the imaging is time-
consuming and labour-intensive, it was not practical to analyse all strains. Therefore, this 
work focused on representative species of the most commonly isolated bacterial genera from 
COME such as Turicella and Staphylococcus, as well as classical otopathogens of COME, 
which were shown to be sensitive to NucB treatment. T. otitidis 27, T. otitidis 29, S.aureus 18, 
S. pneumoniae 11, H. influenzae 21, and A. odontolyticus 14 were selected for this analysis. 
Visualisation of 3D images of CLSM showed that biofilms formed by all these bacteria in the 
absence of NucB generally had a complex structure in which dense, dome-shaped 
microcolonies consisting of several layers of cells covered most of the glass surface, 
occasionally separated by poorly colonised zones (see Figure 5. 4 and Figure 5. 5). There was 
considerable variation in biofilm thickness and structure between different species, and 
between different strains within the same species. For example, biofilms formed by A. 
odontolyticus 14 were more extensive and thicker than those formed by other bacterial species 
and consisted of unorganised, multicellular layers of dense microcolonies covering most of 
the surface with an average thickness of 51.6 μm. Biofilms produced by T. otitidis 27 were 
more extensive, thicker and structurally different than those produced by T. otitidis 29. Both 
live (green) and dead (red) cells were visualised when biofilms were stained by 
LIVE/DEAD® BacLight™ stain, and in general the proportions of live cells were far greater 
than dead/compromised cells within the biofilms of all bacterial species.  
Consistent with the CV quantification of NucB efficacy against COME isolates, 
biofilm formation by all tested species was significantly inhibited in the presence of 100 units 
ml-1  of NucB compared with negative controls (Figure 5. 4). Observation of 3D reconstructed 
CLSM images showed that biofilms developed in the presence of NucB by all tested species 
were substantially less extensive than those of the untreated controls, and they generally 
consisted of randomly distributed single cells or very small clusters of cells on the surface. 
Again, inspection of the CLSM images showed that proportions of live cells to 
dead/compromised cells in biofilms formed in the presence of NucB were almost equal to 
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those formed in the absence of NucB, confirming that NucB has no obvious killing effect on 
bacterial cells within biofilms. 
Visualisation of 3D rendered CLSM images showed that the structure of each biofilm 
treated with NucB was different from that of the negative controls. To obtain quantitative 
information about these structural changes, COMSTAT was used to determine the important 
structural parameters such as biomass, average thickness and roughness coefficient of the 
biofilm (Table 5. 2).  Generally, the average biomass of biofilms reflected the visual 
observations, and significant reductions (p < 0.05) of between 60-85% were observed in 
biofilms of all tested species formed in the presence of NucB compared with controls. 
Biomass levels of S. pneumoniae 11 and S. aureus 18 biofilms were the most strongly 
reduced by NucB, and each was decreased by more than 80% in the presence of the enzyme. 
By contrast, T. otitidis 27, T. otitidis 29, and H. influenzae 21 biofilm biomasses were 
decreased on average by 65% compared with untreated controls. Also consistent with visual 
observations, the average thickness of biofilm formed by all tested species was significantly 
(p < 0.05) reduced by 50-80% in the presence of NucB. Biofilms of S. pneumoniae 11 and S. 
aureus 18 were also strongly reduced in thickness by 75-85%, whereas the thickness of 
biofilms formed by T. otitidis 27, T. otitidis 29, and H. influenzae 21 was reduced on average 
by 60%. The roughness coefficient of biofilms formed by all tested COME isolates in the 
presence of NucB was significantly changed compared to biofilms formed in the absence of 
NucB, once again consistent with a shift in biofilm architecture upon treatment with NucB.  
Again in agreement with CV data, visualisation of CLSM images further showed that 
48 h old pre-formed biofilms of the selected COME isolates were substantially dispersed by 
the addition of 100 units of NucB in Tris buffer, for 1 h at 37°C aerobically, compared with 
controls treated with Tris buffer with no NucB (see Figure 5. 5). Generally, NucB treated pre-
established biofilms of all tested COME isolates were less extensive than the control biofilms, 
and consisted of either irregularly scattered isolated cells with very small clumps of cells or a 
single layer of cells containing many cell-free zones. Again, no differences in the viability of 
biofilm cells were detected between NucB treated biofilms and control biofilms. Quantitative 
analysis of the CLSM images by COMSTAT software showed that the average biomass and 
average thickness of the pre-established biofilms formed by the selected COME isolates were 
significantly (p < 0.05) reduced, by 55-80%, when they were incubated with 100 units ml-1 of 
NucB compared to the control biofilms (Table 5. 3). Biofilms of A. odontolyticus 14 and 
H.influenzae 21 were remarkably sensitive to NucB treatment. In both cases, the average 
biomass and thickness of biofilms was reduced by more than 76% compared to the untreated 
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controls. Consistent with CV data and visual observations of the CLSM images, the average 
biomass and thickness of the pre-formed biofilms of T. otitidis 27, T. otitidis 29, S. 
pneumoniae 11 and S.aureus 18 were also significantly decreased by 55-70 % compared to 
the negative controls. Finally, pre-established T. otitidis 27, T. otitidis 29, and S. aureus 18 
biofilms exposed to NucB were significantly altered in roughness coefficient compared to the 
untreated controls. However, in the case of A. odontolyticus 14, H. influenzae 21, and S. 
pneumoniae 11 no significant changes in biofilm roughness were evident even though there 
were clear differences in biofilm architecture (see Figure 5. 5). 
In conclusion, quantitative data obtained by COMSTAT support the qualitative data 
obtained from the observation of 3D rendered CLSM images and show that the architecture of 
biofilms formed by selected COME isolates is significantly different following exposure to 
NucB during or after biofilm formation compared with controls lacking enzyme. By contrast, 






Figure 5. 4 Effects of NucB on biofilm structure and formation by COME isolates observed by CLSM. 
Biofilms were grown on glass surfaces in the presence or absence of 100 units ml-1 of NucB for 24-48 h and visualised with CLSM using 
LIVE/DEAD® BacLight™ stain. Cells with green signals (Syto9) are alive and cells with red signals (propidium iodide) are dead or damaged. 
Upper lines represent x–y plane, lower lines represent 3D reconstruction of a z stack. The scale bars represent 20 µm for upper lines, and 30 µm 
for lower lines. Images show that biofilms formed by the selected COME isolates in the presence NucB were remarkably less extensive than that 
of untreated controls.   
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Table 5. 2 COMSTAT analysis of biofilm formation by the COME isolates in the 







Roughness coefficienta  
S. pneumoniae 11 (-) NucB 2.8 (0.4) 9.5 (1.5) 0.5 (0.2) 
(+) NucB 0.4 (0.0)** 1.8 (0.3)** 1.5 (0.1)** 
H. influenzae 21 (-) NucB 3.3 (0.7) 12.9 (2.3) 0.8 (0.2) 
(+) NucB 0.9 (0.3)** 5.7 (2.7)* 1.4 (0.1)* 
S. aureus 18 (-) NucB 3.3 (0.5) 7.7 (1.1) 0.6 (0.1) 
(+) NucB 0.6 (0.1)** 2 (0.3)** 1.3 (0.1)** 
T. otitidis 27 (-) NucB 4.8 (0.6) 10.9 (1.4) 0.8 (0.1) 
(+) NucB 1.9 (0.7)* 5.7 (1.9)* 1.5 (0.2)* 
T. otitidis 29 (-) NucB 2 (0.5) 9.7 (2.5) 0.8 (0.1) 
(+) NucB 0.6 (0.1)* 3.1 (0.8)* 1.5 (0.1)** 
 
aData [mean (SE)] were generated from images of three randomly selected areas on each 
coverslip from at least three independent experiments. NucB significantly altered the structure 
of biofilms formed by the selected COME isolates, leading to significant reductions in biofilm 
biomass, average thickness, and roughness coefficient compared to no NucB controls (*p < 





Figure 5. 5 Effects of NucB on the structure of established biofilms of COME isolates observed by CLSM. 
Biofilms were grown on glass surfaces for 48 h, treated with NucB (100 units ml-1 ) for 1 h at 37°C and visualised with CLSM using LIVE/DEAD® 
BacLight™ stain. Cells with green signals (Syto9) are alive and cells with red signals (propidium iodide) are dead or damaged. For each biofilm, upper 
panels represent x–y plane, lower panels represent 3D reconstruction of a z stack. The scale bars represent 20 µm for upper panels, and 30 µm for 
lower panels. Images show that NucB substantially dispersed pre-formed biofilms of selected COME isolates compared to control biofilms. 
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S. pneumoniae 11 
(-) NucB 8.4 (1.7) 24.7 (4.1) 0.6 (0.2) 
(+) NucB 3.0 (1.1)** 11.8 (2.9)* 1.0 (0.2) 
H.influenzae 21 
(-) NucB 6.2 (1.1) 21.6 (3) 0.7 (0.1) 
(+) NucB 1.0 (0.2)*** 5.2 (1.7)*** 1.1 (0.2) 
S.aureus 18 
(-) NucB 4.8 (1.1) 21.6 (3.2) 0.4 (0.1) 
(+) NucB 2.3 (0.6)* 9.0 (2.6)** 1.3 (0.1)*** 
T. otitidis 27 
(-) NucB 9.6 (1.6) 23.9 (1.6) 0.5 (0.1) 
(+) NucB 4.4 (1.2)* 8.7 (1.3)*** 1.2 (0.1)*** 
T. otitidis 29 
(-) NucB 4.3 (0.7) 8.4 (1.6) 1 (0.1) 
(+) NucB 1 (0.1)*** 3.5 (0.4)* 1.3 (0.1)* 
A. odontolyticus 14 
(-) NucB 10.7 (2.3) 51.6 (10.6) 0.6 (0.1) 
(+) NucB 2.0 (0.26)*** 9.4 (1.38)*** 0.9 (0.1) 
aData [mean (SE)] were generated from images of three randomly selected areas on each 
coverslip from at least three independent experiments. NucB greatly altered pre-formed 
biofilms structure by significantly reducing biomass and average thickness of biofilms 
compared to the untreated controls ( *p < 0.05, **p< 0.01, ***p< 0.001; One-Way ANOVA 




5.6 Discussion  
Using the 96-well MTP model and CV staining assay, more than 90% of the COME 
isolates that were assayed in this Chapter formed biofilms in vitro, and around 70% of them 
were strong biofilm forming (SBF) strains. This is not surprising as it has been suggested that 
more than 99% of microorganisms can demonstrate the phenotypic characteristic of biofilm 
formation (Costerton et al., 1978). Although no previous studies have systematically screened 
COME isolates for their biofilm formation capacity as performed in this study, several studies 
have focused on in vitro and in vivo biofilms formed by classical otopathogens implicated in 
the aetiology of COME including S. pneumoniae and H. influenzae  (Hall-Stoodley and 
Stoodley, 2009, Starner et al., 2006, Van Hoecke et al., 2016). All strains of S. pneumoniae, 
H. influenzae, and S. aureus that were isolated in this study also showed strong biofilm 
formation ability. T. otitidis and CoNS are frequently isolated from MEEFs of children with 
COME (Daniel et al., 2012b, Gomez-Garces et al., 2004, Holzmann et al., 2002, Papp et al., 
2016). Their roles in the aetiology of COME are debated as they also have been cultured from 
the external ear canal of healthy individuals, although the frequency of T. otitidis detection in 
patients with COME appears to be higher than in controls (Funke et al., 1994, Gomez-Garces 
et al., 2004, Holzmann et al., 2002). Interestingly, most of the T. otitidis strains that were 
assayed formed robust biofilms in vitro under the conditions employed. Furthermore, in 
agreement with this study, CoNS isolated from patients with COME and CRS also showed 
phenotypic and genotypic characteristics compatible with the formation of biofilms in vitro 
and in vivo (Paluch-Oles et al., 2011). The ability to form biofilms may potentially protect 
these species against hostile external insults such as antimicrobials and host immune actions 
(Longauerova, 2006). Furthermore, T. otitidis and CoNS have also been found to be 
associated with other infection-related conditions such as medical implant-associated 
infections for CoNS, and mastoiditis, auricular and a cervical abscess caused by T. otitidis 
(Paluch-Oles et al., 2011, von Graevenitz and Funke, 2014). It is likely that these 
microorganisms are opportunistic pathogens. 
Consistent with the roles of eDNA in facilitating initial microbial adhesion during 
early biofilm formation and in maintaining the structural integrity of established biofilms, 
NucB was effective in inhibiting biofilm formation and disrupting established biofilms in 
more than 75% of the COME isolates. Staphylococci and T. otitidis were the most frequently 
cultured bacteria in MEEFs of COME patients and the majority of strains investigated here 
were sensitive to NucB treatment. S. aureus and CoNS including S. epidermidis, which is 
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closely related to S. auricularis, have been shown to be sensitive to rhDNase (Dornase alfa), 
DNase I and NucB in previous studies (Qin et al., 2007a, Shields et al., 2013, Tetz et al., 
2009, Kaplan et al., 2012, Sugimoto et al., 2018), indicating a critical importance of eDNA 
within the biofilm matrix of these species. Importantly, biofilms formed by S. pneumoniae 
and H. influenzae, which are two of the most commonly implicated pathogens in COME, 
were significantly inhibited and dispersed by NucB treatment. Evidence from previous studies 
clearly indicates that eDNA is a key structural component within the biofilm matrix of S. 
pneumoniae and H. influenzae (Domenech and Garcia, 2018, Hall-Stoodley et al., 2008, 
Jurcisek et al., 2017, Tetz et al., 2009), which may explain their significant sensitivity to 
NucB. Several distinct mechanisms have been reported to be responsible for the accumulation 
of eDNA within the biofilm matrix of S. pneumoniae and H. influenzae including cellular 
autolysis, the formation of extracellular vesicles, and active release of DNA from the bacterial 
cytoplasm to the extracellular environment through an inner-membrane pore complex 
(Jurcisek et al., 2017, Domenech and Garcia, 2018). 
A. odontolyticus is a commensal of the oral cavity that can cause serious infections in 
individuals with defects in the mucosal barrier and/or with immune deficiency. Although A. 
odontolyticus has been reported to be associated with about 25 cases of invasive pathology 
over last 50 years including cardiopulmonary, mediastinal, bacteraemia, and soft tissue 
infections (Broly et al., 2016), it has not been isolated in middle ear disease. Therefore, it was 
considered interesting to study the biofilm formation capacity and sensitivity to NucB 
treatment of this strain. NucB had a substantial effect on A. odontolyticus biofilms. In our 
laboratory, we have also observed that Actinomyces oris MG1, an isolate originally from the 
oral cavity, also forms biofilms that are markedly sensitive to treatment with DNases such as 
NucB or DNase I (N. Jakubovics, unpublished data). Therefore, a reliance on eDNA for 
biofilm formation may be a characteristic of Actinomyces species. NucB also significantly 
reduced S. pneumoniae biofilms. However, the sensitivity of biofilms formed by other 
streptococcal species to NucB was variable. S. oralis 20 biofilms were significantly dispersed 
and inhibited by NucB, but S. oralis 14 and S. pyogenes 11 were not significantly sensitive to 
NucB. This finding is consistent with other research which also reported marked differences 
in  DNase sensitivity between different species of bacteria or occasionally, between different 
strains of the same species (Lappann et al., 2010, Shields et al., 2013). It is not clear why 
some strains are more sensitive to NucB than others. This could be due to the differences in 
the pathways of eDNA production or in the dependence for eDNA to maintain biofilm 
structural stability. Genomic DNA sequencing of these different strains may help to reveal the 
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genes responsible for release of eDNA into the biofilm matrix. T. otitidis would be an 
interesting target for this investigation, because marked variations in NucB sensitivity were 
detected between different strains of T. otitidis. Apparently eDNA production and 
accumulation is strictly regulated and relies on several factors such as growth phase and the 
availability of nutrient source. Other factors such as growth conditions including temperature 
and pH, differences in the structure of eDNA, production and accumulation of inhibitors, 
differences in the nuclease activity of DNases against eDNA within biofilm matrix, and the 
type of surfaces used to grow bacterial biofilms were also found to have significant impact on 
DNase-mediated biofilm control (Lappann et al., 2010, Shields et al., 2013).      
Using CLSM and quantitative image analysis by COMSTAT, significant alterations in 
the structure of biofilms formed by six different strains could be observed (T. otitidis 27, T. 
otitidis 29, S.aureus 18, S. pneumoniae 11, H. influenzae 21, and A. odontolyticus 14). This 
was displayed by substantial reductions in biomass and average thickness of the biofilms 
when compared with the negative controls, suggesting that degradation of eDNA by NucB 
within the matrix of established biofilms or during biofilm formation by these isolates had 
weakened the biofilm architecture and led to biofilm collapse, or prevented the eDNA from 
enabling biofilm formation in the first place. Consistent with the present study, established 
biofilms of S. pneumoniae clinical isolates treated with rhDNase (Dornase alfa) showed 
significant reductions in biomass and average thickness in a dose-dependent manner 
regardless of their biofilm formation capacity (Hall-Stoodley et al., 2008). These studies 
highlight the important role of eDNA in maintaining structural integrity of biofilm in this 
species. Similarly, eDNA is considered one of the key structural constituents of the biofilm 
matrix of H. influenzae and has been shown to exhibit an important role in protecting in vivo 
biofilms of H. influenzae against the antimicrobial action of human β-defensin-3 (hBD-3), an 
important antimicrobial host defence peptide which is critical in innate immunity of the 
middle ear mucosa (Jones et al., 2013). Interestingly, degradation of eDNA within the in vitro 
biofilm matrix of H. influenzae enhanced the antimicrobial activity of recombinant hBD-3 and 
markedly reduced overall biomass and thickness of biofilms. These observations are in 
agreement with the high sensitivity of H. influenzae strains to NucB treatment that was 
observed in this study. 
Quantitative analysis of biofilms using CLSM imaging and COMSTAT analysis 
showed higher levels of dispersal and inhibition of biofilms formed by COME isolates than 
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those observed in the 96-well MTP model. For example, when testing biofilm inhibition, 
NucB significantly reduced biofilm biomass of, S. aureus 18, S. pneumoniae 11, H. influenzae 
21, T. otitidis 27, and T. otitidis 29 by 56.5%, 45%, 56.3%, 47.3%, and 65%, respectively, as 
quantified using the 96-well MTP biofilm model and CV staining. By comparison, biomass of 
biofilms formed by the same bacteria was significantly reduced by 81.8%, 85.7%, 72.7%, 
60.4%, and 70%, respectively, as quantified using combined CLSM and COMSTAT analysis. 
A similar finding was shown with S. aureus SB14 and SB17 biofilms in Chapter 3. As discussed 
previously, growing biofilms on different surfaces, glass in the case of the CLSM imaging and 
polystyrene for the 96-well MTP and CV staining model, may cause variability in the reliance 
of biofilms on eDNA for the structural support. Second, the CLSM approach shows bacterial 
cells only, whereas the CV staining technique quantifies overall biofilm biomass including 
cells and extracellular matrix, which may have affected the measurements of dispersal and 
inhibition of biofilm formation by NucB. 
 Although the underlying aetiology of COME is unclear, there is increasing evidence 
that bacterial biofilms are the key stimulus of the chronic inflammatory process that leads to 
overproduction and accumulation of effusion fluid in the middle ear of COME patients. There 
is a clear deficiency in the current treatment of COME as evidenced by the significant rate of 
recurrence following myringotomy and grommet insertion (Kubba et al., 2000, Vlastarakos et 
al., 2007). Therefore, there is pressing need for the development of better treatment 
techniques that can be used to improve the current treatment options. This study showed that 
most COME-associated microorganisms formed robust biofilms in vitro that were efficiently 
inhibited and dispersed by NucB treatment, indicating that NucB may be useful in the therapy 
of COME. Further validation of these in vitro data is required in a more realistic animal model 





Chapter 6. General Discussion  
The most important inherited challenge in targeting otopathogens associated with otitis 
media including COME is the ability to isolate and identify the microbial population, and 
monitor the abundance of each species (Stol et al., 2013, Rettig and Tunkel, 2014). 
Traditionally, S. pneumoniae, H. influenzae and M. catarrhalis are the most frequently 
isolated otopathogens in approximately 40% of patients with COME using conventional 
culture methods (Ngo et al., 2016). More fastidious microorganisms including A. otitis, T. 
otitidis and P. acnes are also often isolated, though their role in infection is not so clear 
(Leskinen et al., 2002, Harimaya et al., 2006, von Graevenitz and Funke, 2014, Ngo et al., 
2016, Barron et al., 2019). Initial attempts to replicate laboratory procedures recommended by 
UKSMI (PHE, 2014) had limited success for isolating fastidious microorganisms including A. 
otitis, H. influenzae, and Propionibacterium acnes, even though these were detected using 
culture independent methods. Culturing techniques were improved by processing MEEF 
samples immediately following sample collection, extending the incubation of initial cultures 
for up to 2 weeks, and adopting stringent precautions to prevent contamination. These 
optimisation steps dramatically increased the diversity of species that were cultured. 
Overall,16 different species were isolated from 21 MEEF samples collected from 12 patients 
on three different agar media. The microbial communities present in MEEFs of COME 
patients were dominated by T. otitidis, A. otitis, and CoNS including Staphylococcus 
epidermidis and Staphylococcus auricularis. Bacterial strains identified in our cohort were 
broadly consistent with those previously observed in other studies (Daniel et al., 2012b, Papp 
et al., 2016, Min et al., 2019, Barron et al., 2019, Harimaya et al., 2006, von Graevenitz and 
Funke, 2014, Bosley et al., 1995). However, T. otitidis and A. otitis were identified in our 
cohort at higher frequencies (52.4% and 38.1%, respectively) than reported in these studies 
(0-10% and 0-4.7 % respectively). It is possible that the adoption of the improved culture 
techniques in this study, particularly the extended incubation period, may have been 
responsible for the increased isolation frequency. 
Recently, the development of culture-independent technologies such as 16S rRNA 
gene sequencing have allowed a non-selective, quantitative characterisation of the microbial 
communities present in complex samples such as MEEFs. It is important to note that 16S 
rRNA gene sequencing has a number of limitations, particularly for low biomass samples. 
Many of the extraction kits are contaminated with microbial DNA and it is important to 
include negative controls. In this study, many of the major contaminating sequences were 
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identified and removed by sequencing and analysing DNA extraction blanks. However, since 
this work was done, new guidelines have been published that recommend the use of multiple 
negative controls (Eisenhofer et al., 2019). Overall, the 16S rRNA gene sequencing 
performed here identified A. otitis, CoNS, Moraxella catarrhalis, T. otitidis, and Haemophilus 
influenzae as the most common species in MEEFs of patients with COME. Importantly, there 
was excellent agreement between microbial culture and culture-independent analysis, 
providing confidence in the microbiological analyses. Consistent with this study, recently 
published papers using both traditional culture dependent and 16S rRNA gene sequencing 
techniques have found that six main species or genera of bacteria as the most common 
microorganisms in COME: A. otitis, H. influenzae, staphylococci (mainly CoNS), T. otitidis, 
Moraxella catarrhalis and S. pneumoniae (Van Hoecke et al., 2016, Boers et al., 2018, Chan 
et al., 2017b, Min et al., 2019, Kolbe et al., 2019, Papp et al., 2016). The use of culture-
independent methods has shown that A. otitis and T. otitidis have a high prevalence in COME, 
and are consistent with both our culture and 16S rRNA sequencing data (Ari et al., 2019, 
Kolbe et al., 2019, Boers et al., 2018, Chan et al., 2017b). A. otitis appears to be more 
dominant than T. otitidis in the previously published literature, likely due to lack of 
appropriate primer pairs for the identification of T. otitidis (von Graevenitz and Funke, 2014). 
It is difficult to differentiate T. otitidis from closely-related commensal Corynebacterium 
species, and in fact it has recently been propsed that T. otitidis should be reclassified as 
Corynebacterium otitidis (Baek et al., 2018, von Graevenitz and Funke, 2014). 
The role of T. otitidis, A. otitis and staphylococci in the pathogenesis of COME is still 
unclear due to their high abundance in EEC (Stroman et al., 2001, Chan et al., 2017b), which 
is a potential source of contamination of samples. Even when proper procedures for collecting 
MEEF samples are followed, including sterilisation of EEC and adopting measures to avoid 
contact with it during sampling, the possibility of a sample becoming contaminated with a 
EEC commensal flora cannot be eliminated (Buzatto et al., 2017, Chan et al., 2017b, Daniel et 
al., 2012b). Evidence supporting the potential pathogenicity of T. otitidis, A. otitis and 
staphylococci, and the possible mechanism of transmission into the middle ear through 
retrograde ascension of the Eustachian tube from the adenoids was considered in chapter 4 
and chapter 5. This retrograde ascension is thought to be important for transmission of three 
major otopathogens (S. pneumoniae, H. influenzae and M. catarrhalis) to the middle ear, 
since these species are commonly increased in the adenoids when COME is present 
(Marchisio et al., 2003, Chan et al., 2017b, Van Hoecke et al., 2016). T. otitidis, A. otitis and 
staphylococci (mainly CoNS) are rarely detected in the adenoid. The pattern of high 
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abundance of T. otitidis, A. otitis and staphylococci in the EEC and middle ear and low 
abundance in adenoids suggests that EAC can also serve as a reservoir for these species to 
reach the middle ear, possibly through a perforated tympanic membrane (whether from 
spontaneous rupture or in the presence of grommet tube) as discussed in chapter 4 (Lappan et 
al., 2018, Chan et al., 2017b). Although I did not investigate the microbial species in the EEC, 
comparisons were made between the middle ear microbiome and that of adenoids. In general, 
the microbial profiles of adenoids were more diverse than those observed in MEEFs of 
patients with COME. Consistent with recent microbiome studies, the microbiome of adenoids 
in our cohort consisted mainly of Haemophilus spp., Prevotella spp., Streptococcus spp., 
Fusobacterium spp., Veillonella spp., and Porphyromonas spp. (Boers et al., 2018, Chan et 
al., 2017b, Johnston et al., 2019, Jervis-Bardy et al., 2015). However, the microbiome of 
adenoids of patients with COME appeared to be less diverse than those of patients without 
COME (controls) and they were concurrently colonised by the three classical otopathogens 
(H. influenzae, S. pneumoniae, and M. catarrhalis), in addition to other bacterial species that 
were detected at lower levels in MEEFs of the same patients. This finding supports the notion 
that the co-colonisation of adenoid with otopathogens is an important predisposing factor for 
the development of COME. 
I attempted to directly demonstrate translocation events by sequencing the genomes of 
two paired species from adenoids and MEEFs, with the idea that identification of identical 
clones would be strong evidence for transmission between the two environments. However, 
all strains were distinct from one another and direct evidence for translocation through the 
Eustacian tube is therefore still lacking. On the other hand, commensal genera such as 
Corynebacterium and Dolosigranulum, that were observed at very low relative abundance in 
our cohort, have been detected at high abundance in the nose and adenoids of healthy controls 
and at low relative abundance in the nasopharynx of children with middle ear infections 
(Laufer et al., 2011, Man et al., 2019, Pettigrew et al., 2012b). This suggests that either the 
risk for middle ear infections including COME increases by a reduction in the abundance of 
these key adenoid commensals. Alternatively, middle ear infections themselves or antibiotic 
treatment may result in the loss of these important commensals creating a state of dysbiosis. 
One implication is that probiotic bacteria may be an efficient alternative approach to prevent 
the onset or recurrence of otitis media (Marchisio et al., 2015). The work from chapter 4 
provided an overview of the overall bacterial communities present in the MEEFs and 
adenoids of patients with COME. Most importantly, a wide range of representative fresh 
clinical isolates, which included both classical otopathogens (H. influenzae, S. pneumoniae, 
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and S. aureus) and novel potential otopathogens (A. otitis, T. otitidis, and CoNS (, S. 
auricularis)), were obtained that could be used in in vitro biofilm models to assess the anti-
biofilm activity of NucB in Chapter 5. 
The majority of COME isolates exhibited a strong capacity to form biofilms in vitro, 
although the clinical isolates of A. otitis were excluded from the analysis due to their 
fastidious growth requirements. Previous studies have studied the biofilm-forming ability of 
the classical otopathogens implicated in COME including S. pneumoniae, H. influenzae, and 
S. aureus (Daniel et al., 2012a, Hall-Stoodley et al., 2008, Jones et al., 2013). However, the 
ability of other COME isolates has not been thoroughly explored. It appears that eDNA was 
critical for more than 75% of biofilms formed by the COME isolates tested since NucB 
significantly inhibited biofilm formation and dispersed established biofilms. In particular, all 
strains of S. pneumoniae, H. influenzae and S. aureus were sensitive to NucB. S. aureus 
strains isolated from two cases of COME exhibited similar behaviour to that shown by CRS 
clinical isolates assayed in chapter 3, since they formed robust in vitro biofilms that were 
substantially susceptible to NucB treatment. Consistent with these findings, a recent study 
also found that CoNS were the most frequently cultured bacteria from MEEFs of children 
with COME and the detection rate of Methicillin resistant S. aureus (MRSA) was 
significantly higher in children with recurrent COME than those with non-recurrent COME 
(Min et al., 2019). This work further supports my decision to select S. aureus as a model 
microorganism relevant to COME in chapter 3. The finding that eDNA was frequently 
important in biofilm formation was also consistent with previous research. For example, in 
vitro and in vivo biofilms formed by S. pneumoniae, H. influenzae and S. aureus have been 
shown to contain significant amounts of eDNA and were susceptible to DNase treatment 
(Hall-Stoodley et al., 2008, Jones et al., 2013, Cavaliere et al., 2014a, Jurcisek and Bakaletz, 
2007, Sugimoto et al., 2018). Overall, there is accumulating evidence that DNase enzymes 
such as NucB may potentially be effective for controlling biofilms associated with COME. 
In accordance with previously published studies (Lappann et al., 2010, Shields et al., 
2013, Sugimoto et al., 2018), the results here also demonstrated differences in DNase 
sensitivity between different species of bacteria or occasionally, between different strains of 
the same species. There was variability in the efficacy of NucB against biofilms formed by 
different Streptococcus spp. and T. otitidis, for example. It is not clear why some strains are 
more sensitive to DNase than others. This could be due to differences in the pathways of 
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eDNA production or in the adhesion of cells to the eDNA matrix. It appears that eDNA 
production and accumulation is strictly regulated and relies on several factors such as growth 
phase and the availability of nutrient source (Zetzmann et al., 2015b, Windham et al., 2018) . 
It has been found that eDNA plays an important role during early stages of H. pylori biofilm 
formation but does not play a significant structural role in mature biofilms (Windham et al., 
2018, Grande et al., 2012). The authors have attributed this shift to the contribution of other 
biofilm matrix components that may take on the role of maintaining structural stability as the 
biofilm matures. Furthermore, Zetzmann et al. (2015b) have shown that Listeria 
monocytogenes forms DNase-sensitive biofilms in diluted complex medium and these 
biofilms contained abundant eDNA within the matrix. By contrast, in full strength medium 
biofilms were resistant to DNase I treatment and lacked eDNA within their matrix, suggesting 
that low nutrient medium may favour bacterial cell lysis and the release of chromosomal 
DNA. Other factors such as growth conditions including temperature and pH, interspecies and 
intraspecies variability in the composition of the extracellular matrix of the biofilm, 
differences in the structure of eDNA, and type of surfaces used to grow bacterial biofilms 
were also found to have significant impacts on DNase-mediated biofilm control (Zetzmann et 
al., 2015b, Sugimoto et al., 2018, Windham et al., 2018). It has been shown that the structural 
role of eDNA is not proportional to its level within the matrix of many DNase sensitive S. 
aureus biofilms. However, in a small number of S. aureus strains where polysaccharide-
intracellular adhesins or proteins were present in large amounts within the extracellular matrix 
(ECM), biofilms were insensitive to DNase I treatment. It is likely that these dominant 
components of the ECM may either prevent DNase enzyme from acting on eDNA or 
compensate the structural roles of eDNA within the ECM of these biofilms (Sugimoto et al., 
2018). Comprehensive approaches such as transcriptomics or proteomics help to identify the 
key genes responsible for release of eDNA and other ECM components into the biofilm 
matrix and explain the differences in eDNA sensitivity between closely related strains of the 
same species.   
6.1 Impact and applications of the study 
This study significantly enhances our understanding of the composition of microbial 
populations associated with COME and the efficacy of a DNase, NucB, against relevant in 
vitro biofilms. There have been several previous investigations studying the anti-biofilm 
action of DNases, but very few have looked at biofilm-associated ear diseases, particularly 
COME. Most previous studies have focused on investigating eDNA and DNase-sensitivity of 
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the classical pathogens implicated in middle ear infections such as S. pneumoniae (Hall-
Stoodley et al., 2008), H. influenzae (Jones et al., 2013, Cavaliere et al., 2014b), S. aureus 
(Mann et al., 2009, Sugimoto et al., 2018), and P. aeruginosa (Whitchurch et al., 2002, 
Swartjes et al., 2013). This study built on this body of previous work and broadened the 
investigation to a much wider range of microbial strains freshly isolated from children with 
COME. A key finding was that biofilms formed by the majority of the tested COME isolates 
were significantly dispersed, inhibited or structurally altered by NucB treatment. These 
observations add further weight to the hypothesis that eDNA is a key structural component 
within the ECM of biofilms formed by a wide range of bacteria associated with COME and 
that NucB has promise as a novel eDNA-targeting approach to control biofilm diseases 
including COME. 
While our study has shown promising results in vitro, it is important to determine the 
extent to which eDNA is important in clinical otitis media including COME. Recently 
published in vivo studies have also identified both host- and bacterial-derived extensive 
strands of eDNA matrix which are often associated with DNABII proteins such as integration 
host factor (IHF), and histone-like protein (HU) in the MEEF samples recovered from 
children with rAOM (Thornton et al., 2013), COME (Barron et al., 2019) and in persistent 
otorrhea samples retrieved from paediatric patients with tympanostomy tubes (Idicula et al., 
2016). Targeting these extensive strands of eDNA directly using Dornase alfa was associated 
with complete and rapid fragmentation of this DNA matrix in 7 MEEF samples collected 
from children with rAOM (Thornton et al., 2013). Alternatively, indirect targeting of eDNA 
using antibody against DNABII proteins has been shown to: 1) induce disruption of biofilms 
and rapid resolution of the disease in an experimental model of H. influenzae-induced otitis 
media (Goodman et al., 2011), 2) promote dissolution of sputum solids collected from patient 
with cystic fibrosis (Gustave et al., 2013) and exudate samples retrieved from EEC of children 
with persistent post-tympanostomy tube otorrhoea (Idicula et al., 2016), 3) prevent 
development of experimental otitis media in a multispecies model of ascending disease 
(Novotny et al., 2017), and 4) trigger disruption of H. influenzae biofilms in the chinchilla 
model of experimental otitis media by redirecting the immune response toward immuno-
protective domains of DNA-binding (DNABII) proteins (Novotny et al., 2019). Therefore, the 
presence and ubiquity of eDNA in clinical specimens of the different types of otitis media 
including COME can serve as an important clinical target for our novel eDNA-directed 
approach (NucB) to control biofilm associated diseases including COME.  
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Before an agent such as NucB can be used in clinical applications, it is essential to 
ensure that they are non-toxic and safe for human use. Our results, though preliminary, have 
provided evidence that NucB is a safe anti-biofilm agent as it had no cytotoxicity to human 
bronchial epithelial cells relevant to the middle ear cavity. It is important to further investigate 
the immunogenic effect of NucB on human cells in vitro by measuring the release of 
inflammatory markers such cytokines, determining glutathione and leukocyte proliferation, 
before progressing to investigate the safety of NucB using an animal model. There is some 
evidence from this study and other studies that NucB, as a DNase, would very likely to be 
safe for the use in the clinical setting (Chan et al., 2018).  
 If NucB is shown to be safe for use, there are a number of different options available 
for delivery of the enzyme. Drug formulations such as ear drops generally contain salts at low 
concentrations and could be administered locally into the middle ear following myringotomy 
and grommet insertion to reduce recurrence of disease and the need for further surgery. 
Furthermore, our preliminary results have shown that NucB can be effective in combination 
with antibiotics. Potentially, NucB could be incorporated with antibiotics either in ear drops 
or in other drug formulations such as biodegradable modified-release antibiotic pellets (Daniel 
et al., 2012a). A combination of NucB and antibiotics potentially can also be applied locally 
to treat persistent post-tympanostomy otorrhoea. In a recent clinical trial, it was shown that 
Dornase alfa can facilitate the clearing of grommets in 59% of children with clogged 
grommets, though this effect was not significantly different from treatment with antibiotics 
(Chan et al., 2018). 
 Another potential approach for the local delivery of NucB for the treatment of COME 
is through the transtympanic route. NucB can potentially be incorporated into phage-based 
therapeutic preparations to pass through the intact tympanic membrane into the middle ear 
cavity for the treatment of biofilms associated with otitis media including COME. In 
experimental animal models, phage-based products armed with specific peptide sequences 
have been used to deliver payload across the tympanic membrane into the middle ear cavity 
with minimal or no delivery into the inner ear (Kurabi et al., 2018). Other forms of trans-
tympanic drug delivery system that potentially can be used to deliver NucB for the treatment 
of COME include the penta-block copolymer of poloxamer 407–polybutylphosphoester 
(P407-PBP). This system has been developed to deliver an entire course of 
antimicrobial therapy to the middle ear when applied once to the tympanic membrane through 
the EEC (Yang et al., 2016). The product flows easily during application and forms a strong 
hydrogel on the tympanic membrane. When this therapy was tested on H. influenzae-induced 
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experimental otitis media, it eradicated AOM in the chinchilla model in 100% of cases, 
whereas only 63% of animals receiving 1% ciprofloxacin alone had cleared infection by day 
7. NucB can also potentially be incorporated into mouthwash or nasal spray to control 
biofilms associated with dental diseases or chronic rhinosinusitis, respectively (Jakubovics 
and Burgess, 2015, Shields et al., 2013). Alternatively, NucB could be used to coat artificial 
surfaces such as polymethylmethacrylate (PMMA), stainless steel or titanium, that are 
commonly used in the manufacture of prosthetic medical devices including dentures, dental 
implants or orthopaedic implant materials, in order to delay or prevent medical device-related 
biofilm infections (Swartjes et al., 2013, Jakubovics and Burgess, 2015, Khatoon et al., 2018).  
Another important issue necessary for the application of NucB in the clinical setting is 
to develop systems for the cost-effective production at scales that would be needed for clinical 
use. Towards this goal, an optimized B. licheniformis NucB expression system has been 
developed that potentially could be scaled up (Rajarajan et al., 2013). 
6.2 Limitations of the study and future work 
The work presented in this thesis has provided a greater understanding of the 
composition of microbial populations associated with MEEFs and adenoids in patients with 
COME and the role of eDNA in maintaining stability of in vitro biofilms formed by 
representative microbial isolates. However, there are a number of limitations that need to be 
considered.  
Here, bacterial communities colonising the middle ear and adenoids of children with 
COME were characterised using culture-independent 16S rRNA gene sequencing. In general, 
this approach can provide a comprehensive overview of the composition of microbiome from 
which DNA is present at the time of sampling. However, it does not provide information on 
the viability and the function of microorganisms in their environment. Additionally, there are 
some important biases to consider when conducting these studies (Eisenhofer et al., 2019). 
The efficacy of DNA extraction methods and amplicon primers can be variable across 
different bacterial species, which can ultimately result in underrepresentation of some 
microorganisms. Samples can possibly be contaminated by DNA from different sources 
including laboratory reagents, people, environment, DNA extraction kits, and cross-
contamination from other high biomass samples and sequencing runs from adjacent wells or 
tubes which can heavily confound true biological signals within low biomass samples or 
environments (Eisenhofer et al., 2019, Salter et al., 2014). In this study, the use of an 
optimised microbial identification approach that incorporated both improved culture methods 
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and culture-independent 16S rRNA gene sequencing techniques enabled a more complete 
characterisation of microbial communities of COME than either technique alone. This is of 
particular importance in order to validate that species isolated from MEEFs were 
representative of the total microbial population present. Together, these methods showed that 
COME samples are dominated by T. otitidis, A. otitis, and CoNS and also harboured a wide 
range of other bacterial species including H. influenzae, S. pneumoniae, and M. catarrhalis. 
Furthermore, preliminary microbiome and genomic comparisons of the co-occurrence of 
COME pathogens in paired MEEFs and adenoids from 3 patients revealed more complex 
microbial profiles in adenoids that were concurrently colonised with similar bacterial species 
to those found in MEEFs, including major paediatric otopathogens such as H. influenzae, S. 
pneumoniae, M. catarrhalis and a variety of other bacterial species. Bacterial genera such as 
Haemophilus, Streptococcus, and Moraxella that colonise adenoids may contain both 
pathogenic species and commensal species. Therefore, there is a need to characterise these 
genera at the species and even the strain level. 
Genome sequencing is the most powerful approach to characterise microbial strains 
and to explore differences between closely related isolates. Here, genome sequencing was 
employed in a preliminary attempt to identify identical strains in paired MEEF and adenoid 
swabs. However, streptococcal species that were detected in both sample types from the same 
patient were not genetically identical. Therefore, there was no clear evidence that strains had 
translocated between adenoids and the middle ear. The hypothesis that adenoids act as a 
source for otopathogens in COME needs further validation. Further microbiome 
investigations should focus on establishing causal relationships between microorganisms and 
COME. In particular, it is important to assess the role of controversial pathogens such as T. 
otitidis, A. otitis, and CoNS in addition to the major paediatric otopathogens such as H. 
influenzae, S. pneumoniae, M. catarrhalis as this may lead to new avenues for treatment. This 
could be addressed by the characterisation of microbial communities present in matched 
adenoids and MEEFs from a larger cohort of COME patients with appropriate controls using 
both traditional culture and 16S rRNA gene sequencing techniques, detailed bioinformatics 
analysis and full genome comparisons of similar species isolated from both the adenoids and 
middle ear of the same patient. More advanced culture-independent techniques such as 
metagenomics would enable investigation of the functional roles and characteristics of the 
microbial community by identifying the entire coding potential of the microbial community. 
Proteomics could allow characterisation of the expression of proteins, although currently this 
approach may be limited by the need for relatively large quantities of biomass. 
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Transcriptomics is more sensitive and would allow characterisation of mRNA expression. 
Together, these approaches could be applied to further explore the functional role and causal 
relationships of the middle ear microbiome. 
Another limitation to our work is that the in vitro biofilm models used in this research 
may not be closely relevant to the in vivo biofilms found in COME patients. A key step will 
be the development of improved model systems that more closely mimic the in vivo 
environment. For example, a well-controlled in vitro model that will simulate epithelial 
mucosa of the middle ear with its secretions would be of great benefit.  This could be 
performed by incorporating human epithelial cells similar to the approach used by Marks et 
al. (2012) to model in vivo biofilms of S. pneumoniae or a 3-D host tissue model. It would be 
interesting to assess the anti-biofilm action of NucB against biofilms cultured in these more 
realistic in vitro models and ultimately in already established animal models of otitis media 
and biofilms (Goodman et al., 2011, Novotny et al., 2019). Data from models such as these 
would provide strong proof-of-concept evidence to support further development and 
ultimately human clinical trials. 
Our results have provided evidence that NucB can potentially increase the efficacy of 
antibiotics against in vitro biofilms. It is important to note that this analysis was limited to 
only one type of antibiotic (Co-amoxiclav) and a limited number of S. aureus clinical isolates. 
It would be interesting to extend this research, including assessing the efficacy of NucB in 
combination with other types of penicillin (amoxicillin), macrolides (azithromycin), 
aminoglycosides (gentamicin), and quinolones (ciprofloxacin). In addition, these 
combinations could be assessed against biofilms formed by a greater number of relevant 
clinical isolates from cases of COME. This analysis could be performed using the methods 
optimised in this thesis such as colorimetric XTT and MBEC assays. It is important to 
consider including total viable count calculations during determination of the minimum 
biofilm eradication concentration (MBEC) values of antibiotics when using the MBEC assay 
in addition to the measurement of absorbance (A650) that was performed in this investigation. 
If DNases such as NucB are to be used in a clinical setting using the potential formulations 
that were previously described in section 6.1, it is of particularly important to ascertain their 
efficacy in treatment solutions. Our preliminary results have shown that NucB efficacy was 
not affected when it was combined with high concentrations of Co-amoxiclav. Further 
investigations are required to assess compatibility of NucB with common components of ear 
drops, nasal sprays or mouthwash products. It will be important to design a formulation that 
permits optimal activity of NucB if it is to prove useful at disrupting COME biofilms in vivo.  
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6.3 Conclusion   
In conclusion, the work presented in this thesis has provided a detailed characterisation 
of microbial populations associated with COME through incorporating a combination of 
improved culture and culture-independent techniques. This approach is of particular 
importance in order to provide a rich resource of representative isolates from COME patients 
which were shown to have the ability to form robust biofilms in vitro. NucB has been shown 
to be potentially nontoxic on human cells and exhibited a potent anti-biofilm action against 
the majority of COME isolates. Several clinical characteristics of COME are typical of 
biofilm infection. Greater understanding of the role of bacterial biofilms in the pathogenesis 
of COME will allow the development of novel therapeutic approaches to prevent recurrence 
of the disease. NucB alone or in combination with antibiotics may potentially be a potent and 
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Appendix E:  Sponsorship review letter  
From: Johnston, Andrew [mailto:Andrew.Johnston@nuth.nhs.uk]  
Sent: 05 June 2015 16:25 
To: Reda, Mohamed 
Cc: Nick Jakubovics 
Subject: Sponsorship review 7514 
 
Dear Mohamad & Nick,    
 
Project title: Biofilms study in chronic otitis media with effusion and adenoids 
 
R&D ref: 7514 
 
Apologies for the delay in responding, we have had a high number of request as well as 
moving offices.   
 
Thank you for submitting the above project to The Newcastle upon Tyne Hospitals NHS 
Foundation Trust for sponsorship.  After consideration the supplied documentation has been 
reviewed and we are pleased to confirm that the Trust is able to act as your research sponsor 
in principle, subject to obtaining all relevant national and local authorisations.  
  
Before I can electronically authorise your form as sponsor’s representative, I just need to 




Filter Question 9 – It appears that this study is an educational project therefore tick ‘yes’ and 
complete sections re: academic supervisors etc. 
 
A5-1 - please complete section with R&D ref. number and protocol version and date 
 
A30 - please remove line stating consent forms will be destroyed. 
 
A45 – at the end of the study the Trial Site File along with consent forms must be archived in 
accordance with the Joint Research Office SOP 
 
A52 – consent forms must not be destroyed.  The original consent must be stored in the Trial 
Site File, with a copy filed in the patient notes and a copy passed to the patient.  At the end of 
the study all documents must be archived as stated above.  
 
A64-1 – please add my details – address as email signature 
 
A68-1 – please add Joanna Ho as lead NHS R&D contract – address as per email signature 
 
A76-2 - The University may need to cover the 'design' of the study as this is a university PhD 
study.   Who is the protocol author?  Kelly Lovelock, University Insurance Officer should be 
able to help out with this.  Email is: insurance@newcastle.ac.uk.  Kelly is likely to request a 







Please add version number and date to each page & ensure any of the above IRAS changes 
are reflected in the protocol. 
 
 




Since the 01 June 2014 the process of applying to REC has changed. Guidance regarding this 




Please note that SPONSORSHIP is not the same as granting NHS Permission for the 
study.  Once all signatures have been gained you may apply for NHS Permission, your 
allocated R&D Officer is Joanna Ho who can provide further advice regarding this 
process.  Only once you receive a signed letter from a Research Governance Manager on 
Trust letter-headed paper can the study proceed within NUTH.  
  
 







Research Management and Governance Manager  
 
Newcastle upon Tyne Hospitals NHS Foundation Trust 
  
Newcastle Joint Research Office 
Regent Point 
Regent Farm Road 
Newcastle upon Tyne 
NE3 3HD 
 
Tel: 0191 282 5969 










This message may contain confidential information. If you are not the intended recipient 
please inform the 
sender that you have received the message in error before deleting it. 
Please do not disclose, copy or distribute information in this e-mail or take any action in 
reliance on its contents: 
to do so is strictly prohibited and may be unlawful. 
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Appendix I: R&D valid submission checklist  
R&D Valid Submission Checklist 
Principal Investigator Mr Mohamed ElBadawey 
Full Study Title 
Investigation of Biofilms associated with Chronic Otitis Media 
with Effusion and Adenoids Hypertrophy. 
R&D reference 7514 
NIHR CSP reference (if 
applicable) 
N/A 
Clinical Directorate ENT 
 
Does this research project include a new device that has previously not been used in 
human or a new interventional procedure not carried out before in the Trust? 
No 
If answered yes to the above, has this research project been reviewed by the New 
Interventional Procedures Committee? See guidance document for further details 
Yes / No 
 






NIHR Industry Costing Template: 
* Portfolio: This should always be completed by Sponsor and provided to 
the team for review and feedback. 
Non Portfolio: If not provided by Sponsor, the local team will have to 
complete this  
MANDATORY  
Evidence of team lead review and authorisation of Industry Costing Tool: 
this should be in the form of an email from the relevant Research Team 
Lead 
MANDATORY  
Pharmacy Costing breakdown +/or confirmation of Pharmacy approval of 
NIHR Industry Costing Template (for CTIMPs, provided by Trust Pharmacy) 
MANDATORY  
Non-Commercial Projects 
NuTH Costing Tool – the costing tool must have been reviewed and 
approved by the relevant Research Team Lead prior to submission, please 
ensure an email confirming this is also submitted with the costing tool 
Yes  
Confirmation of Funds  -  one of the following must be provided 
*Grant Award Letter YES  
Email from sponsor confirming funding arrangements YES  










* NHS R&D Form fully authorised by all required signatories via IRAS 
(pdf & XML) 
YES  
NHS SSI Form (draft) YES   
* Research Protocol with version and date YES  
* Participant Information Sheet and Consent Form with version and date YES  
* All other participant related documents (GP letter, questionnaires, 
patient diaries, posters etc) 
YES  
For ctIMP projects:  Confirmation from Pharmacy that they have received 
Pharmacy Manual from Sponsor  
N/A  
2-page CV for Principal Investigator  YES  
GCP Training Certificate for Principal Investigator (please see guidance) YES  
* Evidence of Sponsorship if not confirmed by Study Agreement or 
authorised copy of NHS R&D Form 
MANDATORY  
* Evidence of Insurance or Indemnity (studies with non-NHS sponsors or 
protocol authors who hold honorary NHS contracts)  
YES/CSP/NA  
* Investigator Brochure/ Summary of Product Characteristics - ctIMPs only NA  
Signed Investigator Responsibilities Form MANDATORY  
Draft Contract/Agreements with completed financial appendix 
If sponsor will not provide a completed financial appendix, then R&D 
will require email confirmation of this from sponsor  
YES/NA 
 
Recruitment End Date  please note this is not the study end date 
recorded in the IRAS documents, if unsure please check with sponsor 
MANDATORY 
 
Documents marked with * do not need to be sent to NuTH FT R&D if they are available via 
the NIHR Coordinated System for gaining NHS Permission (CSP) document repository.  
NuTH FT must be listed as a research site on Part C of the NHS R&D Form in order for the 
R&D team to be able to access the study documents in the document repository.  
The NIHR CSP Reference must be provided for any documents marked as available on CSP 
 
 
Documents listed below are not mandatory for study submission for 








Favourable Ethical opinion from NHS Research Ethics Committee 
(REC) 
Yes  
Notice of Acceptance letter from MHRA  NA  
Caldicott approval (it is advisable to submit this as early as possible to 
prevent delays) or confirmation this has been applied for 
NA  
Confirmation of any PIC sites used to aid recruitment at NuTH NA  
Other approvals if relevant – eg CAG, IRMER, ARSAC  NA  
Has this project been submitted for adoption to the NIHR Portfolio? 










R&D may request further information or documentation after review of the submission 
 
If you have any questions about the above please contact the R&D team: 
 
The Newcastle upon Tyne Hospitals NHS Foundation Trust 
Newcastle Joint Research Office, Research & Development 
Level 1, Regent Point 
Regent Farm Road  
Gosforth  












Appendix J: Conferences and Meetings Attendance  
1. 23-26 June 2015: EUROBIOFILMS 2015 - Fourth European Congress on 




Title: Extracellular DNA in biofilms associated with chronic otitis media with effusion 
Chronic otitis media with effusion (COME) is the most common cause of acquired hearing 
loss and elective surgery in children in the developed world. Numerous studies have 
implicated bacterial biofilm infections of middle ear as an important contributor to the 
pathogenesis of COME. Biofilm polymeric matrix shelters bacterial cells and protects them 
from antimicrobial therapy and the host immune system. Increasing evidence indicates that 
extracellular DNA (eDNA) is a key structural component within the matrix of many microbial 
biofilms. Therefore, the addition of DNase enzymes could potentially inhibit biofilm 
formation, disperse pre-established biofilms, or increase the susceptibility of biofilms to 
antibiotics. This study aimed to assess the efficacy of a DNase, NucB from Bacillus 
licheniformis, to inhibit biofilm formation by clinically relevant strains of Staphylococcus 
aureus.  Initial experiments, using crystal violet staining, indicated that biofilm formation by 




changes in biofilms were identified using confocal laser scanning microscopy (CLSM), 
IMARIS, and COMSTAT 2 computer programs. Further investigations will include testing 
the inhibitory effect of NucB on a variety of different bacterial species from COME patients 
using crystal violet assays and quantification of NucB effects on the structure of biofilms by 
CLSM, IMARIS, and COMSTAT2 computer programs. 
 
2. 5-7 October 2016: ESGB & EPASG international conference “Antimicrobial 
resistance in microbial biofilms and options for treatment”, Ghent, Belgium (oral 
presentation). 
Title: Antibiofilm Activitiy of the marine DNase, NucB, in biofilms associated with 
chronic otitis media with effusion. 
Chronic otitis media with effusion (COME) is the most common disease of the ear in 
childhood. Numerous studies have confirmed bacterial biofilm infections as an important 
contributor to the pathogenesis of COME. Increasing evidence indicates that extracellular 
DNA (eDNA) is a key structural component within the matrix of many microbial biofilms. 
The aim of this study to assess the antibiofilm activity of a DNase, NucB, from Bacillus 
licheniformis against in vitro biofilms of COME clinical isolates. NucB treatment of some 
clinical isolates biofilms at concentrations range of 100-5 units/mL showed significant dose- 
dependent inhibition of biofilm formation and dispersion of pre-established biofilms 
quantified by 96-well microtiter plate crystal violet assay. Profound structural changes in 
biofilms were identified without affecting cells viability using confocal laser scanning 
microscopy (CLSM) imaging of LIVE/DEAD® stained biofilms grown on glass coverslips. 
There was more than 50% reduction in biomass, average thickness of the biofilms when 100 
units/mL of NucB either included during biofilm formation for 24h or incubated for 1h with 
pre-established biofilms (48h) as calculated using COMSTAT 2. Just below 50% reduction in 
XTT conversion rate was observed in biofilms of these clinical biofilms which had been 
subjected to antimicrobial treatment at concentration 8000 – fold or greater than the minimal 
inhibitory concentration (MIC). Addition of NucB (100 units/mL) on these biofilms 
significantly increased their sensitivity to antimicrobial killing by more than 20% compared 
with antimicrobial treatment alone and this sensitisation was more with lower antimicrobial 
concentration . In summary, NucB showed efficient antibiofilm and antimicrobial –sensitizing 
actions against tested clinical isolates. NucB, alone or in combination with antibiotics, may 
potentially help in controlling biofilms associated infections including COME.  
3. 18 May 2017: Annual COHR Research Afternoon, Newcastle (poster 
presentation). 
The same poster of  EUROBIOFILMS 2015 (displayed above) was presented. Poster 
award winner. 
 
 
 
 
 
 
